


# BUNDESREPUBLIK DEUTSCHLAND

PAI/EP04 | 11577



## Prioritätsbescheinigung über die Einreichung einer Patentanmeldung

Aktenzeichen:

103 48 407.8

Anmeldetag:

17. Oktober 2003

Anmelder/Inhaber:

Prof. Martin Widschwendter, Mieming/AT

Erstanmelder: Epigenomics AG, 10435 Berlin/DE

Bezeichnung:

Prognostic and Diagnostic Markers Markers for cell  
proliferative disorders of the breast tissues

IPC:

E 03 B 11/16

Die angehefteten Stücke sind eine richtige und genaue Wiedergabe der ur-  
sprünglichen Unterlagen dieser Patentanmeldung.

München, den 29. Dezember 2004  
Deutsches Patent- und Markenamt  
Der Präsident  
Im Auftrag

Kahlra

BEST AVAILABLE COPY



## Prognostic and Diagnostic Markers for cell proliferative disorders of the breast tissues

The present invention relates to prognostic and diagnostic markers for cell proliferative disorders of the breast tissues. The present invention therefore provides methods and nucleic acids for the analysis of biological samples for features associated with the development of breast cell proliferative disorders.

### Background of the invention

This patent application relates to diagnosis and prognosis of breast cancer. Today involvement of axillary lymph nodes and tumour size are the most important prognostic factors in breast cancer. Although the presence or absence of metastatic involvement in the axillary lymph nodes is the most powerful prognostic factor available for patients with primary breast cancer, it is only an indirect measure reflecting the tumours' tendency to spread. In approximately one-third of women with breast cancer and negative lymph nodes the disease recurs, while about one-third of patients with positive lymph nodes are free of recurrence ten years after loco-regional therapy. These data highlight the need for more sensitive and specific prognostic indicators, ideally reflecting the presence or absence of tumour-specific alterations in the bloodstream that may eventually even after years lead to metastasis. It is now widely accepted that adjuvant systemic therapy substantially improves disease-free and overall survival in both pre- and postmenopausal women up to the age of 70 years with lymph node-negative or lymph node-positive breast cancer (Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 351: 1451-1467, 1998.2, 3). It is also generally accepted that patients with poor prognostic features benefit the most from adjuvant therapy, whereas some patients with good prognostic features may be overtreated (Goldhirsch et al.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol., 19: 3817-3827, 2001.). Moreover many other factors have been investigated for their potential to predict disease outcome, but in general they have only limited predictive value. Recently, interesting prognostic parameters including gene-expression profiles, cell cycle regulating

06.11.08  
proteins and occult cytokeratin-positive metastatic cells in the bone marrow have been added to the list of prognostic factors, but their prognostic relevance needs to be further evaluated.

Changes in the status of DNA methylation, known as epigenetic alterations, are one of the most common molecular alterations in human neoplasia, including breast cancer (Widschwendter and Jones: DNA methylation and breast carcinogenesis. *Oncogene*, 21: 5462-5482, 2002). Cytosine methylation occurs after DNA synthesis by enzymatic transfer of a methyl group from the methyl donor S-adenosylmethionine to the carbon-5 position of cytosine. Cytosines are methylated in the human genome mostly when located 5' to a guanosine. Regions with a high G:C content are so-called CpG islands. It has been increasingly recognized over the past four to five years that the CpG islands of a large number of genes, which are mostly unmethylated in normal tissue, are methylated to varying degrees in human cancers, thus representing tumor-specific alterations. The presence of abnormally high DNA concentrations in the serum of patients with various malignant diseases was described several years ago. The discovery that cell-free DNA can be shed into the bloodstream has generated great interest. Numerous studies have demonstrated tumor-specific alterations in DNA recovered from plasma or serum of patients with various malignancies, a finding that has potential for molecular diagnosis and prognosis. The nucleic acid markers described in plasma and serum include oncogene mutations, microsatellite alterations, gene rearrangements and epigenetic alterations, such as aberrant promoter hypermethylation (Anker et al.: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev.*, 18: 65-73, 1999). During recent years some studies have reported cell-free DNA in serum/plasma of breast cancer patients at diagnosis (for example: Silva et al.: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. *Cancer Res.*, 59: 3251-3256, 1999) and in some cases persistence after primary therapy (for example: Silva et al.: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. *Ann. Surg. Oncol.*, 9: 71-76, 2002). Nevertheless an increasing number of studies have reported the presence of methylated DNA in serum/plasma of patients with various types of malignancies, including breast cancer, and the absence of methylated DNA in normal control patients (for example: Wong et al.: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. *Cancer Res.*, 59: 71-73, 1999). So far, only few studies have addressed the prognostic value of these epigenetic alterations in patients' bloodstream (Kawakami et al.: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. *J. Natl. Cancer Inst.*, 92: 1805-1811, 2000; Lecomte et al.: Detection of free-circulating

tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. *Int. J. Cancer*, 100: 542-548, 2002).

It will be appreciated by those skilled in the art that there exists a continuing need to improve methods of early detection, classification and treatment of breast cancers. In this application prognostic and diagnostic DNA methylation-based markers for breast cancer are disclosed.

5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost during PCR amplification. Currently the most frequently used method for analysing DNA for 5-methylcytosine is based upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behaviour. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridisation behaviour, can now be detected as the only remaining cytosine using "normal" molecular biological techniques, for example, by amplification and hybridisation or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analysed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. *Nucleic Acids Res.* 1996 Dec 15;24(24):5064-6). Using this method, it is possible to analyse individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analysed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyse very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.

An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Fraga and Esteller: DNA Methylation: A Profile of Methods and Applications. *Biotechniques* 33:632-649, Sept. 2002.

05.11.04

To date, barring few exceptions (e.g., Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. *Eur J Hum Genet.* 1997 Mar-Apr;5(2):94-8) the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and either completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation imprint. *Nat Genet.* 1997 Nov;17(3):275-6) or individual cytosine positions are detected by a primer extension reaction (Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). *Nucleic Acids Res.* 1997 Jun 15;25(12):2529-31, WO 95/00669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. *Nucleic Acids Res.* 1997 Jun 15;25(12):2532-4). In addition, detection by hybridisation has also been described (Olek et al., WO 99/28498).

Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic DNA. *Bioessays.* 1994 Jun;16(6):431-6, 431; Zeschnigk M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. *Hum Mol Genet.* 1997 Mar;6(3):387-95; Feil R, Charlton J, Bird AP, Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. *Nucleic Acids Res.* 1994 Feb 25;22(4):695-6; Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines. *Gene.* 1995 May 19;157(1-2):261-4; WO 97/46705, WO 95/15373, and WO 97/45560.

An overview of the Prior Art in oligomer array manufacturing can be gathered from a special edition of *Nature Genetics* (*Nature Genetics Supplement*, Volume 21, January 1999), published in January 1999, and from the literature cited therein.

Fluorescently labelled probes are often used for the scanning of immobilised DNA arrays. The simple attachment of Cy3 and Cy5 dyes to the 5'-OH of the specific probe are particularly suitable for fluorescence labels. The detection of the fluorescence of the hybridised probes

may be carried out, for example via a confocal microscope. Cy3 and Cy5 dyes, besides many others, are commercially available.

Matrix Assisted Laser Desorption Ionisation Mass Spectrometry (MALDI-TOF) is a very efficient development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionisation of proteins with molecular masses exceeding 10,000 daltons. *Anal Chem.* 1988 Oct 15;60(20):2299-301). An analyte is embedded in a light-absorbing matrix. The matrix is evaporated by a short laser pulse thus transporting the analyte molecule into the vapour phase in an unfragmented manner. The analyte is ionised by collisions with matrix molecules. An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, the ions are accelerated at different rates. Smaller ions reach the detector sooner than bigger ones.

MALDI-TOF spectrometry is excellently suited to the analysis of peptides and proteins. The analysis of nucleic acids is somewhat more difficult (Gut I G, Beck S. DNA and Matrix Assisted Laser Desorption Ionisation Mass Spectrometry. *Current Innovations and Future Trends.* 1995, 1; 147-57). The sensitivity to nucleic acids is approximately 100 times worse than to peptides and decreases disproportionately with increasing fragment size. For nucleic acids having a multiply negatively charged backbone, the ionisation process via the matrix is considerably less efficient. In MALDI-TOF spectrometry, the selection of the matrix plays an eminently important role. For the desorption of peptides, several very efficient matrixes have been found which produce a very fine crystallisation. There are now several responsive matrixes for DNA, however, the difference in sensitivity has not been reduced. The difference in sensitivity can be reduced by chemically modifying the DNA in such a manner that it becomes more similar to a peptide. Phosphorothioate nucleic acids in which the usual phosphates of the backbone are substituted with thiophosphates can be converted into a charge-neutral DNA using simple alkylation chemistry (Gut IG, Beck S. A procedure for selective DNA alkylation and detection by mass spectrometry. *Nucleic Acids Res.* 1995 Apr 25;23(8):1367-73). The coupling of a charge tag to this modified DNA results in an increase in sensitivity to the same level as that found for peptides. A further advantage of charge tagging is the increased stability of the analysis against impurities which make the detection of unmodified substrates considerably more difficult.

05.11.04  
Genomic DNA is obtained from DNA of cell, tissue or other test samples using standard methods. This standard methodology is found in references such as Fritsch and Maniatis eds., Molecular Cloning: A Laboratory Manual, 1989.

#### Description

The present invention provides methods and nucleic acids for the analysis of biological samples for features associated with the development of breast cell proliferative disorders. The invention is characterised in that the nucleic acid of at least one member of the group of genes according to Table 1 is/are contacted with a reagent or series of reagents capable of distinguishing between methylated and non methylated CpG dinucleotides within the genomic sequence of interest. The present invention makes available a method for ascertaining genetic and/or epigenetic parameters of genomic DNA. The method is for use for the determining the prognosis of breast cell proliferative disorders. The invention presents improvements over the state of the art in that by means of the methods and compounds described herein a person skilled in the art may carry out a sensitive and specific detection assay of cellular matter comprising cancerous breast tissue. This is particularly useful as it allows the analysis of samples of body fluids which may contain only a minimal amount of cell proliferative disorder cellular matter, and enables the detection of said cells and the identification of the organ from which they originated (in this case breast). To date there are no known clinically utilisable means for the detection of breast cancer using genetic methylation markers to analyse bodily fluid samples, such as blood, lymphatic fluids, nipple aspirate and plasma. The generated information is useful in the selection of a treatment of the patient. If a positive prognosis is determined a further treatment might be redundant, while in a case of a poor prognosis a stronger treatment might be necessary.

Furthermore, the method enables the analysis of cytosine methylations and single nucleotide polymorphisms.

The genes that form the basis of the present invention are preferably to be used to form a "gene panel", i.e. a collection comprising the particular genetic sequences of the present invention and/or their respective informative methylation sites. The formation of gene panels allows for a quick and specific analysis of specific aspects of breast cancer. The gene panel(s) as described and employed in this invention can be used with surprisingly high efficiency for

05.11.04

the diagnosis, treatment and monitoring of and the analysis of a predisposition to breast cell proliferative disorders.

In addition, the use of multiple CpG sites from a diverse array of genes allows for a relatively high degree of sensitivity and specificity in comparison to single gene diagnostic and detection tools. Of the genes known to be specifically methylated in breast cancer, the particular combination of the genes according to the invention provides for a particularly sensitive and specific means for the identification of cell proliferative disorders of breast tissues.

The object of the invention is most preferably achieved by means of the analysis of the methylation patterns of one or a combination of genes taken from the group taken from the group ESR1, APC, HSD174B4, HIC1 and RASSF1A (see, for example, Table 1) and/or their regulatory regions. The invention is characterised in that the nucleic acid of one or a combination of genes taken from the group ESR1, APC, HSD174B4, HIC1 and RASSF1A are contacted with a reagent or series of reagents capable of distinguishing between methylated and non methylated CpG dinucleotides within the genomic sequence of interest.

The object of the invention can also be achieved by the analysis of the CpG methylation of one or a plurality of any subset of the group of genes ESR1, APC, HSD174B4, HIC1 and RASSF1A, in particular the following subsets are preferred:

- RASSF1A and APC,
- RASSF1A, and
- APC

The present invention makes available a method for ascertaining genetic and/or epigenetic parameters of genomic DNA. The method is for use in the improved diagnosis, treatment and monitoring of breast cell proliferative disorders.

The disclosed invention further provides a method for determining the phenotype of a subject with a breast cell proliferative disorder comprising

- a) obtaining a biological sample containing genomic DNA from said subject,
- b) analysing the methylation pattern of one or more target nucleic acids comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1

05.11.04

and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in the biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides, and c) determining the phenotype of the individual by comparison to two known phenotypes, a first phenotype characterised by hypermethylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation of the analysed target nucleic acid and better prognosis

The DNA may be obtained from any form of biological sample including but not limited to cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Genomic DNA must then be isolated from the sample using any means standard in the art. The isolated DNA is treated with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides. This may be carried out by any means standard in the art including the use of restriction endonucleases. However, it is preferably carried out with bisulfite (sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behaviour. If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturing reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of non-methylated cytosine nucleobases to uracil. The converted DNA is then used for the detection of methylated cytosines. The methylation status of one or more of the genes ESR1, APC, HSD17B4, HIC1 and RASSF1A and/or their regulatory regions is then analysed. This analysis may be carried out by any means standard in the art including the above described techniques. In the final step of the method the methylation pattern of the DNA obtained from the subject is compared to that of two known phenotypes. The first phenotype is characterised by hypermethylation or methylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation or no methylation of the analysed target nucleic acid and better prognosis. It is particularly preferred that the genes APC and RASSF1A are analysed. By determining which of the two phenotypes the subject belongs to it is possible to determine a suitable treatment to her breast cell proliferative disorder.

05.11.04

The method according to the invention may be used for the analysis of a wide variety of cell proliferative disorders of the breast tissues including, but not limited to, ductal carcinoma *in situ*, lobular carcinoma, colloid carcinoma, tubular carcinoma, medullary carcinoma, metaplastic carcinoma, intraductal carcinoma *in situ*, lobular carcinoma *in situ* and papillary carcinoma *in situ*.

Furthermore, the method enables the analysis of cytosine methylations and single nucleotide polymorphisms within said genes.

The object of the invention is achieved by means of the analysis of the methylation patterns of one or more of the genes ESR1, APC, HSD174B4, HIC1 and RASSF1A and/or their regulatory regions. In a particularly preferred embodiment the sequences of said genes comprise SEQ ID NOS: 1 to 5 and sequences complementary thereto.

The object of the invention may also be achieved by analysing the methylation patterns of one or more genes taken from the following subsets of said aforementioned group of genes. In one embodiment the object of the invention is achieved by analysis of the methylation patterns of the genes RASSF1A and APC and wherein it is further preferred that the sequence of said genes comprise SEQ ID NOS: 5 and 3, respectively. In a further embodiment the object of the invention is achieved by analysis of the methylation patterns of the gene RASSF1A and/or its regulatory sequences, and wherein it is further preferred that the sequence of said gene comprises SEQ ID NO: 5. The object of the invention may also be achieved by analysis of the methylation pattern of the gene APC and/or its regulatory sequences, and wherein it is further preferred that the sequence of said gene comprises SEQ ID NO: 3.

In a preferred embodiment said method is achieved by contacting said nucleic acid sequences in a biological sample obtained from a subject with at least one reagent or a series of reagents, wherein said reagent or series of reagents, distinguishes between methylated and non methylated CpG dinucleotides within the target nucleic acid.

In a preferred embodiment, the method comprises the following steps:

In the first step of the method the genomic DNA sample must be isolated from sources such as cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood,

plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Extraction may be by means that are standard to one skilled in the art, these include the use of detergent lysates, sonification and vortexing with glass beads. Once the nucleic acids have been extracted the genomic double stranded DNA is used in the analysis.

In one embodiment the DNA may be cleaved prior to the next step of the method, this may be by any means standard in the state of the art, in particular, but not limited to, with restriction endonucleases.

In the second step of the method, the genomic DNA sample is treated in such a manner that cytosine bases which are unmethylated at the 5'-position are converted to uracil, thymine, or another base which is dissimilar to cytosine in terms of hybridisation behaviour. This will be understood as "pretreatment" or "chemical pretreatment" hereinafter.

The above described treatment of genomic DNA is preferably carried out with bisulfite (sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behaviour. If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturating reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of non-methylated cytosine nucleobases to uracil. The converted DNA is then used for the detection of methylated cytosines.

Fragments of the pretreated DNA are amplified, using sets of primer oligonucleotides, and a preferably heat-stable, polymerase. Because of statistical and practical considerations, preferably more than six different fragments having a length of 100 - 2000 base pairs are amplified. The amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Usually, the amplification is carried out by means of a polymerase chain reaction (PCR).

The design of such primers is obvious to one skilled in the art. These should include at least two oligonucleotides whose sequences are each reverse complementary or identical to an at least 18 base-pair long segment of the following base sequences specified in the appendix:

SEQ ID NO 6 to 26. Said primer oligonucleotides are preferably characterised in that they do not contain any CpG dinucleotides. In a particularly preferred embodiment of the method, the sequence of said primer oligonucleotides are designed so as to selectively anneal to and amplify, only the breast cell specific DNA of interest, thereby minimising the amplification of background or non relevant DNA. In the context of the present invention, background DNA is taken to mean genomic DNA which does not have a relevant tissue specific methylation pattern, in this case, the relevant tissue being breast tissues.

According to the present invention, it is preferred that at least one primer oligonucleotide is bound to a solid phase during amplification. The different oligonucleotide and/or PNA-oligomer sequences can be arranged on a plane solid phase in the form of a rectangular or hexagonal lattice, the solid phase surface preferably being composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold, it being possible for other materials such as nitrocellulose or plastics to be used as well.

The fragments obtained by means of the amplification may carry a directly or indirectly detectable label. Preferred are labels in the form of fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer, it being preferred that the fragments that are produced have a single positive or negative net charge for better detectability in the mass spectrometer. The detection may be carried out and visualised by means of matrix assisted laser desorption/ionisation mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

In the next step the nucleic acid amplificates are analysed in order to determine the methylation status of the genomic DNA prior to treatment.

The post treatment analysis of the nucleic acids may be carried out using alternative methods. Several methods for the methylation status specific analysis of the treated nucleic acids are described below, other alternative methods will be obvious to one skilled in the art.

The analysis may be carried out during the amplification step of the method. In one such embodiment, the methylation status of preselected CpG positions within the genes ESR1, APC, HSD17B4, HIC1 and RASSF1A and/or their regulatory regions may be detected by use of methylation specific primer oligonucleotides. The term "MSP" (Methylation-specific PCR)

refers to the art-recognized methylation assay described by Herman et al. *Proc. Natl. Acad. Sci. USA* 93:9821-9826, 1996, and also disclosed in US Patents No. 5,786,146 and No. 6,265,171. The use of methylation status specific primers for the amplification of bisulphite treated DNA allows the differentiation between methylated and unmethylated nucleic acids. MSP primers pairs contain at least one primer which hybridises to a bisulphite treated CpG dinucleotide. Therefore the sequence of said primers comprises at least one CG, TG or CA dinucleotide. MSP primers specific for non methylated DNA contain a 'T' at the 3' position of the C position in the CpG. According to the present invention, it is therefore preferred that the base sequence of said primers is required to comprise a sequence having a length of at least 10 nucleotides which hybridises to a pretreated nucleic acid sequence according to SEQ ID NOs.: 6 to 26 and sequences complementary thereto wherein the base sequence of said oligomers comprises at least one CG, TG or CA dinucleotide.

In one embodiment of the method the methylation status of the CpG positions may be determined by means of hybridisation analysis. In this embodiment of the method the amplificates obtained in the second step of the method are hybridised to an array or a set of oligonucleotides and/or PNA probes. In this context, the hybridisation takes place in the manner described as follows. The set of probes used during the hybridisation is preferably composed of at least 4 oligonucleotides or PNA-oligomers. In the process, the amplificates serve as probes which hybridise to oligonucleotides previously bonded to a solid phase. The non-hybridised fragments are subsequently removed. Said oligonucleotides contain at least one base sequence having a length of 10 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG or TpG dinucleotide. In a further preferred embodiment the cytosine of the CpG dinucleotide, or in the case of TpG, the thiamine, is the 5<sup>th</sup> to 9<sup>th</sup> nucleotide from the 5'-end of the 10-mer. One oligonucleotide exists for each CpG or TpG dinucleotide.

The non-hybridised amplificates are then removed. In the final step of the method, the hybridised amplificates are detected. In this context, it is preferred that labels attached to the amplificates are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.

In a preferred embodiment of the method the methylation status of the CpG positions may be determined by means of oligonucleotide probes that are hybridised to the treated DNA con-

currently with the PCR amplification primers (wherein said primers may either be methylation specific or standard).

A particularly preferred embodiment of this method is the use of fluorescence-based Real Time Quantitative PCR (Heid et al., Genome Res. 6:986-994, 1996) employing a dual-labelled fluorescent oligonucleotide probe (TaqMan™ PCR, using an ABI Prism 7700 Sequence Detection System, Perkin Elmer Applied Biosystems, Foster City, California). The TaqMan™ PCR reaction employs the use of a nonextendible interrogating oligonucleotide, called a TaqMan™ probe, which is designed to hybridise to a GpC-rich sequence located between the forward and reverse amplification primers. The TaqMan™ probe further comprises a fluorescent "reporter moiety" and a "quencher moiety" covalently bound to linker moieties (e.g., phosphoramidites) attached to the nucleotides of the TaqMan™ oligonucleotide. For analysis of methylation within nucleic acids subsequent to bisulphite treatment it is required that the probe be methylation specific, as described in U.S. 6,331,393, also known as the Methyl Light assay. Variations on the TaqMan™ detection methodology that are also suitable for use with the described invention include the use of dual probe technology (Lightcycler™) or fluorescent amplification primers (Sunrise™ technology). Both these techniques may be adapted in a manner suitable for use with bisulphite treated DNA, and moreover for methylation analysis within CpG dinucleotides.

A further suitable method for the use of probe oligonucleotides for the assessment of methylation by analysis of bisulphite treated nucleic acids is the use of blocker oligonucleotides. The use of such oligonucleotides has been described by D. Yu, M. Mukai, Q. Liu, C. Steinman in BioTechniques 23(4), 1997, 714-720. Blocking probe oligonucleotides are hybridised to the bisulphite treated nucleic acid concurrently with the PCR primers. PCR amplification of the nucleic acid is terminated at the 5' position of the blocking probe, thereby amplification of a nucleic acid is suppressed wherein the complementary sequence to the blocking probe is present. The probes may be designed to hybridise to the bisulphite treated nucleic acid in a methylation status specific manner. For example, for detection of methylated nucleic acids within a population of unmethylated nucleic acids suppression of the amplification of nucleic acids which are unmethylated at the position in question would be carried out by the use of blocking probes comprising a 'CG' at the position in question, as opposed to a 'CA'.

For PCR methods using blocker oligonucleotides, efficient disruption of polymerase-mediated amplification requires that blocker oligonucleotides not be elongated by the polymerase. Preferably, this is achieved through the use of blockers that are 3'-deoxyoligonucleotides, or oligonucleotides derivatised at the 3' position with other than a "free" hydroxyl group. For example, 3'-O-acetyl oligonucleotides are representative of a preferred class of blocker molecule.

Additionally, polymerase-mediated decomposition of the blocker oligonucleotides should be precluded. Preferably, such preclusion comprises either use of a polymerase lacking 5'-3' exonuclease activity, or use of modified blocker oligonucleotides having, for example, thioate bridges at the 5'-terminii thereof that render the blocker molecule nuclease-resistant. Particular applications may not require such 5' modifications of the blocker. For example, if the blocker- and primer-binding sites overlap, thereby precluding binding of the primer (e.g., with excess blocker), degradation of the blocker oligonucleotide will be substantially precluded. This is because the polymerase will not extend the primer toward, and through (in the 5'-3' direction) the blocker - a process that normally results in degradation of the hybridized blocker oligonucleotide.

A particularly preferred blocker/PCR embodiment, for purposes of the present invention and as implemented herein, comprises the use of peptide nucleic acid (PNA) oligomers as blocking oligonucleotides. Such PNA blocker oligomers are ideally suited, because they are neither decomposed nor extended by the polymerase.

Preferably, therefore, the base sequence of said blocking oligonucleotides is required to comprise a sequence having a length of at least 9 nucleotides which hybridises to a pretreated nucleic acid sequence according to one of SEQ ID NOS: 6 to 26 and sequences complementary thereto, wherein the base sequence of said oligonucleotides comprises at least one CpG, TpG or CpA dinucleotide.

In a further preferred embodiment of the method the determination of the methylation status of the CpG positions is carried out by the use of template directed oligonucleotide extension, such as MS SNuPE as described by Gonzalgo and Jones (Nucleic Acids Res. 25:2529-2531).

In a further embodiment of the method the determination of the methylation status of the CpG positions is enabled by sequencing and subsequent sequence analysis of the amplicate generated in the second step of the method (Sanger F., et al., 1977 PNAS USA 74: 5463-5467).

The method according to the invention may be enabled by any combination of the above means. In a particularly preferred mode of the invention the use of real time detection probes is concurrently combined with MSP and/or blocker oligonucleotides.

A further embodiment of the invention is a method for the analysis of the methylation status of genomic DNA without the need for pretreatment. In the first and second steps of the method the genomic DNA sample must be obtained and isolated from tissue or cellular sources. Such sources may include cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Extraction may be by means that are standard to one skilled in the art, these include the use of detergent lysates, sonification and vortexing with glass beads. Once the nucleic acids have been extracted the genomic double stranded DNA is used in the analysis.

In a preferred embodiment the DNA may be cleaved prior to the treatment, this may be by any means standard in the state of the art, in particular with restriction endonucleases. In the third step, the DNA is then digested with one or more methylation sensitive restriction enzymes. The digestion is carried out such that hydrolysis of the DNA at the restriction site is informative of the methylation status of a specific CpG dinucleotide.

In a preferred embodiment the restriction fragments are amplified. In a further preferred embodiment this is carried out using the polymerase chain reaction.

In the final step the amplicates are detected. The detection may be by any means standard in the art, for example, but not limited to, gel electrophoresis analysis, hybridisation analysis, incorporation of detectable tags within the PCR products, DNA array analysis, MALDI or ESI analysis.

The aforementioned method is preferably used for ascertaining genetic and/or epigenetic parameters of genomic DNA.

In order to enable this method, the invention further provides the modified DNA of one or a combination of genes taken from the group ESR1, APC, HSD174B4, HIC1 and RASSF1A as well as oligonucleotides and/or PNA-oligomers for detecting cytosine methylations within said genes. The present invention is based on the discovery that genetic and epigenetic parameters and, in particular, the cytosine methylation patterns of said genomic DNAs are particularly suitable for improved treatment and monitoring of breast cell proliferative disorders.

The nucleic acids according to the present invention can be used for the analysis of genetic and/or epigenetic parameters of genomic DNA.

In another aspect of the present invention, the object of the present invention is achieved using a nucleic acid containing a sequence of at least 18 bases in length of the pretreated genomic DNA according to one of SEQ ID NOS: 6 to 25 and sequences complementary thereto.

The modified nucleic acids could heretofore not be connected with the ascertainment of disease relevant genetic and epigenetic parameters.

The object of the present invention is further achieved by an oligonucleotide or oligomer for the analysis of pretreated DNA, for detecting the genomic cytosine methylation state, said oligonucleotide containing at least one base sequence having a length of at least 10 nucleotides which hybridises to a pretreated genomic DNA according to SEQ ID Nos: 6 to 26. The oligomer probes according to the present invention constitute important and effective tools which, for the first time, make it possible to ascertain specific genetic and epigenetic parameters during the analysis of biological samples for features associated with a patient's response to endocrine treatment. Said oligonucleotides allow the improved treatment and monitoring of breast cell proliferative disorders. The base sequence of the oligomers preferably contains at least one CpG or TpG dinucleotide. The probes may also exist in the form of a PNA (peptide nucleic acid) which has particularly preferred pairing properties. Particularly preferred are oligonucleotides according to the present invention in which the cytosine of the CpG dinucleotide is within the middle third of said oligonucleotide e.g. the 5<sup>th</sup> - 9<sup>th</sup> nucleotide from the 5'-end of a 13-mer oligonucleotide; or in the case of PNA-oligomers, it is preferred for the cytosine of the CpG dinucleotide to be the 4<sup>th</sup> - 6<sup>th</sup> nucleotide from the 5'-end of the 9-mer.

The oligomers according to the present invention are normally used in so called "sets" which contain at least two oligomers and up to one oligomer for each of the CpG dinucleotides within SEQ ID NOS: 6 to 26.

In the case of the sets of oligonucleotides according to the present invention, it is preferred that at least one oligonucleotide is bound to a solid phase. It is further preferred that all the oligonucleotides of one set are bound to a solid phase.

The present invention further relates to a set of at least 2<sup>n</sup> (oligonucleotides and/or PNA-oligomers) used for detecting the cytosine methylation state of genomic DNA, by analysis of said sequence or treated versions of said sequence (of the genes ESR1, APC, HSD174B4, HIC1 and RASSF1A, as detailed in the sequence listing and Table 1); and sequences complementary thereto). These probes enable improved treatment and monitoring of breast cell proliferative disorders.

The set of oligomers may also be used for detecting single nucleotide polymorphisms (SNPs) by analysis of said sequence or treated versions of said sequence of the genes ESR1, APC, HSD174B4, HIC1 and RASSF1A.

It will be obvious to one skilled in the art that the method according to the invention will be improved and supplemented by the incorporation of markers and clinical indicators known in the state of the art and currently used as diagnostic or prognostic markers. More preferably said markers include node status, age, menopausal status, grade, estrogen and progesterone receptors.

The genes that form the basis of the present invention may be used to form a "gene panel", i.e. a collection comprising the particular genetic sequences of the present invention and/or their respective informative methylation sites. The formation of gene panels allows for a quick and specific analysis of specific aspects of breast cancer treatment. The gene panel(s) as described and employed in this invention can be used with surprisingly high efficiency for the treatment of breast cell proliferative disorders by prediction of the outcome of treatment with a therapy comprising one or more drugs which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion. The analysis of each gene of the panel contributes to the evaluation of patient responsiveness, however, in a less preferred embodiment the

patient evaluation may be achieved by analysis of only a single gene. The analysis of a single member of the 'gene panel' would enable a cheap but less accurate means of evaluating patient responsiveness, the analysis of multiple members of the panel would provide a rather more expensive means of carrying out the method, but with a higher accuracy (the technically preferred solution).

According to the present invention, it is preferred that an arrangement of different oligonucleotides and/or PNA-oligomers (a so-called "array") made available by the present invention is present in a manner that it is likewise bound to a solid phase. This array of different oligonucleotide- and/or PNA-oligomer sequences can be characterised in that it is arranged on the solid phase in the form of a rectangular or hexagonal lattice. The solid phase surface is preferably composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold. However, nitrocellulose as well as plastics such as nylon which can exist in the form of pellets or also as resin matrices are suitable alternatives.

Therefore, a further subject matter of the present invention is a method for manufacturing an array fixed to a carrier material for the improved treatment and monitoring of breast cell proliferative disorders. In said method at least one oligomer according to the present invention is coupled to a solid phase. Methods for manufacturing such arrays are known, for example, from US Patent 5,744,305 by means of solid-phase chemistry and photolabile protecting groups.

A further subject matter of the present invention relates to a DNA chip for the improved treatment and monitoring of breast cell proliferative disorders. The DNA chip contains at least one nucleic acid according to the present invention. DNA chips are known, for example, in US Patent 5,837,832.

Moreover, a subject matter of the present invention is a kit which may be composed, for example, of a bisulfite-containing reagent, a set of primer oligonucleotides containing at least two oligonucleotides whose sequences in each case correspond to or are complementary to a 18 base long segment of the base sequences specified in SEQ ID NOS: 6 to 26 and/or PNA-oligomers as well as instructions for carrying out and evaluating the described method.

In a further preferred embodiment said kit may further comprise standard reagents for performing a CpG position specific methylation analysis wherein said analysis comprises one or more of the following techniques: MS-SNuPE, MSP, Methyl light, Heavy Methyl, and nucleic acid sequencing. However, a kit along the lines of the present invention can also contain only part of the aforementioned components.

Typical reagents (e.g., as might be found in a typical MethylLight®-based kit) for MethylLight® analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); TaqMan® probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

Typical reagents (e.g., as might be found in a typical Ms-SNuPE-based kit) for Ms-SNuPE analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); optimized PCR buffers and deoxynucleotides; gel extraction kit; positive control primers; Ms-SNuPE primers for specific gene; reaction buffer (for the Ms-SNuPE reaction); and radioactive nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery reagents or kit (e.g., precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components.

Typical reagents (e.g., as might be found in a typical MSP-based kit) for MSP analysis may include, but are not limited to: methylated and unmethylated PCR primers for specific gene (or methylation-altered DNA sequence or CpG island), optimized PCR buffers and deoxynucleotides, and specific probes.

The oligomers according to the present invention or arrays thereof as well as a kit according to the present invention are intended to be used for the improved treatment and monitoring of breast cell proliferative disorders. According to the present invention, the method is preferably used for the analysis of important genetic and/or epigenetic parameters within genomic DNA, in particular for use in improved treatment and monitoring of breast cell proliferative disorders.

The methods according to the present invention are used, for improved detection, treatment and monitoring of breast cell proliferative disorder.

The present invention moreover relates to the diagnosis and/or prognosis of events which are disadvantageous or relevant to patients or individuals in which important genetic and/or epigenetic parameters within genomic DNA, said parameters obtained by means of the present invention may be compared to another set of genetic and/or epigenetic parameters, the differences serving as the basis for the diagnosis and/or prognosis of events which are disadvantageous or relevant to patients or individuals.

In the context of the present invention the term "hybridisation" is to be understood as a bond of an oligonucleotide to a completely complementary sequence along the lines of the Watson-Crick base pairings in the sample DNA, forming a duplex structure.

In the context of the present invention, "genetic parameters" are mutations and polymorphisms of genomic DNA and sequences further required for their regulation. To be designated as mutations are, in particular, insertions, deletions, point mutations, inversions and polymorphisms and, particularly preferred, SNPs (single nucleotide polymorphisms).

In the context of the present invention the term "methylation state" is taken to mean the degree of methylation present in a nucleic acid of interest, this may be expressed in absolute or relative terms i.e. as a percentage or other numerical value or by comparison to another tissue and therein described as hypermethylated, hypomethylated or as having significantly similar or identical methylation status.

In the context of the present invention the term "regulatory region" of a gene is taken to mean nucleotide sequences which affect the expression of a gene. Said regulatory regions may be located within, proximal or distal to said gene. Said regulatory regions include but are not limited to constitutive promoters, tissue-specific promoters, developmental-specific promoters, inducible promoters and the like. Promoter regulatory elements may also include certain enhancer sequence elements that control transcriptional or translational efficiency of the gene.

In the context of the present invention the term "chemotherapy" is taken to mean the use of drugs or chemical substances to treat cancer. This definition excludes radiation therapy (treatment with high energy rays or particles), hormone therapy (treatment with hormones or hormone analogues (synthetic substitutes) and surgical treatment.

In the context of the present invention, "epigenetic parameters" are, in particular, cytosine methylations and further modifications of DNA bases of genomic DNA and sequences further required for their regulation. Further epigenetic parameters include, for example, the acetylation of histones which, cannot be directly analysed using the described method but which, in turn, correlates with the DNA methylation.

In the following, the present invention will be explained in greater detail on the basis of the sequences, figures and examples without being limited thereto.

Figure 1 shows the Kaplan-Meier estimated overall survival curves for the gene APC, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

Figure 2 shows the Kaplan-Meier estimated overall survival curves for the gene RASSF1A, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

Figure 3 shows the combined Kaplan-Meier estimated overall survival curves for the genes APC and/or RASSF1A, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

SEQ ID NOs: 1 to 5 represent 5' and/or regulatory regions and/or CpG rich regions of the genes according to Table 1. These sequences are derived from Genbank and will be taken to include all minor variations of the sequence material which are currently unforeseen, for example, but not limited to, minor deletions and SNPs.

SEQ ID NOs: 6 to 26 exhibit the pretreated sequence of DNA derived from the genomic sequence according to Table 1. These sequences will be taken to include all minor variations of

the sequence material which are currently unforeseen, for example, but not limited to, minor deletions and SNPs.

### Examples

Using MethylLight, a high-throughput DNA methylation assay, the inventors analysed 39 genes in a gene evaluation set, consisting of ten sera from metastasised patients, 26 patients with primary breast cancer and ten control patients. In order to determine the prognostic value of genes identified within the gene evaluation set, the inventors finally analysed pretreatment sera of 24 patients having had no adjuvant treatment (training set) to determine their prognostic value. An independent test set consisting of 62 patients was then used to test the validity of genes and combinations of genes, which in the training set were found to be good prognostic markers.

In the gene evaluation set the inventors identified five genes (ESR1, APC, HSD17B4, HIC1 and RASSF1A). In the training set, patients with methylated serum DNA for RASSF1A and/or APC had the worst prognosis ( $p < 0.001$ ). This finding was confirmed by analysing serum samples from the independent test set ( $p = 0.007$ ). When analysing all 86 investigated patients, multivariate analysis showed methylated RASSF1A and/or APC serum DNA to be independently associated with poor outcome, with a relative risk for death of 5.7. DNA methylation of particular genes in pretherapeutic sera of breast cancer patients, especially of RASSF1A/APC, is more powerful than standard prognostic parameters.

The gene evaluation set consisted of patients with recurrent disease ( $n=10$ ; sera obtained at diagnosis of metastasis in the bone, lung, brain or liver) and pretherapeutic sera of recently diagnosed primary breast cancer patients ( $n=26$ ; age range: 36.1 yrs to 83.9 yrs. (mean: 59.3 yrs.); two, 18 and six patients had pT1, pT2 and pT3 cancers, respectively; 15, ten and one patients had lymph node-negative, - positive and unknown disease, respectively) and normal controls ( $n=10$ ; age range: 20.5 to 71.5 yrs. (mean: 44.6 yrs.); all underwent a core biopsy and were confirmed to have benign disease of the breast).

To assess prognostic significance the inventors used pretherapeutic sera in independent training ( $n=24$ ) and test ( $n=62$ ) sets consisting of patients who did not receive any adjuvant treatment after surgery.

Systemic adjuvant therapy was either not necessary or the patients were not eligible or refused any further treatment. The primary surgical procedure included breast-conserving lumpectomy or modified radical mastectomy and axillary lymph node dissection. Median age of the study population was 60 years (range, 28 to 86 yrs.). After a median follow-up of 3.7 yrs. (range: one month to 12.2 yrs.) 17 of the 86 patients (20 %) had died. Distribution of aberrant serum DNA methylation of the 86 patients and association with clinical and histopathological characteristics are shown in Table 2.

Patients' blood samples were drawn prior to therapeutic intervention. The blood was centrifuged at 2000 g for 10 min at room temperature, and 1 mL aliquots of serum samples were stored at -30°C. Genomic DNA from serum samples was isolated using the High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's protocol with some modifications for multiple loading of the DNA extraction columns to gain a sufficient amount of DNA. Thus, 4 x 200 $\mu$ l of a serum sample were each mixed with 200 $\mu$ l of working solution (binding buffer supplemented with polyA carrier RNA) and 50 $\mu$ l proteinase K [18 mg/ml] and incubated for 10 minutes at 72°C. After adding 100 $\mu$ l isopropanol the solution was mixed, loaded onto the extraction column and centrifuged for 1 minute at 8000g. The flow-through was pipetted back into the same column reservoir and centrifuged a second time. This procedure was repeated four times for each serum sample. After these "pooling steps" the DNA isolation was processed as described in the manufacturer's protocol. For DNA elution 55 $\mu$ l of AE-buffer (Qiagen, CA, USA) were added, incubated for 20 min at 45°C and centrifuged for three minutes at 12.000g. For both, normal sera and cancer sera analysis the same amount of serum for DNA extraction was used.

Sodium bisulfite conversion of genomic DNA was performed as described previously (Eads et al.: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res., 28: E32, 2000).

Sodium bisulfite-treated genomic DNA was analysed by means of the MethyLight, a fluorescence-based, real-time PCR assay, as described previously (Eads et al 2000, see above, Eads et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61: 3410-3418, 2001). Briefly, two sets of primers and probes, designed specifically for bisulfite-converted DNA, were used: a methylated set for the gene of interest and a reference set,  $\beta$ -

actin (*ACTB*), to normalise for input DNA. Serum samples of patients with recurrent disease revealed the highest amount of  $\beta$ -actin, whereas no difference between  $\beta$ -actin values from serum samples of patients with primary breast cancer and sera of normal controls was observed. Specificity of the reactions for methylated DNA was confirmed separately using *SssI* (New England Biolabs)-treated human white blood cell DNA (heavily methylated). The percentage of fully methylated molecules at a specific locus was calculated by dividing the *GENE:ACTB* ratio of a sample by the *GENE:ACTB* ratio of *SssI*-treated white blood cell DNA and multiplying by 100. The abbreviation PMR (percentage of fully methylated reference) indicates this measurement. For each MethylLight reaction 10  $\mu$ l of bisulfite-treated genomic DNA was used.

A gene was deemed methylated if the PMR value was  $> 0$ . Primer and probes specific for methylated DNA and used for MethylLight reactions are listed in Supplemental Data.

The inventors used Pearson's Chi<sup>2</sup> or – in the case of low frequencies per cell – Fisher's exact method to test associations between categorically clinicopathological features. The Mann-Whitney-U-Test was used to assess differences between non-parametric distributed variables. Overall survival was calculated from the date of diagnosis of the primary tumour to the date of death or last follow-up. Overall survival curves were calculated with the Kaplan-Meier method. Univariate analysis of overall survival according to clinicopathological factors (histological type, tumour stage, nodal status, grading, menopausal status, hormone receptor status (estrogen and/or progesterone receptor positivity), estrogen and progesterone receptor status) and gene methylation were performed using a two-sided log-rank test.

Multivariate Cox proportional hazards analysis was used to estimate the prognostic effect of methylated genes.

A p value  $< 0.05$  was considered a statistically significant difference. All statistical analyses were performed using SPSS Software 10.0.

The inventors initially investigated 39 genes in the sera of ten patients with metastasised breast cancer for the presence of aberrant methylation. The 33 genes positive in the sera of the metastasised patients were further evaluated in an independent sample set of pretherapeutic sera of 26 patients with primary breast cancer and ten healthy controls. An overview of the

frequency of methylation in the investigated serum samples is given in Table 3. The most appropriate genes for our further analyses were determined to be those that met one of the following criteria: (i) unmethylated in serum samples from healthy controls and > 10% methylated in serum samples from primary breast cancer patients, or (ii) ≤ 10% methylated in serum samples from healthy controls and >20% methylated in serum samples from primary breast cancer patients. A total of five genes, namely ESR1, APC, HSD17B4, HIC1 and RASSF1A, met at least one of these criteria (Table 3).

Pre-treatment serum samples from patients included in the training set were used to evaluate the prognostic value of the methylation status of these five genes. In this training set the inventors identified ESR1, APC or RASSF1A methylation in primary breast cancer patients' sera to be markers of poor prognosis, whereas HSD17B4 reached only borderline significance and aberrant methylation of HIC1 showed no significant results (Table 4). Furthermore, various combinations of the investigated genes were analyzed. Patients were classified as methylation-positive if at least one of the genes included in the combination showed aberrant methylation. Patients with methylated serum DNA for RASSF1A and/or APC had the worst prognosis ( $P < 0.001$ ), even worse than when each gene was analysed individually (Table 4).

The highly significant prognostic value for APC and/or RASSF1A methylation in serum samples from breast cancer patients was confirmed by analysing the test set ( $P = 0.007$ , log rank test). ESR1 and APC methylation as single genes or the combinations ESR1/RASSF1A and ESR1/APC no longer had prognostic significance (Table 4).

Combined analysis of the training and test sets ( $n=86$ ) showed correlation between ESR1 and RASSF1A ( $P = 0.005$ ) and between ESR1 and APC ( $P = 0.031$ ), whereas no correlation was observed between RASSF1A and APC. In patients with advanced tumours RASSF1A and ESR1 methylation and in patients with progesterone receptor-negative tumours APC methylation was more prevalent in pretherapeutic sera, while no further associations were seen between clinicopathological features and DNA methylation of APC, ESR1 or RASSF1A (Table 5). RASSF1A methylation in pretherapeutic sera was more prevalent in older than in younger patients, whereas age had no effect on DNA methylation of ESR1 or APC.

Univariate analysis of all 86 investigated patients (training set plus test set) revealed prognostic significance for tumour size, lymph node metastases and methylation status of APC,

RASSF1A and the combination of RASSF1A/APC (Table 6; Fig. 1). Due to the fact that ESR1 methylation correlates with APC as well as with RASSF1A methylation, the inventors did not test the triple combination in the univariate or the multivariate analyses of all 86 patients.

The Cox multiple-regression analysis included tumour size, lymph node metastases, age and methylation status of the investigated genes. Beside lymph node status, methylated RASSF1A and/or APC serum DNA was strongly associated with poor outcome, with a relative risk for death of 5.7 (Table 7).

Prognosis in patients with newly diagnosed breast cancer is determined primarily by the presence or absence of metastases in draining axillary lymph nodes. Nevertheless, the life-threatening event in breast cancer is not lymph node metastasis per se, but haematogenous metastases which mainly affect bone, liver, lung and brain. The inventors therefore aimed to develop a prognostic test that is sensitive for haematogenous metastases and could be performed in patients' pretherapeutic serum.

In recent years several studies have reported cell-free tumour-specific DNA in serum/plasma of breast cancer patients at diagnosis. Aberrant methylation of serum/plasma DNA of patients with various types of malignancies, including breast cancer, has been described (see above).

In light of these observations, the inventors examined the methylation status of 39 genes, which, on the one hand, are known to be frequently methylated in breast cancer and other malignancies (Jones and Baylin: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002; Widschwendter and Jones: DNA methylation and breast carcinogenesis. Oncogene, 21: 5462-5482, 2002) and, on the other hand, were reported to be abnormally regulated in tumours of patients with poor prognostic breast cancer (van't Veer et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530-536, 2002; van de Vijver et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347: 1999-2009, 2002) Because levels of circulating DNA in metastasised patients are known to be higher (Leon et al.: Free DNA in the serum of cancer patients and the effect of therapy Cancer Res., 37: 646-650, 1977) and because the loss of genetic heterogeneity of disseminated tumour cells with the emergence of clinically evident metastasis was recently reported (Klein et al.: Genetic heterogeneity of single disseminated

tumour cells in minimal residual cancer. *Lancet*, 360: 683-689, 2002), the inventors firstly investigated these 39 genes in ten sera of metastasised patients to determine the overall prevalence of methylation changes in breast cancer. As a next step the inventors analysed the 33 genes that were positive in the metastasised patients, in the pre-treatment sera of 26 patients with primary breast cancer and in ten benign controls in order to identify the most important genes for further analysis. Eventually the inventors came up with five genes (ESR1, APC, HSD17B4, HIC1 and RASSF1A), which were primarily analysed in a group of 24 patients (training set). To confirm the significance of this result the inventors tested these genes in an independent set of 62 patients (test set). In order to apply the strictest criteria for testing the potential of a prognostic factor, the inventors investigated these markers in women, who had not undergone adjuvant systemic treatment. DNA methylation of APC and RASSF1A in pretherapeutic sera, both frequently methylated and abnormally regulated in human primary breast cancers (Dammann et al.: Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. *Cancer Res.*, 61: 3105-3109, 2001; Virmani et al.: Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. *Clin. Cancer Res.*, 7: 1998-2004, 2001), turned out to be a strong independent prognostic parameter. These genes are involved in pathways counteracting metastasis: mediation of intercellular adhesion, stabilisation of the cytoskeleton, regulation of the cell cycle and apoptosis (Fearnhead et al.: The ABC of APC. *Hum. Mol. Genet.*, 10: 721-733, 2001; Dammann et al.: Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. *Histol. Histopathol.*, 18: 665-677, 2003). Methylated DNA in patients' pretherapeutic serum coding for these two genes reflects poor prognosis. The source of the tumour-specific DNA and its definite role in metastasis remains elusive. Circulating tumour-specific altered genetic information may serve as a surrogate marker for circulating tumour cells that ultimately cause distant metastases. An alternative, but equally attractive, hypothesis is that circulating altered DNA per se may cause de novo development of tumour cells in organs known to harbour breast cancer metastases. This so-called "Hypothesis of Genometastasis" suggests that malignant transformation might develop as a result of transfection of susceptible cells in distant target organs with dominant oncogenes that circulate in the plasma and are derived from the primary tumour. Interestingly, irrespective of the source of DNA in the serum, it is noteworthy that some genes provide prognostic information when methylated in patients' sera, whereas genes like HIC1, which is

methylated in about 40% and 90% of primary and metastasised breast cancer patients, respectively, but in only 10% of healthy individuals, are not at all a prognostic parameter.

Irrespective of the mechanistic role of methylated DNA with regards to metastasis in breast cancer patients, these epigenetic changes in serum have several advantages as indicators of poor prognosis as compared to currently used or studied prognostic parameters: DNA in serum is stable and can be analysed by a high-throughput method like MethylLight. Compared to bone marrow aspiration, a simple blood draw (which can be repeated any time throughout the follow-up period) is sufficient. The more screening mammographies are performed, the more small cancers are treated and after histopathological examination no tumour material will remain to perform RNA- and/or protein-based assays for risk evaluation. This application therefore demonstrates a useful and easy approach for risk assessment of breast cancer patients.

Table 1

Gene	Genomic sequence	Bisulphite sequence
HIC1 NM 006497	1	6, 7, 16 and 17
HSD17B4 NM 000414	2	8, 9, 18 and 19
APC NM 000038	3	10, 11, 20 and 21
ESR1 NM 000125	4	12, 13, 22 and 23
RASSF1A NM 170715	5	14, 15, 24 and 25

Table 2. Characteristics of training and test sets.

Characteristics	Training Set (N=24)	Test Set (N=62)	P Value*
Size of tumour			0.024
T1	62.5	79	
T2	37.5	13	
T3 + T4	0	7	
Histologic type			n.s
Invasive ductal	67	63	
Invasive lobular	8	13	
Others	25	24	

Tumor grade			n.s.
1	46	44	
2	33	39	
3	17	10	
Lymph node metastases			n.s.
No	75	65	
Yes	12.5	11	
Unknown	12.5	24	
Menopausal status			n.s.
Premenopausal	33	16	
Postmenopausal	67	84	
Estrogen-receptor status			n.s.
Positive	54	40	
Negative	42	45	
Progesteron-receptor status			n.s.
Positive	58	45	
Negative	38	40	
Hormone-receptor status			n.s.
Positive	63	50	
Negative	33	36	

\*P values for the comparison of numbers of patients were calculated by means of the Chi<sup>2</sup> test. n.s., not significant; Median age: training set (54.2 years; 37.6-83.2), test set (65.7 years; 28.2-86.2), P = 0.052 ; Follow-up: training set (8.0 years; 1 month to 12.2. years), test set (3.1 years; 1 month to 11. years) P < 0.001.

Tumour grade was unknown in six cases.

Hormone-receptor status was unknown in ten cases.

Tumour size was unknown in one case.

Table 3. Frequency of methylated serum DNA in the gene evaluation set.

Gene	Healthy Controls (N = 10)	Primary Breast Can-	Recurrent Breast Can-
		cer (N = 26)	cer (N = 10)
percent positive			
ESR1	0	27	70
APC	0	23	80
HSD17B4	0	12	30
CDH13	0	8	40
ESR2	0	4	20
MGMT	0	4	10
SYK	0	4	10
HIC1	10	39	90
RASSF1A	10	23	80
GSTP1	10	12	60
MYOD1	20	27	80
CDH1	20	20	90

PTGS2	30	39	100
PGR	30	46	80
CALCA	40	50	60
HLAG	60	69	100
BLT1	60	85	100
ARHI	100	100	100
MLLT7	100	100	100
TFF1	100	100	100
SOCS2	0	0	40
SOCS1	0	0	30
TERT	0	0	30
DAPK1	0	0	30
TIMP3	0	0	20
BRCA1	0	0	20
GSTM3	0	0	20
MT3	0	0	20
TWIST	0	0	10
MLH1	0	0	10
CYP1B1	0	0	10
TITF1	0	0	10
FGF18	0	0	10
CDKN2A	n.d.	n.d.	0
HSPA2	n.d.	n.d.	0
PPP1R13			
B	n.d.	n.d.	0
TP53BP2	n.d.	n.d.	0
REV3L	n.d.	n.d.	0
IGFB2	n.d.	n.d.	0

n.d., not done

Table 4. Univariate analysis of methylation status in *training* and *test sets*.

Genes	Training Set (N=24) P Value	Test Set (N=62) P Value
ESR1	0.018	0.555
APC	0.002	0.307
HSD17B4	0.056	
HIC1	0.796	
RASSF1A	0.042	0.014
RASSF1A/APC	<0.001	0.007
ESR1/APC	0.001	0.951
ESR1/RASSF1A	0.032	0.138

\*P values for each variable were calculated by means of the log rank test.

Table 5. Frequency of methylated genes according to clinicopathological features.

Characteristics	No. of Patients	ESR1	APC	RASSF1 A	RASSF1 A and/or APC
		% positive			
Size of tumour					
T1	64	14	11	9	19
T2	17	12	12	19	31
T3 + T4	4	75	25	50	50
Histologic type					
Invasive ductal	55	18	15	11	22
Invasive lobular	10	20	0	30	30
Others	21	10	10	10	20
Tumor grade					
1	38	11	11	13	21
2	32	19	16	16	31
3	10	30	10	11	11
Lymph node metastases					
No	58	12	9	9	18
Yes	10	20	30	20	40
Unknown	18	28	11	22	28
Menopausal status					
Premenopausal	18	28	11	11	22
Postmenopausal	68	13	12	13	22
Estrogen-receptor					
Positive	38	16	11	16	21
Negative	38	16	16	11	27
Progesterone-receptor					
Positive	42	14	5	14	18
Negative	34	18	24	12	33
Hormone-receptor status					
Positive	46	15	9	15	20
Negative	30	17	20	10	31

Tumour grade was unknown in six cases. Hormone-receptor status was unknown in ten cases. Tumour size was unknown in one case. DNA methylation of RASSF1A for one case was missing. Chi<sup>2</sup> Pearson: Tumour size – ESR1 (P = 0.005); Tumour size – RASSF1A (P = 0.049); Progesterone-receptor – APC (P = 0.036); Median age – RASSF1A methylated (79.0 yrs.; 49.6 to 86.2), RASSF1A unmethylated (59.4 yrs.; 28.2 to 82.3.) P = 0.009

Table 6. Results of univariate analysis.

Variable	No. of Patients Who Died/Total No.	Relative Risk of Death (95% CI)	P Value
Size of tumour			
T1	10/64		
T2	5/17	2.2 (0.6 - 7.8)	0.018

T3 + T4	2/4	5.4 (0.7 - 42.9)	
Histologic type			0.296
Invasive ductal	13/55	0.4 (0 - 3.1)	
Invasive lobular	1/10	0.5 (0.1 - 2.1)	
Others	3/21		0.310
Tumor grade			
1	6/38	2.1 (0.7 - 6.7)	
2	9/32	1.3 (0.2 - 7.9)	
3	2/10		0.005
Lymph node metastases			
No	7/58	7.3 (1.7 - 31.7)	
Yes	5/10	2.8 (0.8 - 10.3)	
Unknown	5/18		0.062
Menopausal status			
Premenopausal	1/18	5.2 (0.6 - 42.4)	
Postmenopausal	16/68		0.369
Estrogen-receptor			
Positive	10/38	1.9 (0.6 - 5.9)	
Negative	6/38		0.766
Progensterone-receptor			
Positive	9/42	1.1 (0.3 - 3.2)	
Negative	7/34		0.799
Hormone-receptor			
status			
Positive	10/46	1.1 (0.4 - 3.5)	
Negative	6/30		0.370
ESR1 methylation			
Unmethylated	13/72	1.8 (0.5 - 6.7)	
Methylated	4/14		0.001
APC methylation			
Unmethylated	12/76	5.3 (1.3 - 21.3)	
Methylated	5/10		0.001
RASSF1A methylation			
Unmethylated	11/74	6.9 (1.8 - 26.5)	
Methylated	6/11		<0.001
RASSF1/APC methylation			
Unmethylated	7/66	9.5 (2.9 - 31.4)	
Methylated	10/19		

Table 7. Multivariate Analysis.

Variable	Relative Risk of Death (95% CI)	P Value
Size of tumour		0.19
T2 (vs. T1)	2.7 (0.8-9.3)	
T3 + T4 (vs. T1)	2.9 (0.4-20.5)	0.039
Lymph node metastases		
Yes (vs. no lymph node metastases)	3.9 (1.1-13.9)	

05.11.04

Unknown ( vs. no lymph node metastases)	5.2 (1.2-22.4)	
Age	1.0 (1.0-1.1)	0.06
RASSF1A and/or APC methylated (vs. unmethylated)	5.7 (1.9-16.9)	0.002

Table 8 Sequences of the primers and probes

HUGO Gene Nomenclature	Forward Primer Sequence	Reverse Primer Sequence	Probe Oligo Sequence
ACTB	TGGTGATGGAGGGTTAGTAAGT	AACCAAATAAAACCTTAACCTCCCTTAAT	6FAM-ACCACCAACACAAATAACAAACACA-BHQ1
APC	GAACCAAAACGCTCCCCAT	TTATATGTCGGTTACGTGCGTTTATAT	6FAM-CCCGTCGAAAACCCGCGATTABHQ1
ARH1	GCGTAAGCGGAATTATGTTGTT	CCGCGATTTTATATTCCGACTT	6FAM-6ACTCCGCCAACTTCGCCAAAA-BHQ1
BLT1	GCGTGGTTTATCGGAAGG	AAACCGTAATTCGGCTCG	6FAM-CCGGCGTTTCCGTTACCGA-BHQ1
BRCA1	GAGAGGTTGTTGTTAGGGTAGTT	CGGCCAATCGCAATTATAAT	6FAM-ATTCGCCAATACACAACAAACCAATAAACG-BHQ1
CALCA	GTTTGGAAAGTATGAGGGTGACG	TTCCCGCGCTATAAATTCG	6FAM-CGCCCCACCCGACCTTCGCAAT-BHQ1
CDH1	AATTATTAGGTTAGAGGGTTATTCGCT	TCCCCAAAAACGAAACTAACGAC	6FAM-AACGCAAAACGGCCCGACCA-BHQ1
CDH13	AATTTCGTTGTTGTTGTTGCT	CTACCCCGTACCGAACGATCC	6FAM-ACCCGACCCCGAACCCGCG-BHQ1
CDKN2A	TGGAGTTTTCGGTTGATTGGTT	AACAACGGCCGACACTCTCC	6FAM-CGCGCACACCCAAACCGCTT-BHQ1
CYP1B1	GTGCGTTGGACGGGAGTT	AAACGGGACCTAACAAACGAA	6FAM-CGACCCATAAAACGCCAACGCCG-BHQ1
DAPK1	TCTGTCGTCGTTTCGGTTAGTT	TCCCTCCGAAACGCTATCG	6FAM-CGATAAAAACCGAACGCCGACGA-BHQ1
ESR1	GGCGTTTCGTTGGGATTG	GCCGACACCGGAACCTCAA,	6FAM-CCGACCCAAACGCTCGCCG-BHQ1
ESR2	TTTGAAATTGTAGGGCGAAGAGTAGG	ACCCGTCGCAACTCGAAATAA	6FAM-CGACCGTACGCATCGCCGC-BHQ1
FGF18	ATCTCCTCTCCGGTCTCT	TCGCGCGTAGAAAACGTTT	6FAM-CCC CGT TCT CCG TCC CTT ACC TCC-BHQ1
GSTM3	GCG CGA ACG CCC TAA CT	AAC GTC GGT ATT AGT CGC GTT T	6FAM-AAACTACGACGAAACTCCAA-BHQ1
GSTP1	GTCGGCGCTGTATTAGTATTG	AAACTACGACGACGAAACTCCAA	6FAM-CAACATCGTCTACCCAAACACACTTCCTA-CG-BHQ1
HIC1	GTTAGGGGGTTAGGGCGTC	CCGAACGCCCTCATCGTAT	6FAM-CGCG GCT CAC ACG CTC AAA AAC CT-BHQ1
HLA-G	CAC CCC CAT ATA CGC GCT AA	GGT CGT TAC GTT TCG GGT AGT TTA	BHQ1-CCCAACTTTCGCAACTCACC
HSD17B4	TATCGTTGAGGGTTCGACGGG	GGG AGC GGA TTG GGT TTG	6FAM-CCCGCGCCGATAACCAATACCCA-BHQ1
HSPA2	CAC GAA CACT AC CAA CAA CTC		6FAM-CCG CGC CCA ATT CCC GAT TCT-BHQ1

AACT	CGG GAA GAG TAG GGA ATT TTT AGA GT CACTCTCCGAAACGAAACG	6FAM-ACG CCC GCT CGC CCA CCT-BHQ-1 6FAM-CGAAACGATAACGCCAACGGCA-BHQ-1 6FAM- CCCGCTACCTAAACGCTTACGCG- BHQ-1
IGFBP2	TTA GGG ATT AGC GTT TTG GGA TT CGC CGG TGC GTA GGG	6FAM-AAA CAC ATT CCT ACC AAT CTT CAA AAA ATC GCG-BHQ-1 6FAM-AAA CGC GCG ACT TAA CTA ATA ACA ACA AAT AAC GA-BHQ-1 6FAM- CTCCAAACACCCGACTACTATATCCCGAAA- BHQ-1 6FAM- ATCATCTCCGAAAATCTCAAATCCCAAATAATAC
MGMT	TCTTCGTCCTCCCTAAACG	G-BHQ-1 6FAM-AAA AAT CCG CGA CGC CCT CGA-BHQ-1 6FAM-TTTCCGCCAAATATCTTTCTTCGCA- BHQ-1 6FAM-CCCTCCCAAACGGCCCCA-BHQ-1 6FAM-CTC AAA TAA CGC CGC GAC TCC GC- BHQ-1 6FAM-ACAAATTCCGCTAACGACTATCGCGCA- BHQ-1 6FAM-CTC AAA TAA CGC CGC GAC TCC GC- BHQ-1 6FAM-CCG AAA AAC TCA AAA CAC CGC AAA ATC AT-BHQ-1 6FAM-CCCTAACGCCCGAACAAACG-BHQ-1 6FAM-CCCAATCCCTCCGCCACGTAAGAA-BHQ-1 6FAM- CCCTCCGCCAAATAACTATACTCACTAC
MLH1	CCT CAC GAT ACC TCC CCT CAA CGA TAA ACG AAC TTC TCC AAA CAA	TTATAATTTCGAGGGGGTTAGTGT CCT CAC CCA CGG ACA TCA TC GAGCGGTAGTAGGTAGCG
MLLT7	TAT TTT TCG TAT CGT TTT CGG GTT A CGGAAACCCATCTTCACGCTAA	TTG TTT TTG TCG CGG TGA TT GGCACTTCTCTTAAACAAAC CGAAATCCGGCGAAA ACCTTAATCCAAATCTACTCATATCTA AAA CTCTCCAAAATTACCGTACCGCG
MT3		
MYOD1	TCCGACACGCCCTTCC	TCGAACTCTACTAACTCCGTACTACCGA TCG GAG CGG TGG GTA TAG TTC AATTCCACCGCCCCAAAC- ACACGCTCCAACCGAAATACG
PGR		TAT TTT TCG TAT CGT TTT CGG GTT A CGGAAACCCATCTTCACGCTAA
PPPIR13B		TTG TTT TTG TCG CGG TGA TT GGCACTTCTCTTAAACAAAC CGAAATCCGGCGAAA ACCTTAATCCAAATCTACTCATATCTA AAA CTCTCCAAAATTACCGTACCGCG
RASSF1A		
PTGS2		
REV3L		
SOCS1		
SOCS2	TCC CTT CCC CGC CATT GGGGCGGATATTGGGG GGATTCGGGGTATAAGACGTT	TAAGGGTACGGGTATTTCGTGA GGGTGGGGTTAAGGGTT CGA AAT AAA CCG AAT CCT CCT TAA
SYK		
TERT		
TFF1		
TIMP3		
TITF1		
TP53BP2	ACC CCC TAA CGC GAC TTT ATC GTAGCGGGGAACGT	TGT TTT GTT TTA GCG TTT ACG T GTT CGA TTG GGG ATT AGT TGG T AAACGGAACGAATCATACCAAC
TWIST		

05.11.04

Epigenomics AG  
E30120

Claims

1. A method for determining the prognosis of a subject with a cell proliferative disorder of the breast tissues, said method comprising analysing the methylation pattern of a target nucleic acid comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1 and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in a biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides.

2. A method for selecting a treatment of a cell proliferative disorder of the breast tissues, said method comprising:

- a) determining the prognosis of a subject according to Claim 1, and
- b) selecting a suitable treatment according to said prognosis.

3. A method for determining the phenotype of a subject with a breast cell proliferative disorder comprising

- a) obtaining a biological sample containing genomic DNA from said subject,
- b) analysing the methylation pattern of one or more target nucleic acids comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1 and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in the biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides, and
- c) determining the phenotype of the individual by comparison to two known phenotypes, a first phenotype characterised by hypermethylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation of the analysed target nucleic acid and positive prognosis.

4. A method according to claims 1 to 3 wherein said prognosis is the life expectancy of said subject.

5. A method according to any one of claims 1 to 4 wherein said target nucleic acid comprises the gene APC and/or its regulatory regions.

6. A method according to any one of claims 1 to 4 wherein said target nucleic acid comprises the gene RASSF1A and/or its regulatory regions.

7. A method according to any one of claims 1 to 4 wherein said target nucleic acids comprise the genes APC and RASSF1A and/or their regulatory regions.

8. A method according to any one of claims 1 to 7, wherein said target nucleic acid or acids comprise essentially one or more sequences from the group consisting of SEQ ID NOs: 1 to 5 and sequences complementary thereto.

9. A method according to claim 5 wherein the sequence of said target nucleic acid comprises essentially of SEQ ID NO: 3.

10. A method according to claim 6 wherein the sequence of said target nucleic acid comprises essentially of SEQ ID NO: 5.

11. A method according to Claim 7, wherein said target nucleic acid or acids comprise essentially of SEQ ID NOs: 3 and 5.

12. A method according to Claims 1 to 11, wherein said cell proliferative disorder of the breast tissue is selected from the group consisting of ductal carcinoma in situ, lobular carcinoma, colloid carcinoma, tubular carcinoma, medullary carcinoma, metaplastic carcinoma, intraductal carcinoma in situ, lobular carcinoma in situ and papillary carcinoma in situ.

13. A nucleic acid molecule consisting essentially of a sequence at least 18 bases in length according to one of the sequences taken from the group consisting of SEQ ID NOs: 6 to 25 and sequences complementary thereto.

14. An oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer consisting essentially of at least one base sequence having a length of at least 10 nucleotides which hybridises to or is identical to one of the nucleic acid sequences according to SEQ ID NOs: 6 to 25.

15. The oligomer as recited in any one of Claims 13 or 14, wherein the base sequence includes at least one CpG dinucleotide.
16. A set of oligomers, comprising at least two oligomers according to any of claims 13 or 14.
17. A set of oligonucleotides as recited in Claim 16, characterised in that at least one oligonucleotide is bound to a solid phase.
18. A set of at least two oligonucleotides as recited in any of claims 14 or 15, which is used as primer oligonucleotides for the amplification of nucleic acid sequences comprising one of SEQ ID NOS: 6 to 25 and sequences complementary thereto.
19. Use of a set of oligonucleotides comprising at least two of the oligomers according to any of claims 16 to 18 for detecting the cytosine methylation state and/or single nucleotide polymorphisms (SNPs) within the sequences taken from the group SEQ ID NOS: 1 to 5 and sequences complementary thereto.
20. A method for manufacturing an arrangement of different oligomers (array) fixed to a carrier material for predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues by analysis of the methylation state of any of the CpG dinucleotides of the group SEQ ID NOS 1 to 5 wherein at least one oligomer according to any of the claims 14 or 15 is coupled to a solid phase.
21. An arrangement of different oligomers (array) obtainable according to claim 20.
22. An array of different oligonucleotide- and/or PNA-oligomer sequences as recited in Claim 21, characterised in that said oligonucleotides are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice.
23. The array as recited in any of the Claims 21 or 22, characterised in that the solid phase surface is composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold.

24. A DNA- and/or PNA-array for predicting breast cell proliferative disorders' response by analysis of the methylation state of any of the CpG dinucleotides of the group SEQ ID NOs: 1 to 5 comprising at least one nucleic acid according to any of the claims 14 to 18.

25. A method according to any one of Claims 1 to 4 comprising the following steps:

- a) obtaining a biological sample containing genomic DNA,
- b) extracting the genomic DNA,
- c) converting cytosine bases in the genomic DNA sample which are unmethylated at the 5-position, to uracil or another base which is dissimilar to cytosine in terms of base pairing behaviour,
- d) amplifying at least one fragment of the pretreated genomic DNA, wherein said fragments comprise one or more sequences selected from the group consisting of SEQ ID NOs: 6 to 25 and sequences complementary thereto, and
- e) determining the methylation status of one or more genomic CpG dinucleotides by analysis of the amplicate nucleic acids.

26. The method as recited in Claim 25, characterised in that Step e) is carried out by means of hybridisation of at least one oligonucleotide according to Claims 14 or 15.

27. The method as recited in Claim 25, characterised in that Step e) is carried out by means of hybridisation of at least one oligonucleotide according to Claims 14 or 15 and extension of said hybridised oligonucleotide(s) by at least one nucleotide base.

28. The method as recited in Claim 25, characterised in that Step e) is carried out by means of sequencing.

29. The method as recited in Claim 25, characterised in that Step d) is carried out using methylation specific primers.

30. The method as recited in Claim 25, further comprising in step d) the use of at least one nucleic acid molecule or peptide nucleic acid molecule comprising in each case a contiguous sequence at least 9 nucleotides in length that is complementary to, or hybridises under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOs: 6 to 25, and complements thereof, wherein said nucleic acid molecule or pep-

tide nucleic acid molecule suppresses amplification of the nucleic acid to which it is hybridised.

31. The method as recited in Claim 25, characterised in that Step e) is carried out by means of a combination of at least two of the methods described in Claims 26 to 30.

32. The method as recited in Claim 25, characterised in that the treatment is carried out by means of a solution of a bisulfite, hydrogen sulfite or disulfite.

33. A method according to any one of Claims 1 to 12 comprising the following steps:

- a) obtaining a biological sample containing genomic DNA,
- b) extracting the genomic DNA,
- c) digesting the genomic DNA comprising one or more of the sequences from the group consisting of SEQ ID NOs: 1 to 5 and sequences complementary thereto with one or more methylation sensitive restriction enzymes, and
- d) determining of the DNA fragments generated in the digest of step c).

34. A method according to claim 33, wherein the DNA digest is amplified prior to step d).

35. The method as recited in any one of Claims 25 to 32 and 34, characterised in that more than six different fragments having a length of 100 - 200 base pairs are amplified.

36. The method as recited in any one of Claims 25 to 32, 34 and 35, characterised in that the amplification of several DNA segments is carried out in one reaction vessel.

37. The method as recited in any one of Claims 25 to 32 and 34 to 36, characterised in that the polymerase is a heat-resistant DNA polymerase.

38. The method as recited in any one of Claims 25 to 32 and 34 to 37, characterised in that the amplification is carried out by means of the polymerase chain reaction (PCR).

39. The method as recited in any one of Claims 25 to 32 and 34 to 38, characterised in that the amplificates carry detectable labels.

40. The method according to Claim 39, wherein said labels are fluorescence labels, radio-nuclides and/or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer.

41. The method as recited in any one of Claims 25 to 32 and 34 to 40, characterised in that the amplificates or fragments of the amplificates are detected in the mass spectrometer.

42. The method as recited in any one of the Claims 40 or 41, characterised in that the produced fragments have a single positive or negative net charge for better detectability in the mass spectrometer.

43. The method as recited in any one of Claims 40 to 42, characterised in that detection is carried out and visualised by means of matrix assisted laser desorption/ionisation mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

44. The method as recited in any one of the Claim 1 to 25 or one of the Claims 25 to 43, characterised in that the genomic DNA is obtained from cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof.

45. A kit comprising a bisulfite (= disulfite, hydrogen sulfite) reagent as well as oligonucleotides and/or PNA-oligomers according to any one of the Claims 14 to 15.

46. A kit according to claim 45, further comprising standard reagents for performing a methylation assay from the group consisting of MS-SNuPE, MSP, Methyl light, Heavy Methyl, nucleic acid sequencing and combinations thereof.

47. The use of a method according to any one of claims 1 to 12 and 25 to 44, a nucleic acid according to claim 13, of an oligonucleotide or PNA-oligomer or a set thereof according to any one of claims 14 to 18, of a kit according to Claim 45 or 46, of an array according to any one of claims 21 to 24 or of a method of manufacturing an array according to claim 20 in the prognosis, diagnosis, treatment, characterisation, classification and/or differentiation of breast cell proliferative disorders.

06-11-04


Epigenomics AG  
E30120

### Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for the prognosis and treatment of a cell proliferative disorder of the breast tissues.


13  
06.11.04

Figure 1




223 05.11.04

Figure 2



3/05.11.04

Figure 3



05.11.04

Sequence listing

<110> Epigenomics AG

<120> Prognostic and diagnostic markers for breast cell proliferative disorders.

<160> 25

<210> 1

<211> 3501

<212> DNA

<213> Homo Sapiens

<400> 1

gcggggctgg	caggggcgt	ccccctggcac	agctcggggc	ctggcagcgg	cgggtggggc	60
atcggtctaa	agctgccacc	cccgcgggga	ggggagcccg	ccccgcgggg	accgcaggta	120
acggggcccg	ggcccccgcg	ggccaggagg	ggaacgggg	cgggcgggcg	agcagcgccc	180
aggggagctc	agggctcgcc	tccgggctct	gccgcccggat	ttggggggccg	cgaggaagag	240
ctgcgagccg	agggcctggg	gccggcgcac	tcctcccgcc	ctgtctgcag	ttggaaaact	300
tttccccaag	tttggggcgg	cggagttccg	ggggagaagg	ggccggggga	gccgcggagg	360
gaggcgccgg	gcccgcgcgt	gtagggccca	ggccgaggcc	gggacgcggg	tggggcgcag	420
gcccgggtca	ggccgcgcgc	cggctgtgcg	ccgtgcccgc	ccggggcgct	gccccctccc	480
tccccctggg	gctgcgtggc	tccccctcc	cccccacctg	cttcctgcct	cagcctcctg	540
ccccgatata	acgcctccc	cgccggggc	ccggcctcg	cgctctgccc	gccacggcag	600
ccgctgcctc	cgctcccccgc	cgccgcgcgc	cccgggccccc	gaccgagggt	tgacagcccc	660
cggccagggc	ggcgcgcagg	cgggcacccgc	gtccccctcc	tccgtatcac	ttcccccaac	720
tggggcaact	tctcccgagg	cgggaggcgc	tgggtcctcg	gtccccttc	tcctactttg	780
gttaaagttc	tccgcctga	atgactttc	ctgaagcgg	cattttactt	aatcggtta	840
actgttccaa	aaaggtcac	tgccctgtaa	cagttttttt	ctcgaaagcc	ccagcaccca	900
gccaggtgcc	ctggggcggt	caggccccc	tggctccccc	tccacccggc	gccgctcacc	960
tcctgtctct	tctcttggtc	cgggggggcc	ggcctgggt	cccaactccag	agggcagccg	1020
gtccttcggc	ggtgcggcagg	ccgcagggt	gatgcccccg	ctcagctgag	gaaaggggaa	1080
gtggaggggg	gaagtgcgg	gtctggggca	ggccggccagg	gcccgcacg	gtctcaccc	1140
ggccgggtgt	tgtcccgca	ggagagtgt	ctgggcagac	gatgctggac	acatggagg	1200
cggccggcca	ctccaggcg	ctgctgtgc	agtcacaaca	ccagcgcacc	aaggcttct	1260
tgtgcgacgt	gateatcg	gtgcagaacg	ccctcttccg	cgccgcacaag	aacgtgtcg	1320
cggccagcag	cgcctaccc	aagtccctgg	tggtgcatga	caacctgc	aacctggacc	1380
atgacatgg	gagcccgcc	gtgttccg	tggtgcgtga	tttcatctac	accggccgc	1440
tggctgacgg	cgcagaggcg	gtgcggccg	cgccgtggc	cccgggggct	gagccgagcc	1500
tgggcgcgt	gtggccgccc	gccagctacc	tgcagatccc	cgacctcg	gcgcgtgtca	1560
agaaacgcct	caagcgccac	ggcaagttact	gccacctgc	ggccggccgc	ggccggccgc	1620
gcggctacgc	gccatgtgt	cgccggggcc	ggggcctgc	ggccggccac	ccggtcatcc	1680
aggcctgtca	cccgccccca	gtcgggctc	cgccgcgc	tgcggggag	ccgcctctcg	1740
gcccagaggc	cgcgtcaac	acgcactgc	ccgagctgt	cgctcg	cccgccccgg	1800
ccgcccact	ctgtgcctcg	gagcgcgt	gtctccctct	ttgtgcct	gacctgtcca	1860
agaagagccc	gcccggctcc	gcggcccg	agcggccgt	ggctgagc	gagctgcccc	1920
cgcccccgg	cagccctccc	agcgcggcc	ccgcgcctca	caaggagcc	cctctcgccc	1980
tgccgtcgct	gcccgcgt	cccttcaga	agctggagga	ggccgcacc	ccttcgacc	2040
catttcgcgg	cgccagcg	agcccggac	ccgagcccc	cgccgc	gacgggccta	2100
gtctctctta	tgcgtggat	aagcacgac	cgccgc	tagctatgg	gacgagctgg	2160
gcccggagcg	cggctccccc	agcgagcg	gcaagagcg	tggggggac	gcccgcgtct	2220
cgccccgggg	gccccggctc	ggcctggc	cgccgc	ctaccctgg	agcctggac	2280
ggcccgccgc	ggccggcgac	ggcga	actaagagcg	cagcaggag	accggtagca	2340
gcgaggaccc	cagccgcct	ggccgc	acc	ccatgc	cacctggc	2400
atggcgaccc	cgcacgttc	gtgt	gacaacc	tgtacgtgt	cattccgt	2460
tccccagctc	tgcgcgt	aacgcgc	tggaggctca	cgtggaggag	gaggaagcgc	2520
tgtacggcag	ggccgaggcg	ggcga	gtgg	ggctca	ggggccccct	2580
ttggaggcgg	cggggacaag	gtcg	ccctgggtgg	cctgggagag	ctgctgcggc	2640
cctaccgcgt	cgcgtcg	gacaagagct	acaaggaccc	ggccacgc	cgccagc	2700
agaagacgca	ctggctgacc	cgcccttacc	catgcacccat	ctggggaa	aagttcacgc	2760
agcgtggac	catgacgc	gccac	cttc	tcgcgt	ttcgacgc	2820

- 2 -

acgcgtgcgg	catgcgggttc	acgcgcagg	accgcctcac	ggagcacatg	cgcacatccact	2880
cggcgagaa	gccctacgag	tgccagggtg	gcggcgccaa	gttcgcacag	caacgcaccc	2940
tcatcagcca	catgaagatg	cacgcgggtg	ggggcgccgc	cggcgccggcc	ggggcgctgg	3000
cgggcttggg	ggggctccccc	ggcgccccgg	ccccgacgg	caagggcaag	ctcgacttcc	3060
ccgagggcgt	cttgcgtgt	gtcgcctca	cggccgagca	gctgagctg	aagcagcagg	3120
acaaggcggc	cgcggccgag	ctgctggcgc	agaccacgca	cttcctgcac	gaccccaagg	3180
tggcgttgg	gaggctctac	ccgctggcca	agttcacggc	cgagctggc	ctcagccccg	3240
acaaggcggc	cgaggtgctg	agccaggggc	ctcacctggc	ggccggggcc	gacggccgg	3300
ccatcgaccg	tttctctccc	acctagagcg	ccccctgcca	gcccgtctg	tcgtgtctgc	3360
gccccctgg	cccgccacccc	agggagcggc	ggggcgccgg	cgcagggccc	actgtccccg	3420
ggacaaccgc	agcgtcgcca	cagtggcggc	tccaccttc	ggcggccctca	cctggcctca	3480
ctgcttcgtg	ccttagctcg	g				3501

&lt;210&gt; 2

&lt;211&gt; 2501

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 2

tttccatagt	gtaaatgtgt	tcccaccact	ctctggagta	atcctactta	aaaccgtttt	60
cagcacaaaa	ttcaaaacatc	taaacatgtat	cttgcgtggc	ttgcgtttgt	ggctttaccc	120
tctttctccc	caaaccttagc	tagtgtttgt	gctgcctgt	atgccttctt	tttcttgcag	180
gggtcgccac	tttaggtcct	ggtcctccct	cagaaagttt	ttcccttcttc	tccccagcgg	240
ggatagggtc	tgttattttt	gacaccattt	gctcacttac	acacatttgg	cacaagtcta	300
ggctgcaccc	ttatttggaaag	tttaccatct	gactctgagt	agcttggagga	tcctatcaaa	360
actcaggaga	tgctcagtaa	atgttgattt	aactatgact	gttctcaaca	tacaaacgca	420
agatcattt	ggaacacttg	tcaaaatgtt	tttgccttctt	gagattctat	tttgggaggt	480
aagcagtggg	ggtccaggac	tctgcatttt	gacagtcccc	tgatgtttgc	atgtagaagt	540
gcagggattt	ttacactgac	aaatctttac	catccctaag	ggggactttc	cttcccaggg	600
gctatctctg	gaagccccctc	aaggataggg	gccgcattgt	gtttctctag	gtcagcaact	660
aaacccagaa	aacgttttatt	gagtgaatga	tgaaacgaca	ggtgaataga	tgaacgcgaag	720
gtgtcgagtt	aactattctt	ctacacaatgt	cctagcagct	ccatttgcctt	ccagccgcag	780
aaatggcccc	ttggaggccaa	gtttccacgc	gatggagtc	actcttaact	acatttcccc	840
ggatttccaag	ggagccgcgc	gctctgcgt	catttccca	ccagaaatcg	gcaagtcaact	900
gaccctcgcc	ccgccccccgc	cattcccccgc	ctccctctgt	cccgcaatcg	gcgtccagcg	960
gctctgttt	ttcgtgtgt	tgcgttgc	ggccttattt	atgggctcac	cgctgaggtt	1020
cgacggggcg	gtggacttgg	tcacccggc	ggggcgaggt	gagcatgca	agtttgagg	1080
ccgcgccttcc	tgctgaggcg	cagctggct	ctctttcgg	gccggcatac	gcccgcagcc	1140
gcagctgagg	tcaccccgct	gaggtggtgg	ggaggggaat	gttatttctt	gaggcaccgc	1200
atctcttgcg	gagggaaagag	ccggaaacac	ctgtctctc	aagcaggtac	agcccgcctt	1260
tccccagcac	cccggtgtgg	gtttcccaag	gtctctgcctg	agaggagagg	ccaggctggg	1320
ctgctgtattt	caaaactggg	tgaaagtctt	ccctgaccct	tatctgtggg	catcgattgt	1380
tactcttctt	gcaattaact	ctcttagatc	tttgccttagt	ctttaaagg	actgaaaagc	1440
cgcgaggggc	gggggcttgg	attttcccc	tgaagcgcag	agatgtcagc	tcctgaaaag	1500
tcattcggtc	gttcaagtgtt	ttttccctc	tgcgttaaga	tttaagttc	gtgagaggac	1560
tttcctttaaa	gagggcgtct	gataagagcc	cttccccgtt	ggagtttgt	tgcttagcaa	1620
gtcacaatct	gttctcgaaa	tccactggag	tcttggcag	gtttaaggc	tcaaattgcgc	1680
acaggggtca	ggcgtatgtat	ggagaaaagaa	aatggagta	ggatgggcac	atctgagggaa	1740
ctggagagca	gagaatttccg	aagtggaccg	gccagttggg	aagtgcctg	tatccagaa	1800
gcggcaaaat	ggaaaattgt	tatgtgaaat	agcccccattt	tttaaagtac	aaaaaaattaa	1860
aacaaadcat	tcataccaaac	atagatgtcg	tgcaatggaga	ttttacatta	gtttctcacc	1920
agtgggtgac	ctctgttaacc	tccaaatgtca	ggatcttgc	cattatgcac	ctttgatttct	1980
ccactggtag	tacccatatac	ctggaaaggc	cctaattgcac	gaatttatttgc	agttatataat	2040
taaacgttac	aaactggaaat	tctgtcaattt	aatccatgt	tacttcata	tctgtatttgc	2100
taaagtggct	tctttagtgc	ccttcagaa	aatgtttca	gtgttgcgt	atagccaaat	2160
attttataacc	catagctgtc	ttgttatctc	tgcatggc	tgtatttggg	tgttagtcat	2220
ccttctaaat	gttttttagga	aaacattttgc	tttacactt	gttttatttgc	taaataatgt	2280
attttacaac	gttgggtgtt	ttaaatcttt	tttgacagct	tttgcataat	tttcatgcac	2340
gaggtccagg	gattacattc	taagacgttt	ttgcgcac	taaggagact	ttccctttca	2400
ggggctatata	ctggaaatca	ttcaaggata	ggactgtctt	ttttgacac	cattagcata	2460
cttacacatg	gtatgcgtta	cattttacac	cagtactcag	t		2501

<210> 3  
 <211> 2470  
 <212> DNA  
 <213> Homo Sapiens

<400> 3

aaagatgatt	aaaagtttaa	ttgttcatct	gaagagttga	tttttttatt	cctgtataaa	60
agggtaactt	tagcagtctc	tgctcatctt	gcccatccgg	ctcttttgt	ggttgtgtaa	120
ggttataact	tctgtgtctc	agtaaaacttg	tgcatgccc	ttttttctc	tgttactacc	180
ttttcttta	ttttgtttta	ttatttgtat	gtaaaattac	ctgttaattt	tatttgaaat	240
gagaaaattt	aagttcaca	ttattcaaat	tctgtcagat	ccctacact	gtcatatgtt	300
ttataatgtt	ctgggttattt	tcagacctgc	ttattaaaaa	gatgtaaaac	aaaataatga	360
tcactcctgt	ggattttcc	tttattttt	agatgtctcc	tttggtgc	ttacttctc	420
acccttgcc	cattgatcag	aggaggggtc	ttaactatgg	gtgaacccta	tatcttactg	480
aagaggttat	gttacatgt	tatttcata	atataactta	catttacata	gtacttttat	540
tttttagcata	cctttttta	ttaatctaa	taatatcact	gtaagttatg	ttgaagcaga	600
ttgttaagtgt	tcatttacaa	attgtgaaat	gaattaaaat	gaaaggc	agattaaatc	660
atgaccaggg	ctgaaattaa	cacacaagac	tcaattttt	tcaaccaaag	actttttag	720
gtgatccctg	cctgcaggac	tcccttcct	cctcagatgt	cattggattt	taccagg	780
actgttagatt	ctagccgtt	tagaactaac	tagatctaag	atgatcccc	tgatttcctt	840
tggtagagtc	ttccaattgc	tgaactccaa	tattgtcg	actagccagt	gttacaac	900
gtctgcctt	ttttgtgtaa	tggatttcat	attacagagg	catttttta	atgtcaagat	960
gtttaagtat	tgcttaagt	caaactactt	aataactttt	agctattaag	taattaagat	1020
aggcaggatt	ttatttgtt	caaaatgatt	tgacctaaac	taaaaagaga	atgtggatct	1080
cctgaatctt	acttggtaa	tcttaatata	actcctagca	ttctataatt	cttcctaaag	1140
tcctcttacc	tggctatctt	ttgtatctt	tttgtctct	ctcttctt	ccagtcataa	1200
taactgcac	actctgc	atttctttt	gacagtct	actcctaagg	tcatccatc	1260
tcttttagta	tctttggcc	tcagttt	gacagcagat	cccaagacca	catatgc	1320
agcatagct	attatagtca	acctttt	taaatgtat	tgaacttt	gttagtaatt	1380
cttatttacc	atcttctat	caaaaaggct	taaagtct	atthaatgt	ctccttcatg	1440
tccattttgt	taaatgattt	cctttttaat	acatctt	acttcagaac	tatttcacca	1500
tggaggatgt	gtaagattt	ccttttatca	aataaaaat	gtgaaatgga	atatgtatc	1560
tcattatcc	attctggct	taaaaatct	tgactatc	ataaaaattca	gaaataaaaat	1620
agtattacta	atataaataa	attttatca	taatttatatt	tcctaagttt	tgctgtaa	1680
aatggtaaa	atatctttaa	aaccttgaag	aaattattac	ttgatagaaa	gtttaatcca	1740
tctgtgagaa	ggcaaattgt	ttcagacaca	actaaatgtt	tctttctat	ttaatttca	1800
tttatcttga	actaagactc	cactgttca	tcctctt	tgctgtact	tgaacaat	1860
tgttttggaa	ccaaaaacta	gcatattaa	acaatttctt	ttaaacgtt	taagat	1920
gtttccttta	cccccttctt	taaaaacaag	cagccactaa	atttttat	agtgaattt	1980
aaaatccctt	ttaaccttat	aggccaagg	gtagccaagg	atggctcag	cttcatat	2040
tcagttgtt	aagcaagtt	aggcactgaa	gatggagaac	tcaaatctt	gacaagagat	2100
agaagataat	tccaaatc	ttacaaaact	gaaaactgag	gcatctaata	tgaaggat	2160
aagactgtt	cttttattt	tagtttatcc	attttattt	agtattcc	tttgcataa	2220
tgaggtt	cactttactt	aaaagtgtat	tttaaattaa	gcaataat	gtaaactt	2280
tcttgcaaaa	gttagcattt	atattttaa	ataagatata	ttgaattcat	tcaatgtatc	2340
atataaagaa	aataagtgt	aaactccat	ggcttagtt	ttcttagt	tttttaagat	2400
taaagagaag	agaccaaata	tagcatact	gtactgagg	aagg	ttctgttct	2460
tagaaaactag						2470

<210> 4  
 <211> 7001  
 <212> DNA  
 <213> Homo Sapiens

<400> 4

aatgcaatgg	aaaaagagag	attgtaaagc	tagaaggctt	aggaattgcc	tcttgattag	60
gtgtggaaagg	caagggaaaa	tcagccctcg	aagaagacag	tgagatttta	atctgggtgg	120
ctggagagac	agtatgtct	ggcacagaca	cggggaaagt	gagagaaca	ccatgtttga	180
gaatggtgc	tcatatttga	acaaggctgc	aatgcccagg	agaccgctgg	aaaagtgggg	240
ctggagacac	attcaacgg	ggagccagat	caatcttac	ccttctt	cacatgtatc	300
cagtaatgtc	cggctggaaac	gtgtgtgtcc	agcaggagag	ggtagggagg	gaagccaaaga	360

gagctggggag cccgagtgaa gtttttgc aaggcagaag agaaagtgcg gcgtgcaca	420
gtatacttc ccacccatgc tcaccaagcc cagggacaag gtcaccaag atgagtttg	480
aagagaatgc tgagagaaa gtgttaaga aaactgcct tactgaactt ttggctaa	540
cttggattgt aagtctctga acaatcaaag cctgtgagga gacagctaac ttcttattc	600
ttcctatgtc aatagtgaac aattgcagat ccccttctt ttccctctcc ttccctgt	660
tcctctcc tccctccctg aatactctt ctttttctg ggactggct agagcatggg	720
tggcattgt tgacctacag gaggcaccac tgcaccaac aaaggtaac agtcttttt	780
ttcaatattt atttatatcc agtattttt tcacatactg actatggaga gagctctctt	840
gtgctcaaac actgcaatac tgggggtctt tcaaagcaca aaaacatata ttgcatt	900
ggcatcatta acattttat ggcttctat ttcttttt tactggctc aagagccact	960
cataaatctc tcaactgcatg ctagtgc cagggccaga gacggccac ttctggcatt	1020
gtgatttagag tcaattaa tccaaagggg tgactaatgt ctggcaacaa agcctccatt	1080
gggtgtcatg tggctggga ccctgagct gggactcta ggagcacctc agtattgcgt	1140
gttagacta tggccgagag aataggtag aagtggtca agagtggt ccatgtgaac	1200
gccactgggaa atgagagac ctgcgtccca atcacggta gtcaactcg aaagcctaaa	1260
atcagttaa aacaaaggta tctacctta tcttatgttc atacctagg ctttaataa	1320
tcacatgtt acagaaagca gtcaactgag ctattcatgg aaagggttgt	1380
gggtttgggt aacgaagtgg aggagatata catttcagct ggaaacacat ccctagaatg	1440
ccaaaacatt tattccaaag tctgggttcc tggtgcattt ggaggcatgg caatgcct	1500
gttcagagac tgggggtctag gcccagtaag gcatttgatc cacatgtatc ccagaaggct	1560
tttatgtta aattatattc ttccggaaaa accacccatg tcctattttg taaacttgat	1620
atccatacac tttgactgg catttattt tagccgtaa actatgattc acagcaagcc	1680
tgttttctt ctgcgttggg gtggcagcag aaagcatagg gtacttcca gcctccaagg	1740
gtagggcaaa gggggctgg gtttctctc cccagtagt ctttctctgg ctgtgcacca	1800
ctgcctccctg tgagcagaca gcaagtc tccactccc cactgcatt catccagcgc	1860
tgtcagtag cccagctgcg tgcgtccgg gaggggtctgc caagtgcct gcctactggc	1920
tgttcccgaa atccctgcca ttccacgcac aaacacatcc acacactctc tgcctact	1980
tcacacactg agccactcgc acatgcgagc acatccctc cttcctctc actctctcg	2040
cccttgactt ctacaagccc atggAACATT tctggaaaga cgttcttgat ccagcagggt	2100
aggctgttt tgatttctct ctctgttagt ttagcatttt gaaaagcaa cttaccttgc	2160
tggctagtgt ctgtatccta gcagggagat gaggattgt gtttcttgat ggggtatgt	2220
tgtgtctct ttttcttca ggactttagt gatttttttgc ccatggca tataatttg	2280
cagggtcaca ttttttaaga gcccattgaa gtgttttttgc catgtttttt aaaaaggcat	2340
ttgaaaattt aaggtgtat ttatggaaat taaatcatct gtaaaaaatt gtttggaaa	2400
gtaatgattt ctggccataa agggaaatat ctgcgtatca cctaattgtgt ttttaccct	2460
ttatttgcg acaatctata gtcattatg taaaactcga ttttggcttca agtacattt	2520
gcatattgtc caacaatgtt ctattttttgc aagaatttgcg taaaatgtat acttgatata	2580
aaatagtcaa aaatgtact cttagtaaca gtaagctgg catttagata gaccatgaac	2640
acttcgtcag atactctgtt ggggttttttgc gatagcaatt aaacaaagg attgatagt	2700
gtatcagagt ctatttaggtt gcagcaaaagg aagtttatttca aaaaaggata actatccaag	2760
atttagacg catgatatac ttccacctatt ttttgcatttca ttaatatgtat tatataatata	2820
tatataatata tatatacaca tataatgtgt tttgtatgtg cgtgtgcattt ttttactttt	2880
aattcgtta aaaactttt tctatttttttgc tttcatctgg atatttgatt ctgcataatcc	2940
tagcccaagt gaaccgagaa gatcgatgg taggactaaa ggatagacat gcagaaatgc	3000
attttaaaaa tctgttagt ggaccagacc gacaatgtaa cataattgcc aaagctttgg	3060
ttcgtgacct gaggttatgt ttgttatgaa aaggtcacat tttatattca gtttctgaa	3120
gttttgggtt cataaccaac ctgtggaaagg catgaacacc catgtgcgc ctaaccaaag	3180
gttttctga atccatcttc acatgagaat tccataatggg accaagtaca gtactgtgt	3240
ccaaacataaa cacacaaatgc aggctgagag aatctcagaa ggttggaa gggctatct	3300
acttggggag cattttgcag aggaagaaaac tgaggctctg gcaggttgc ttcctctgt	3360
ggcaaaatgc agtctttctt atatgtatac cctgaatctc cggcccttc ccctcagatg	3420
ccccctgtca gtcccccctc cgtctaaata tagctgtctg tggctggctg cgtatgcac	3480
cgcacacccc attctatctg ccctatctg gttacagtgt agtctccccc agggctatcc	3540
tatgtacaca ctacgtatcc ttagccaaacg aggagggga atcaaacaga aagagagaca	3600
aacagagata tatcggttgc tggcacggg cacataaggc agcacattag agaaagccgg	3660
cccttggatc cgtcttcgc gtttatttttgc agcccagtct tccctggcc acccttagca	3720
gatcctcgat cggcccccgc ccctggccgt gaaactcgc ctctatccag cagcgcac	3780
aagtaaagta aagttcaggaa aagttgtctt tggatgc tccaaatcg gttgtcctg	3840
gagtgtatgtt taagccatg tcaggcagaa gcaacagtc ctggccgtcc tccagcac	3900
ttgtatgc tatgagctcg ggagaccatg acttaaagtt ggaggccgg gagccagga	3960
gctggcggag ggcgttcgc ctggactgc acttgccttcc gtcgggtcgc cggcttcac	4020
cgagcccgca ggctcccccgg gcaggccgg gcccagatgc cgcgtgcgg cggacatgc	4080
qctqgtcgc ctctaacatcc gggctgtgct cttttccag gtggcccccgg gtttctgag	4140

ccttctgccc	tgcggggaca	cggctctgcac	cctgcccgcg	gccacggacc	atgaccatga	4200
ccctccacac	caaagcatct	gggatggccc	tactgcatac	gatccaagg	aacgagctgg	4260
agccccctgaa	ccgtccgcag	ctcaagatcc	ccctggagcg	gcccctggc	gaggtgtacc	4320
tggacagcag	caagccgc	gtgtacaact	accccggagg	cggcgcctac	gagttcaacg	4380
ccgcggccgc	cgccaacgcg	caggcttacg	gtcagacccg	cctccctac	ggccccgggt	4440
ctgagggctgc	ggcgttcggc	tccaaacggcc	ttgggggttt	ccccccactac	aacagcgtgt	4500
ctccgagccc	gctgatgcta	ctgcacccgc	cgccgcagct	gtgccttac	ctgcagcccc	4560
acggccagca	ggtgcctac	tacctggaga	acgagccca	cggctacacg	gtgcgcgagg	4620
ccggccgc	ggcattctac	agttacccgc	gcccgcgc	ccgcgcggg	tggccgcgc	4680
gcccggcagg	agggagggag	ggagggaggg	agaagggaga	gcctagggag	ctgcgggagc	4740
cgggggacgc	gcaacccgag	ggtgcgcga	gggagcccg	ggcgcgcgc	ccagccccc	4800
ggttctgcgt	gcagcccgog	ctgcgttacg	agtcaagttc	tctcgcggg	cagctaaaaa	4860
aaacgtactc	tccaccact	taccgtccgt	gcgagaggca	gaccgaaag	cccggttcc	4920
ctaacaaaac	acacgttgg	aaaccagaca	aagcagcagt	tatttgtgg	ggaaaacacc	4980
tccaggcaaa	taaacacggg	gctgttgag	tcacttgga	aggtctcgct	cttgcattt	5040
aaagttgggg	gtgtttggag	ttagcagagc	tcagcagagt	tttatttac	ctttatgt	5100
tttgtttaa	tgtgtcccc	aaatttcctt	tcatctagac	tatttgattt	gaaatatgtc	5160
agctatgatg	atgactttct	ggaaagcgat	tcctgtcacc	cgcttcccc	tcctcccccac	5220
cccaacgtct	ggggctttag	agagcgttgg	ggagttgaat	gggtctgatt	tcggagttag	5280
ctggctgagt	ccgcgttgg	gcggattgct	ggcatgtgac	ttctgacagc	cgaaaaattt	5340
ctggctccc	gcgagttaa	aacaagccat	atgaaagcac	aagtgtttaa	aaataatctc	5400
ctggccagcc	agtgacaagc	ctgtcccacc	cggggagaat	gccccggagt	ggcgtgcggg	5460
tcagccaggg	tctgcgcctc	gcagccactg	tggaaggagc	gcggccggc	caggacacag	5520
gagaccactt	tgtgacttca	atggcgaagg	ttgtgtgtcc	tcattttat	ttttttccct	5580
acaagaattt	ttctttctcc	ctctcctctc	cctcccaattt	tctcttgccc	agtttctct	5640
tttgtttttt	gttttttgg	ttcctgatgg	gcctgcagag	ggatttaggt	ggcgttctg	5700
gtgaacacct	tccttaggtt	ccacaggaca	gggttacccc	ggactgggtt	tggaagcttc	5760
agggcccac	atggctgggt	cctgaattag	gcatttccca	actgtacact	ggtatccgga	5820
ctgggttccc	tatatttttc	tgccttgtaa	gcccgtggacc	agttttgtt	cagtattctg	5880
tttccaggga	tatattatac	agaaggaagg	ggactaaagt	gcagtttggc	cccaagggat	5940
actgaagggc	agattctgg	ggtattcagt	gtgcatttcc	agccgcctt	gagaaattta	6000
gagcatccca	cagccacgc	gatccaagct	gtctttactc	aaaagacaaa	caatgaacaa	6060
aactttaaa	ggttggcata	tttcaaattt	attttactt	ttttaattt	gggttaaaac	6120
agagaaaaag	gatttcttct	gcccacctt	tttttttaa	atggaagaac	aaagtacagc	6180
gattaagtct	aattccacac	aacattttaa	actgcttgc	gtgaaggaag	gcactggat	6240
gatgtgaatt	ccataaccc	atgatggact	ccagaaacca	ttttcttccc	tatattaaattt	6300
tcagttctt	tattgcaaat	taatgctgt	gaatttcaat	gggcactaat	gagactgctc	6360
cttggtagat	tatattactgc	cttgcataata	attacaaagt	gaacctggtc	aaatacagag	6420
gggatcgcat	cttattcaaa	attgttcatc	atcccagtga	taagtggat	cagtgtataa	6480
tgccctatct	tacactttct	gcattacatg	atattcaaaac	actcttagaa	taataaaaaaa	6540
agagacaagg	aactttaaaa	ttaaaaaaaa	aacttgccaca	aatgggactc	tgtgtggaaa	6600
ttcagtttta	gaatgatttt	tccctgtgtt	tatttcccg	attatcttcc	ctctttgtt	6660
agaattctgc	ctgttattat	ccagcaagga	aaagaagcat	ctatgcaga	tcttcatatg	6720
gacagatatt	attagtatt	tttccctct	cagttttct	gcttaaatga	ctctgggtat	6780
aaaggaaagg	attgattgg	ctcttttagg	aaactttaag	tttcttaagt	agttctcaaa	6840
agtttgggg	ctgaaagcag	tgtttcaaa	ctgcttgc	tgacccagag	ggtcatgaac	6900
tcagtttagt	gagtctagaa	tattttttaa	aaggactaaa	atggaaagga	atataataga	6960
aaatatcaga	gtgcattgtta	tttgcgttgg	ataagtttt	tg		7001

<210> 5  
<211> 11001  
<212> DNA  
<213> Homo

≤400> 5

ccaagtcaga tggcccccgg ttacctgtgg acaggtcagg catattctga gtctaatggc	60
actccacagg cctaatacct tggagccaga aagcttccag gtaaaaagtc tgaagggggc	120
ctccatgtt cattagatgg actccatgtt ctccagaaga ttttccacac cagggaaat	180
caaaggccca aggcaattct tcctggcttc ttggacaac cctaggcttt ggcattgt	240
gtctggaaac ctttgcattt gttacaatgc ctatacactc ctggaaactgt ttgcagggc	300
ttgtcttcca gcacaattcc tcctccaaggc ttactgttag ctacagccca tcagtccgt	360
ctagtgacaa ccaagaaact aagaactatg tactcacgtt caccccccgg gagtcatgg	420

ccttcaggac aaagctcagg gccttgtcac tggccctgc caggagccgc agccgcaggg	480
gctgctcatc atccaacacgc ttccgcaagt acactgtgaa gggaaagtaa tgatcagaga	540
cagggccagc tgctcagccc ctgcgtc aggtgcgtc gtatataccc tcacataggg	600
cagggtgggg tggaaagccc accttgccc tgacgctcg cgcgtcaaa gagtgc当地	660
ttgcggggcatccaccac caagaacttt cgcagcaggg cctcaatgac ttcaacgtgc	720
cttgtgcgtg acagcacatg caggtgtttt acagcatcct tggcaggta aaaggaagtg	780
cggccctga cacttgtgcc cctgttgcggg cccgcggg catcctgca ggagggtggc	840
ttcttgttgg aggacacaga gacagggcgc accagctca gctgaacctt gatgaagcct	900
gtttaagaac cgtcctgtt ctaaagaaat agagaaacca aaccttgata ataggttcca	960
ggtagatgt cagtctactt gggcttaggc tgggtatgca caaattactt cttgc当地	1020
cccaagataa cctcagttgt gacccttgcgtatcaggca catagctggg tacctgtcc	1080
tccccacgc cccttcctga gcagtcaact caccaggctc atgaagaggt tgctgttgat	1140
ctggcattt tactccttgc tcttcgtc aatctcagttt tgagaaaggt caggtgtc	1200
ccactccaca ggctcgctt gcaagatggg ccagcatgga cacagggccc ttgaggaacc	1260
cagggcttct ctgaaaaatg gcctctggg cagttttttt aaactgactt ctttggccc	1320
cctgtccctg atgtacatat acatagctgg tgccaccctt gaacccacca ctgtcctgg	1380
ttttgcattgc totgggttggtaaaggaaaccaatcat ttggcttctc tctgtgcct	1440
gcctaggggcc tcagcaactga atgttagccctt aaggatcca cagaagcagg ggcaactgaa	1500
ggcacatggc cagggccag gaacagctga gggactctga agagggactc tcattaaag	1560
taaaatcagg ctgggtgtgg tggctcacat ctgcaatccc agcatttttgg gaggctaagg	1620
taggaggatc acttgcattt caggagttt agaccagttt gggcaacata gcaagaccc	1680
atctctacta aaaaaagaaa aaaaaaaattt agccagggtt ggtgggttgc ctgtgtccc	1740
aactgttcag gaggctgagg tgggaggatc gtttggccc gggagatgtc agtacagta	1800
agctattatc gtgtcaactgc actccagcc gggaaactga gtgagaccct gctcaaaaac	1860
acaaaaaaca aaaacaggctt gggcacgtt gctcacgc gtaatttttag cactttgggaa	1920
ggccgaggcg ggtggatcac ctgaggttgcg gagtttggaa ccagcctgac caacatggag	1980
aaaccccgctc tctactaaaa atacaaaattt agccaggcg ggtggccat gctgttaatc	2040
ccagctactt aggaggctga ggcaggagaa ttgctcaaac tcgggaggtt gagggttgcag	2100
tgaactgaga tcgtgccatc gcaactccagc ctggcaaca agagcgaac tcggctcaaa	2160
aaaaaaaaaa aatcgtaaaa atcacacccatttgcacat tctgtatcaca gcacccttagt	2220
tgagttggag tgagggtttt tcctggagaa ggcagccat ttttcttctc tgc当地	2280
cggggccatg acccactgca gggtagaggg agtggagatg ggtgcacatc agtagtccag	2340
ccaccatgg acagagtagt acttggagcc agtctccat gtctcacaca tagtggaaa	2400
aatcactgtg acatgtatgtt taaccttgc ccaagctgca taaaaggcag cttagggca	2460
ggctccaatc tgccagaggtt acacaggcg cttcctggg ggtttctgca cctgc当地	2520
ctgtctggag atttggccca aagatttttt ttttttttgc gacgaagccct cactgtcg	2580
cccaggctgt agtgcgttgc ctggatctt gctactgca agttctgcctt cttgggttca	2640
agcgattctc ctgcctcaga ctcccgagta gctggactt caggcgc当地 ccacaacaac	2700
accggctaa tttttgtatt ttttagtagatg atggattttt accacattgg ccagggttgg	2760
cttgaactcc tgacctcaag tgatccgcctt gccttcaccc cccaaagtgc tggatttaca	2820
ggcgtgaacc atcgatcccg acccagagat ttttactcg accactactt ccccaccc	2880
tctggggactt ggatttttgc cggaaagggtt gagggtggaa cagggcagcc agggctctg	2940
accgactttt ttttccaga ctcccttggc cccactgcat cagcctactt tctgttgc	3000
gtcagatagg cccttagttt aatgcgttgc tcacagacac agctaagctc agcgctgacc	3060
aatactttgtt cccagaagaa ttcccacaag gtttctgtt gatgtatctt gtgccttagcc	3120
caggagagcc agggcttcttcc ctgactccgc cttggagttt ccttaagcac ttaaaccatc	3180
tgatggggac aaatggagag gacagatgg gggcagggtt ggagcgtttt agcagaatgc	3240
tccttaccca gaaccccgctg ctattctgca gccagcaagg atgtggggctt aagaactaag	3300
gccaggggct tacaggaaaa agtttgggg ggggggtt gattttgc tcttttctt	3360
ccccaaatgtt cccaaaggctt cttggatggaa gaagagactt ggagttttt ccccaagatc	3420
aaccttactg gggacaggctt gcaacccctt cgggttagta aaaacaaatg gtgtggccc	3480
tggaaaatgtt gggctggagg ctgtgtatcc agcaggatggat gtgttttttgc agtacacca	3540
cggaagaag tacccagatg ggaggagttt tagggggcagg agaaatgcca gacagactt	3600
agtgcctggg caagaaggaa gatcatttt tttgcagaac agggaggcagc caggatgtt	3660
gctaacttgtt ttttttttttgc gctctgttgc cttacccaaatgagttt cttgttgc	3720
cttcccttcc tggatgttgc cttcccttcc ggtggatggat cttgttgcctt atttccagcc	3780
cttcccttcc tggatgttgc cttcccttcc tttactcaga aaacagactt ggatttagagg	3840
cactgcacag cccttccagg attttaagg agaagagttt ttttttttgc tttccaaac	3900
tgcctgttgg aagaggattt caacaggccat cccaggcttgc tgccacagcag gaccatggaa	3960
tttcccttcc tgcacatagg gacccacccctt ccactctacc actgtccata aaaactgtat	4020
gttttttttttgc tggatgttgc tttccaggc tggatgttgc tggatgttgc tggatgttgc	4080
ttggcttattt gcaatcttgc cttcccttcc tcaagcaattt ctgttgc tca gcttccaaag	4140
tagctggat tacagggttgc tggccaccaca actggctaat tttttgtatt ttttagtgcag	4200

05.11.04

acggggtttc accattttgg ccaggctgg tttgaactcc tgacctcatg atccacccac	4260
ctcggtttc caaagtgtg ggattaaagg tgtgagccac tgcacctggc ctaaaactga	4320
tgttttttc tttttttta acatataact tggacttct cagcctccta ttcttcttt	4380
ttttttttt tttttttga gacagagttc tgctctctca tccaggctgg aatgcagtgg	4440
cccagtctcg actcaactgca acctctgtct tetgggttca agtgataact ctgcctcagc	4500
ctccccagta gctgggatta caggcacaca ccaccatggc cagataattt tttgtattt	4560
tcagtagaca cggggtttg ctatgttggc ctggcaggc tcgaactctt ggcctcaagt	4620
gatctgcctg ccttggcctc cccaaatgtc gagattacag gcatgagtc ccaagcccaag	4680
ccttctttct tttttttgag acagagccctc accctgtcac ccaggttgg gtgcagtggc	4740
acgatctgg ctcaactgca ccttgcctc ccgggttgaag tgattcagtc tcccaagtag	4800
ctgggactac agtcacacac caccatgccc ggctaattt tttatgttta gtagagata	4860
ggtttaccca tttttggccag gctgacctcg aattcctgtat tgcaaatgtat ccacctgcct	4920
tggcctccca aagcattggc attagaggtt tgagccaccc tacttggctt cctttctat	4980
ttttgagaca gagtctcaact ctgtcaactca ggctggagtg cagtggcacg atcttggctc	5040
actgcaaccc ctgcctccca ggtcaagtg atccctctgc ctcaccctcc caagtagctg	5100
ggattacagg tttttccacc cgtggcttag ccttgccttc aattggtag tttttgtgg	5160
ttttccacc tttccacagt gaaaaatggc tcaggactga ctgacatgaa gacaagccca	5220
ggggtctaca ctcaactcaa cccttgcacc caagctctgg gctaagattt tggcgtctg	5280
agcaccaccc attttgttaag gaattttgtt aaattttatc tgaagcatca ctacacaactc	5340
cactttctt acttaaataa ggatttccgc cccatttctg ccaggcatac tgagcttcac	5400
agtcctgtt tttttttctt ggtgccttagg cctgggttc tgacccctt ggtcacacca	5460
atggcatctg gcacacagtt ctccgataat gggatactt aggaggttcc gagacaccc	5520
acagtcctgg gttagtaacc tggatctttt tttccaccc ttttaggcatt ttataatcta	5580
gctttccccc ttccctgtggg taaagtgttc ctgaatgtttt atggtc当地 acaagacttc	5640
tttccctatct attccaaat ctttctccag atccaccctt gggatactt ggtgagggtc cagctggctc	5700
ccacattcca gcagctgggtg acaggccaga acagggaa ggtgagggtc cttcaagtt ttccctaaaca	5760
catacaggag tgcagatggg ggagcaggat ctctctctgc ctccatccat gaggaaaggaa acagaatctt	5820
tacttctcaa ttccctggcga ggactctcc ctctccacat cttcccttag tttccctaaaca	5880
gagggagcag gaggattcga acgccccat cgaggtgtca gtccaaactg ctggcgtccgc	5940
tttagtcata gctggataat gcccggcgtca ggtctaccac aagccatatac gtcgtttttt	6000
ccgtgttcaa cctgtctgtg acagaaacca agggggcccc ggcaccaccc atctaggcg	6060
tggaatcggg gtcttacgca cgggtcccg ggcagggtccc cggccaggac cccggggag	6120
ccacgtagcc aggagggtgg ggctgcccac cgaccaggaa cggcccaacg gaccggggag	6180
ggcggagctc cagcggaccgc ttccccttcc gcccggccgc acccccctggc tcccacctgg	6240
tcccggcgcc gcctgcgagc tccgagtttctt ctcgtctgtc tgctccaggat catttcgaaa	6300
gaaggcgctt ccgcctcgcc catagccgtt cccgcccgtc ccccaactg ggcgtccgt	6360
agccgccaac caccggcccg gtcgcgtcg tgcgtgtacg cgtgtcaggat tgccgtcg	6420
cccgcccg agccgcccgg caaccgtttaa gactgaaacg tagatcgccg ggatcttagt	6480
cttgcgtcat tggggcagga acgccccggc ggacccggc acgcttcgccc cccaggaaatg	6540
acctcatcgcc tccggagctc cactcacaga ccccacctac cacaggaaac gggggccgg	6600
gccagcgccc gggcaagcgc acaagagtgg cctctggccg gaggcgaggg cgggaagggt	6660
cggaagtgc gctgcgccc agcctgggtc agcctgggc cgggtccgt tgccagccgg	6720
ggagtagttt cggagccggc aatccaggtt cccttccca gccccggcga gaatttagcct	6780
ctctgtggccg ccggggaaatc ggcaatttgc acgcttcctt cgcggccac ccaggcagcc	6840
ctcgagaatg cctgcactgt ggcctggccca tcctcgccct tcccatacgcc cctcgcccc	6900
gcgtcacca cgttcgtgtc ccgtccacc ggggttccc agcccaggc cccggggcccg	6960
caacagtcca ggcagacggc cgcgcggcag cggtagtggc aggtgaactt gcaatctgca	7020
gagaggcctg gcggtgaggc ggaggagctc caggtcgccgg aaatgtcccg gagattgaag	7080
ggaagccca gggagagggtc cgctgtcgcc caggtccgc aggcccgacc tatctcagtg	7140
ggttacccca cactgttacg cggactctaa tgggtggccac ctggcgtct gaaaccggc	7200
cggaaggcca caggcagaga ggcctgctca acagttggat ctctatcgcc tagcacagaa	7260
cttccccctt cctcatggc aaaaaaaaaa acaacaacaa aaaactgcgtt ctgtttttt	7320
tcacccaggttggatgttgcatttccatccacc gcaacccctggc cctccctgggt	7380
tcaagcgatt cttctgcctc agcctccctga gtaccttagga ttacaggcgc ccccccacccat	7440
gcccagctaa tttttgtatt ttttagtagat acggggtttc accatgttag ccaggctgg	7500
ctcaaaactcc tggatgttgcatttccatccacc ggcctggccct tccaaagtgc tggactaca	7560
ggcttggcc accgcaccccg gccccttactt gggaaacgtat atggaaataca tctggccatt	7620
tacttgaagg aaaaactaaa caccttaac ctacgtctgc cctgtgggt tcacctgtct	7680
ctactccctt cagaccaaga cactggctc tatacactt aatccctcgcc ctgcactctc	7740
ccctctaccc actccagcca ggcttgcctc ttccctccagg aaactgcccggacagggtc	7800
ctcagcgatc tggactac caaatggat cagttttcc attctccatt tccacccctt	7860
cagcatcatt tgaagcttgc tcccttgac tcccaaggggc tacactctcc cagttttccet	7920
	7980

cctacccct	gcagctcctg	ctcagctcct	ttgcagattc	tgactcaact	tccatatctc	8040
acgatgaagt	ctgggctcag	tcctgatcac	tggcctggc	tgtctacatt	catctgcccc	8100
agatccacgg	ctgaaacact	gacctaacc	ctcagactag	atcctccgt	ccagtacctt	8160
cactaggatg	tctaaaagac	gttcaagtg	aacatggca	aaatttaatt	ccctttctt	8220
cagcctact	gctacacttg	cccagcttc	tcttgcagc	aaaaatgcc	actaggctcc	8280
cagttactgg	agacaaaagc	ccaaacttat	ctttgatttc	tcccttgct	ctacctctga	8340
taaacatgcc	caaatacatcc	tgcttcttat	ctccatggct	actttatttc	tcttgagaa	8400
cgctgcaatg	tcccagccct	gttctttttt	ttttttttt	tttttttgag	acagagtctc	8460
actctgtcgc	caaggctgga	gggcagtggc	acgatctcg	ctcactgca	cctccgcctc	8520
ctgtgttcaa	gcaatttcc	cacctcagcc	tcccagtag	ctgggattac	aggcaccgc	8580
cactacgcct	ggctcatttt	tttttatttt	tttagtagaca	tgaggttca	ccatgttggc	8640
caggctggtc	ttgaactcct	gacctcagg	gatccacccg	cctccgcctt	ccgaagtgtct	8700
gggattacag	gcatgagcca	ccgcgctcg	ccccttgttc	attcttgc	ttctgtcaca	8760
actttgtct	ccccccagct	gaatttgtga	tgtcttctt	taccggatga	gagggtctcc	8820
atgcacacac	agacctggga	cactatccat	ccacaagttc	ctaaataggc	cagagcagtg	8880
atgctcaacc	cagactccat	gttacaataa	tttggggagt	ttttaaaatt	tactgatgcc	8940
taggttccac	tcccagcagt	tgattcaaca	ggtctgcgt	gggatccagg	ctagccccga	9000
ggactgtaaa	agcacccctg	gtgattccag	ctgggtctt	cccagggag	agcaaccctt	9060
gcttgctggc	gattcccagg	ggtgcagaag	gactgtggg	tgtgtggct	cgtgcattt	9120
ttagcatctg	attcaactggg	tcagaaaagg	gtgttgc	aataaaagact	caacaaaact	9180
cctgcttgca	ggggggccac	caaaggttt	aaattttcc	aggctccctc	ccataggtgg	9240
taatttccct	tcaccctaaa	gttctggag	ggggcatga	gtgttggaga	agaggcaagc	9300
ctgggaagat	ggactccgag	gacagtaggc	acaaaccctt	tctcaagaag	ggccaaggca	9360
ttttaaagat	aagaaactta	aatcagct	attttacat	ataagcagcc	acctctgctc	9420
atctgtggcc	cagatacag	tggagtgcga	caaggataa	accattttcg	cgactcttc	9480
agcgatgggg	cgaaagtaac	gacactagtc	ctcggagct	gtccccgc	accctctctg	9540
ccgcgacttg	accgcggcg	actgcgctc	cccttggct	cccccttccgc	tctcgtaggc	9600
gcgcggggcc	actactcacg	cgcgactgc	aggccttgc	gcacgacg	ccagatgaag	9660
tcgccacaga	ggtcgcacca	cgtgtgcgt	gcgggccccg	cgggctggaa	gcgggtggcca	9720
cgccaggcgg	ccagctgccc	tgtgggggt	cacgcgg	cccgcgat	gcgcagcgc	9780
ttggcacgct	ccagccgggt	gcggcccttc	ccagcgcgc	cagcgggtgc	cagctccgc	9840
agctcaatga	gctcaggctc	ccccgacatg	gcccggttgg	gcccgtgctt	cgctggctt	9900
gggcgttagc	aagcgcgggc	cgggcgggc	cacaggcgg	gcccgcactt	cagcgcctcc	9960
cccaggatcc	agactggcgc	gcgggaagga	gctgaggaga	gcccgcata	gaaaacctgg	10020
gtcaggggac	tgtggggccc	gaaggcgggg	ctggcgcgc	tctcgagag	cccccccccgc	10080
cttgccttc	cttccctct	tgtccccctc	ctcacacccc	accccgacg	gccacaacga	10140
cgcgaccgc	aaagcaccac	gcccggatac	ccgtgtttt	ggaggccagc	tttactgtgc	10200
tagaggaaga	gggtccccac	atccggccct	ggccctctg	gtccgggtt	ctgaagcaac	10260
acacttggcc	tacccactgg	gtggggcagg	aagtctcg	cttcactt	gggtgaggag	10320
gagggagatc	gttcagcagc	tttaccgccc	gctctgtct	ccactgcg	gactggggct	10380
ccggcagagg	ctggaccgt	atcttggat	tcaggggtc	attctgggt	gattccctt	10440
gcatgggtgg	tcggccctca	gcaactgcag	ccctcattt	gctctgtc	cctgggctgc	10500
caggacacaa	gtcttccat	gttttccca	gtgttgc	tggcactcc	tgcaggcagg	10560
tgggtattga	ggatggcaat	gcatgtgggg	gatgtgggg	tagggctt	aggtccaagg	10620
ttcttagata	ccctcacct	cagcaatacc	actcattct	gcatcgt	cagcgtttag	10680
aaggcctctg	actgcagtaa	gcacagcggg	gcccgtct	agccactg	tctagcacat	10740
ccagcctgt	ggtctcagcc	cacctgggg	aaagtca	ggctctggaa	10800	
ggtgggggca	ccccacccac	atccatgcct	cctgc	ctccaccctc	cctgcccatt	10860
ccacaggcct	tacccctcg	cctgcagccg	cagtcctgc	tctgagggc	tgaacacatg	10920
ctggagctgg	tgcttggcaa	ttgcctgca	tttctcg	ccagccgctc	10980	
ccagatttct	ggatctagg	a			11001	

<210> 6  
 <211> 3501

<212> DNA

<213> Artificial Sequence

<220>  
 <223> chemically treated genomic DNA (Homo sapiens)

<400> 6

gcgggggttgg tagggcggtt gttttggat agttcgggggt ttggtagcgg cgggtgggg

atcggttaag	agttgttatac	gtcgccccca	ggggagttcg	tttcgtcgaa	atcgtaggtt	120
acgggtcg	gggttcgcg	gtttaggagg	gaaacgggg	cggccggcg	agtacgggt	180
aggggagttt	agggttcgtt	ttcggtttt	gtcgtcgat	ttgggggtcg	cgaggaagag	240
ttgcgagt	agggttggg	gtcggcgat	tttttcgtt	ttgtttgtcg	ttgaaaatt	300
tttttttaa	tttggggcgg	cgaggttcg	ggggagaagg	gtcgggggaa	gtcgcggagg	360
gaggcg	gttcgcgcgt	gtagggttt	gtcggggatc	gggacgcggg	ttggggcgtag	420
gttcgggtt	gggtcgtagt	cggttgcgc	tcgtttcg	tcggggcggt	ttttttttt	480
tttttggg	gttgcgttgt	ttttttttt	tttttattt	ttttttgtt	tagtttttt	540
tttcgatata	acgtttttt	cgcgtcggt	tcgggtttcg	cgttttgttc	gttacggtag	600
tcgttgcgtt	cgtttttcgc	gcgggtcg	ttcgggtttc	gatcgagggt	tgatagttt	660
cggttagggc	ggcgttaggg	cgggtatcgc	gtttttttt	ttcgtattat	tttttttaat	720
tgggtaatt	tttttcgagg	cgggaggcg	tggttttcg	ttttttttt	tttttattt	780
gttaaagt	ttcgttttga	atgatttttt	ttgaagcg	tattttattt	aaatcggtt	840
atgtttttt	aaagggttt	tgcgtttgaa	tagtttttt	ttcggaaatt	tttagtattt	900
gttaggtgtt	ttggggcg	taggtcg	tggtttttt	ttatcg	gtcgtttatt	960
ttttgtttt	tttttttgtt	cgggcgggtc	ggtttgggtt	ttattttag	aggtagtcg	1020
gttttcgtc	gggtgtttag	tcgttaggg	gatgtttcg	tttagtttag	ggaaggggaa	1080
gtggagggg	gaagtgtcg	tttgggggtt	ggcgggttag	gcgtcgacg	gtttttattc	1140
ggtcgggtgt	tgtttcgt	ggagagtgt	ttgggttagac	gatgttggat	acgtggagg	1200
cgttcgggtt	tttttaggt	ttgttgcgtt	ttgttgcgtt	ttagcgtatt	aagggtttt	1260
tgtgcacgt	gattatcg	gtgtagaac	tttttttcg	cgcgtataag	aacgtgttgg	1320
cgttagtag	cgttttttt	aagtttttgg	ttgttgcgtt	taatttgcgtt	aatttggatt	1380
atgatatgg	gagttcggtc	gtgttcgtt	ttgttgcgtt	ttcgggggtt	gagtcgagtt	1440
tgggtacgg	cgtagaggcg	gttcgggtcg	cggtcggtt	cgatttcgt	gcgttgcgtt	1500
tgggcgtcg	tttgggtcg	tttagttt	ttgttgcgtt	tttgcgtt	tttgcgtt	1560
agaaacgtt	taagcg	tttgcgtt	tttgcgtt	gggcggccgc	ggcggccggc	1620
gcgggtacgc	ttttatgg	cggtcggtc	ggggtttgcg	ggcgttacg	tcgttattt	1680
aggttggta	ttcgtttttt	gtcgggtttt	cgtcgtcg	tgcgggag	tcgttttcgg	1740
gttttaggt	cgcgttaat	acgtattcg	tcgagtttgc	cgcgtcg	ttcgggttgc	1800
tcgtcgatt	ttgttgcgtt	gagcgtcg	ttttttttt	ttgttgcgtt	ttgttgcgtt	1860
agaagagttc	gtcgggtt	cgccgttag	agcgtcg	tttgcgtt	tttgcgtt	1920
cgcgttcg	tagttttt	acgtcg	tcgtcg	taaggagtc	tttttcgtt	1980
tgtcg	gtcgtcg	ttttttt	ttgttgcgtt	tttgcgtt	tttgcgtt	2040
tatttcg	cggtac	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2100
gtttttttt	tcgttgcgt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2160
gtcgggagcg	cggtttttt	acgtcg	tttgcgtt	tttgcgtt	tttgcgtt	2220
cgttccgggg	tttttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2280
gtttcggcgc	ggggccgcac	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2340
gcgaggatt	tagtcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2400
atggcgagg	cgaggtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2460
tttttagttt	tgagtagtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2520
tgtacggtag	ggtcgaggcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2580
ttggaggccg	cggggata	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2640
tttatcg	cgcgtcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2700
agaagacgt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2760
agcgtgggt	tatgac	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2820
acgcgtcg	tatgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2880
cgggcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	2940
ataaggcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3000
tggcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3060
ataaggcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3120
ttatcgatcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3180
gcgg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3240
ggataatcg	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3300
tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3360
tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3420
tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3480
tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3501

&lt;210&gt; 7

&lt;211&gt; 3501

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 7

tcgagttaa	gtacgaagta	gtgaggtag	gtgaggcgt	cgagaggtgg	agtcgttatt	60
gtggcgacgt	tgccgttgtt	tcgggtata	tggtttgc	gcgtcgtttt	ctcggtttt	120
tggggtgcgg	gttägggtcg	ctagtagcg	ataagacggg	ttggcaggg	gcgttttagg	180
tgggagagaa	acggtcgatg	gttcggcgt	cgggttcgg	cgtaggtga	gcgttttgtt	240
ttagtatttc	ggtcgttttgc	tcggggtga	ggttagttc	ggtcgtgaat	ttgggttagcg	300
ggtagaggtt	ttttagcgtt	atttgggtt	cgttaggaa	gtgcgtgg	tgcggttaga	360
gttcggtcgc	ggtcgttttgc	ttttgttgc	ttaggttag	ttgttcggc	gtgaggcag	420
ttatagtaaa	gacgttttgc	ggaaagtcga	gtttgtttt	gtcgtcgggg	tcggggacgt	480
cggggagttt	tttaaagtgc	gttagcgttt	cggtcgcgtc	ggtcgcgtt	tttacggcgt	540
gtattttat	gtgggtgatg	aggttgcgtt	gttgcgcga	tttgcgtcg	tatatttgt	600
attcgtaggg	tttttcgttc	gagtggatgc	gtatgtttt	cgtgaggcgg	tattggcgcg	660
tgaatcgat	gtcgacgcg	tcgtacgcga	agggtttgag	gtttaggtgg	ttgcgtatgt	720
ggcgcgttat	ggtttacgt	tcgtgaattt	tttttcgt	gatgggttat	gggttagggc	780
gggttagtta	gtgogttttt	tcgtgttgc	gtacgtgtt	cgggtttttt	tagttttgt	840
cgtacgacgc	gtacggtag	ggtcgttaga	gtttttttag	gttattcgg	gttccggcga	900
ttttgttttc	gtcgttttta	aaagggggtt	ttaggtcgg	gtttagtgc	gttatttccg	960
tcgttgcgt	tttgcgtat	tcgttttagt	tgttagggta	gcgcggcggc	ggcgttagt	1020
ttagttgtt	agagttgggg	aagttttgt	cgtacggaa	gtatacgtat	aggttggat	1080
cgaagtttc	gggttcgtt	taggttagt	gcgggtatgg	gtagttttcg	aggtggcgt	1140
taggcgggtt	ggggtttgc	ttgttatacg	tttttcgtt	gttgggtttt	tagtcgtcgt	1200
cgtcgtcgtt	cgcgtcgggt	tcgttttagt	tgttagggta	gcgcggcggc	ggcgttagt	1260
cgagcggggg	ttttcgggc	gagacggcg	cgtttttatt	acgttttcg	tagcgttcgt	1320
tgggggagtc	gcgttttcgg	tttagttcgt	cgttatagtt	attaggttc	gttgcgttt	1380
ttatattacgc	atagaggaga	ttaggttcgt	cggggcggc	gggggttcg	gttttcgggt	1440
tgtcggtgtc	gtcgacaaat	gggtcggaa	gcgggtcgg	tttttttagt	ttttggaaagg	1500
gtacggcgg	tagcgtacgt	agggcgagag	gcgggttttt	gtaggcggc	gggtcggcgt	1560
tgggaggggtt	gttcggcgc	gggggtagtt	cgcgttttagt	tagcgtcgt	tttgcgtcgt	1620
cggagttcgg	cgggtttttt	ttggataaggt	ttaggttata	aagaggggag	tagcggcgtt	1680
tcgaggatata	gagtggcggc	gtcgggtcgg	gttgcacgc	gtatagttcg	gcgttagtcg	1740
tgttgcgtc	gttttttggg	ttcgaggcgc	gttgcgcgt	aggcggcgc	ggaggttcga	1800
ttggggacgg	gttagtaggtt	tggatgtacg	gcgtggcgg	tcgttaggtt	cggttcggcgt	1860
gattataggg	cgcgtatcg	tcgtcgtcgt	cgtcgtcgtt	tcgttaggtgg	tagtattttgt	1920
cgtggcgttt	gaggcgttt	ttgtatacg	ttacgaggc	ggggattttgt	aggttagttgg	1980
ccgcgggttag	tacggcgtt	aggttcgtt	tagtttcgg	gttacggc	gcggcgttag	2040
tcgtttttgc	gtcgttagt	aggcggtcgg	tgtagatgaa	gtttagtatt	aggcggaaata	2100
ccgtcgggtt	tattatgtt	tggttaggt	ttagtaggtt	gttatgtatt	attaggatt	2160
ttaggttaggc	gttgggtggc	tttagtagt	ttttgtcgc	gcggaaagagg	gcgttttgc	2220
ttacgatgt	tacgtcgat	aagaagttt	tggtgcgtt	gttgggttagt	tgtagtagta	2280
gttgggttgg	gtggcgggc	gttttatacg	tgttaggtat	cgtttgtta	gtatattttt	2340
ttgcggggat	atatacggt	cgggtgagag	tcgtcggcgc	tttggcgt	ttgggtttag	2400
ttcgggtattt	ttttttttt	ttttttttt	tttaggtga	gcgggggtat	tagtttcgc	2460
gtttgggtat	cggcgaagga	tcgggtgtt	tttggagtgg	gagtttaggt	cggttcgttc	2520
ggatttaggag	aaggagttag	aggtgagcgg	tcgtcggtgg	aggggaggtt	agggcgggtt	2580
gtacgtttta	gggtattttgg	ttgggtgtt	gggttttgc	gaagaaaatt	gtttaggcgt	2640
agtatttttt	ttggagatag	ttattcgatt	taagtaaaat	gtcgtttta	ggaaaagttt	2700
tttagggcgg	agaattttat	ttaagtaggg	agaaaggagg	tcgaggaatt	acgttttttc	2760
gtttcgggag	aagttttttt	agttggggga	agtatacgg	aggagggggag	cgcggtgttc	2820
gttttggcgt	cgttttggc	gggggttgc	aattttcggt	cgggttccgg	gcggcggcgt	2880
cgcggggagc	ggaggtagcg	gttgcgtgg	cgggtagagc	gcgaaggctcg	gttccggcgc	2940
ggggagggcgc	ttatatcgg	gtaggaggtt	gaggtaggaa	gtaggtgggg	gggaggggggg	3000
agttacgtat	tttttagggg	agggaggggg	tagcgtttcg	ggcgggtacg	gcgtatagtc	3060
gttgcgtgtt	ttgattcgg	tttgcgttt	attcgcgtt	cggtttcgg	ttgggtttta	3120
tacgcgcgg	ttcggcgtt	ttttcgg	tttttcgtt	ttttttttt	tcggaatttc	3180
gtcggtttaa	atttgggaa	aagttttta	atttagata	gggcgggagg	agtcgtcgg	3240
ttttaggttt	tcgggttcgt	gttttttc	gcgtttttt	aattcggcgg	taggttcgg	3300
agtcgagttt	tgagttttt	tggtcgtgt	tcgttcgtt	gattcgttt	tttttttgcgtt	3360
tcgcgggtt	tcgcgggtcg	ttatttgcgg	ttcgggtttt	tcgggtttt	tttttcgcgg	3420

- 11.05.11.06

cggtagt ttttagtcg a gttttattc gtcgttgtt a gtttcgagt ttttgttaggg 3480  
taqcgtttt ttttagttcg t 3501

<210> 8  
<211> 2501  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> chemically treated genomic DNA (Homo sapiens)

<400> 8

tttttatatgt gtaaatgtgt	tttttattttt ttttggagta	attttatatta aatcggtttt	60
tagataaaa tttaaatatt taaatatgtat	tttgggggtt ttgtttttgt	tttttttattt ggttttattt	120
ttttttttt taaatattgt tagtgtttgt	gttgggggtt tagaaaggtt	ttttttttt ttttttaggt	180
gggtcggtat tttaggtttt gttttttttt	ttttttttt atatattttt	ttttttttt tttttagcg	240
ggatagggtt tggttattttt gatattatta	ttttttttt atatattttt	ttttttttt tttttttttt	300
ggttgtatcg ttattgaaag ttatttattt	ttttttttt atatattttt	ttttttttt tttttttttt	360
atttaggaga tggttagtaa atgttgattt	ttttttttt atatattttt	ttttttttt tttttttttt	420
agattattta ggaatattttt taaaatgtt	ttttttttt gagattttt	ttttttttt tttttttttt	480
aagttagtggg ggttttaggt tttgtattttt	ttttttttt tgatgtttt	ttttttttt atgttagaaat	540
gtagggatta ttatattgtat aaattttttt	ttttttttt ttttttaag	ttttttttt ttttttaggg	600
tttattttt gaaagttttt aaggataggg	ttttttttt gggattttt	ttttttttt gtttagtaatt	660
aaatttttagaa aacgtttattt gagtgaatga	ttttttttt gtcgtatgtt	ttttttttt tttttttttt	720
gtgtcgagtt aattttttt ttatataatgt	ttttttttt tttttttttt	ttttttttt ttagtcgttag	780
aaatgtttt tggaaaggtaa gtttttttagc	ttttttttt gagtggagtt	ttttttttt attttttaattt	840
ggatttttaag ggagtcgcgc gttttgcgtt	ttttttttt tttttttttt	ttttttttt ttagaaatcg	900
gattttcggt tcgttttgcgt tatttttgcgt	ttttttttt ttcgttagtgcg	ttttttttt gtaagttattt	960
gttttgggg ttcgtgtgtg tgcgttgta	ttttttttt ggtttttttt	ttttttttt ttagtcgttag	1020
cgacgggcgg gtgggtattgg ttatccgcgc	ttttttttt atgggtttat	ttttttttt cggttaggtt	1080
tcgcgtttt ttttggggcg tagtgggttg	ttttttttt gggggtaggt	ttttttttt gagatgcga	1140
gtagttgagg ttatttcgtt gaggtgggtgg	ttttttttt tttttttttt	ttttttttt aggttggagg	1200
atttttttagg gaggaaagag tcgaaaatat	ttttttttt tttttttttt	ttttttttt tttttttttt	1260
tttttagtat ttccgtgtgg gtttttttaag	ttttttttt tttttttttt	ttttttttt agaggagagg	1320
ttttttttt taaaattggg taaaatgtttt	ttttttttt tttttttttt	ttttttttt ttaggttggg	1380
ttttttttt gtaatttaatt ttttttagatt	ttttttttt tttttttttt	ttttttttt tttttttttt	1440
cgcgagggggc ggggggttggg attcgtttttt	ttttttttt tttttttttt	ttttttttt gaggtatcgt	1500
ttattccgttc gtttagtgg tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	1560
ttttttttt gaggggcggtt gataagagttt	ttttttttt tttttttttt	ttttttttt tttttttttt	1620
gttataattt gttttcgaaa ttttattggag	ttttttttt tttttttttt	ttttttttt tttttttttt	1680
atagggtta ggcgtatgtat ggagaaagaa	ttttttttt tttttttttt	ttttttttt tttttttttt	1740
ttggagagta gagaatttcg aagtggatcg	ttttttttt tttttttttt	ttttttttt tttttttttt	1800
gcggtaaaat gggaaattgt tatgtgaaat	ttttttttt tttttttttt	ttttttttt tttttttttt	1860
aataaattat ttatattaat atagatgttg	ttttttttt tttttttttt	ttttttttt tttttttttt	1920
agtgggtgat ttttgcattt ttttgcattt	ttttttttt tttttttttt	ttttttttt tttttttttt	1980
ttattttttt tagtggat tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2040
taaacgttat aaattggaaat ttgtttaatt	ttttttttt tttttttttt	ttttttttt tttttttttt	2100
taaagtgggtt ttttgcattt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2160
attttatatt tataatgttt tgggttattttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2220
ttttttttt gtttttttagga aaatattttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2280
attttataac gttttgggtt taaaattttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2340
gagggttagg gattatattt taagacgtttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2400
gggggtataat ttgaaaattt ttaaggata	ttttttttt tttttttttt	ttttttttt tttttttttt	2460
tttatataatq qtagttagta tattttat	ttttttttt tttttttttt	ttttttttt tttttttttt	2501

<210> 9  
<211> 2501  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> chemically treated genomic DNA (*Homo sapiens*)

&lt;400&gt; 9

attgagtatt	ggtgtaaaaat	gtattgtata	ttatgtgtaa	gtatgttaat	ggtgtaaaaa	60
gaagtagttt	ttatTTTTga	atgatTTTta	gatatagttt	ttgaaaagga	aagtTTTTT	120
agcgatggta	aaaacgtttt	agaatgtaat	tttggattt	tttgtatgaa	aattatTTaa	180
gagttgttaa	aaaagattta	aaatattaag	cgttggaaaa	tatattattt	ataataaaag	240
taaagtgtaa	ataaaatgtt	ttttaaaaaa	tatttagaag	gtatgtttat	atTTaaatAT	300
atgtttatgt	agagataatt	agatagttat	gggtataaaa	tatttggta	tttattaata	360
ttgaaagtat	ttttgaaag	gtatgtataag	aagttatTTT	attaatatag	atatgaaagt	420
atataggaaat	taattgtatag	aattttatgtt	tgtaacgttt	aatatataat	ttaaataatt	480
taatgtattag	ggTTTTTTta	ggtataaggT	attattatgt	gagaattaaa	gggtataat	540
gttaagattt	ttgtatTTgg	aggTTataga	ggTTTTTat	ttggagaaaa	ttaatgtaaa	600
atTTTTatgt	atagtatTTa	ttgtggatg	aatggTTTgt	tttaattttt	tgtatTTTaa	660
aaaatggggT	tatttataat	aataattttt	tatttgcg	ttttgaaat	ataggtaatt	720
tttttattgg	tcggTTTT	tcggaatttt	ttgtTTTTa	gtttttaga	tgtttttatt	780
ttatTTTTat	ttttttttt	tattatacgt	ttgatTTTTg	tcgtatTTg	agttataat	840
tttggtaa	atTTtagTgg	atTCgagaa	tagattgtga	tttggtaatg	atataaattt	900
taacggggaa	gggTTTTat	tagacgttt	ttttaaagaa	gtttttttta	cgaatttaaa	960
atTTTACGAT	agagggaaat	aaatattgaa	cgatcgaaatg	atTTTTAGG	agttgatatt	1020
tttgcgtttt	agggggcggaa	ttttagTTT	cgTTTTcgc	gtttttttag	ttttttaaaa	1080
gattaggtaa	agatttaaga	gagttaatgg	taggaagagt	aataatcgat	gtttatagat	1140
aagggttagg	gagaattttt	atTTtagTTT	gttattatgt	gttttagTTg	gttttttttt	1200
tttaggttag	ttttggaaag	tttatatcgg	ggTTTgggg	agaaggggt	tgtatTTgtt	1260
tgagagat	gggtttttcg	gtttttttt	tttaagaga	tcgggtgttt	taagaataat	1320
tatTTTTT	tttatttattt	tagcgggggt	atTTtagTTg	cggttgcgcg	cgtatgtcgg	1380
ttcgaaaaga	gtagttagtt	gcgttttagt	aaggggcgg	gtttttaatt	ttcgtatgtt	1440
tatttggTT	cgcgtcgg	attagtattt	ttcgttgcgc	gaatttttagc	ggtgagTTtta	1500
tgaataaggT	ttgttaacgt	atatacga	ataagttagag	tcgttggacg	tcgattgcgg	1560
gataggagga	ggcggggaaat	ggcggggggc	ggacgggggt	tagtggattt	tcgatttttg	1620
gttaggaagat	gagcgttagag	cgcgcggtt	ttttggattt	tttggaaatg	tagttaagag	1680
tgattttatt	cgttggaaag	tttggTTTT	aggggtattt	tttgcgtt	gaagtaatgg	1740
gagttgttag	gatttgcgt	gaagaatagt	taattcgata	tttgcgttt	attattttat	1800
ttgtcgtttt	attattttat	taataaacgt	ttttgggtt	tagtggta	tttagagaaaa	1860
tagtatgcgg	tttttatttt	tgagggTTT	ttagagatag	ttttggaa	ggaaagtTTT	1920
tttttaggat	ggtaaagatt	ttttagtgc	ataatttttT	tatTTTata	tgtaaatatt	1980
aggggattt	taaaatgtag	agttttggat	tttatttgc	tatTTTTaa	aatagaattt	2040
taaggggtaa	aaatattttt	ataagtgtt	ttaaatgtatt	ttgcgtttgt	atTTgagaa	2100
tagttatagt	ttaattaata	tttatttgcgt	atttttgcgt	tttgatagg	atTTtaagt	2160
tatTTtagat	tagatggtaa	atttttaata	acgtgttagt	ttagatttgc	gattaatgtg	2220
tgtaagttag	ttaatgggt	taaaataat	agattttatt	ttcgttgggg	agaaagagga	2280
aaaatTTTT	gaaggaggat	taggattaa	agtggcgtt	ttgttaaaga	aagaagggtt	2340
ttataggtag	tataaatatt	agtttagTTT	ggggagaaag	aggtaaagt	tataaaagta	2400
aagtttagaa	gattatgttt	agatgttga	attttgtgtt	gaaaacggtt	ttaagttagga	2460
ttatTTTaa	gagtggTgg	aatatattt	tattatggaa	a		2501

&lt;210&gt; 10

&lt;211&gt; 2470

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 10

aaagatgatt	aaaagtttaa	ttgtttattt	gaagaggtga	ttttttattt	tttgcataaa	60
agggtatTTT	tagtagTTTT	ttttttttt	gttatttgcg	ttttttttgt	gggtgtgtaa	120
gttataatt	tttgcgtttt	agtaaattt	tgtatgttt	tttttttttt	tgttattatt	180
ttttttttt	tttgcgtttt	ttatTTTgt	gtaaaattat	ttgttaattt	tatttgcata	240
gagaaatttt	aagttttata	ttatTTTaa	ttgttttagat	tttttttttt	tttatatgtt	300
ttataatgt	ttgggttattt	ttagatttgc	tttgcgtttt	tttgcgtttt	tttgcgtttt	360
ttatTTTgt	ggattttttt	tttatttttgc	agatgtttt	tttgcgtttt	tttgcgtttt	420

05.11.04

atttttgtt tattgattag aggaggggtt ttaatttatgg gtgaatttttta tattttattg	480
aagaggttat gtttatgtt tattttata atataattttt tattttatata gtatttttat	540
ttttgtata tttttttta ttaattttaa taatattttt gtaagttatg ttgaagtaga	600
ttgtaaatgtt ttattttataa attgtgaaat gaattaaaat gaaaggtaa agattaaatt	660
atgatttaggt ttgaaatataa tatataagat ttaatttttt ttaattttaaag attttttgtt	720
gtgatttttgg tttttaggtt tttttttttt ttttagatgt tattttttttt tattttttttt	780
attgttagatt ttatgcgtt taaattttaaat tagatttaag atgatttttt tgattttttt	840
tggttagatgtt ttttaattgtt tgaattttaa tattttttttt tttttttttt tttttttttt	900
gtttttttta tttttgttaa tggatttttattt attatagagg tttttttttt tttttttttt	960
gtttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1020
aggtaggattttt taaaatgtt taaaatgtt taaaatgtt taaaatgtt taaaatgtt	1080
tttgaattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1140
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1200
taattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1260
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1320
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1380
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1440
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1500
tggaggatgtt gtaagattttt tttttttttt tttttttttt tttttttttt tttttttttt	1560
ttttaattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1620
agtattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1680
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1740
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1800
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1860
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1920
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1980
aaaattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2040
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2100
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2160
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2220
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2280
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2340
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2400
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2460
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2470

&lt;210&gt; 11

&lt;211&gt; 2470

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 11

ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	60
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	120
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	180
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	240
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	300
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	360
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	420
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	480
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	540
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	600
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	660
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	720
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	780
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	840
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	900
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	960
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1020

08-11-04

ataaaaatgga tatgaaggag agtattaaat gaagatttt a	1080
ggtaaataag aattattaat ataaagtta attatatta tttaaaaggt tgattataat	1140
agtttatgtt atggatatg tggtttggg atttgttgc tttaaattga gttaaaaga	1200
tattnaaaga gaatggatga ttttaggat agagattgtt aaagagaaat gaagtagagat	1260
ttggtagtta ttatgattgg gaaagaagag gagagataaa gaagatataa aagatagtt	1320
ggtaagagga ttttaggaag aattatagaa tgttaggat tatattaaga ttaattaagt	1380
aagatttagg agatttat tttttttt gtttaggtt aattattttt gaataaataa	1440
aattttgtt attttaatta ttaatagtt aaaaagtatt aagtagttt tatttaagta	1500
atatttaat attttgat taaaaaatg ttttgcattt atgaaattta ttatataaaa	1560
taaggttagt aggttgcattt atggattgt tacgataata ttggagttt gtaattggaa	1620
gattttttaa aaggaaatta ggggatttt ttagattttt gttagttt taacggtag	1680
aatttatagt aaatttggta taatttaatg atatttggg aggaagggg gttttgttag	1740
tagggattat ttataaaaatg ttttgcattt aaaaatgtt gttttgttgc ttaatttttag	1800
ttttgggtt gatttaattt ttgtttttt atttaattt attttataat ttgttaatgt	1860
atatttataaa ttgtttttaa tataattttt agtgcattt tttagattaa taaaaaaagg	1920
tatgttaaaa ataaaagtat tatgttaatg taattttat tatgaaaata tatgttaat	1980
ataattttt tagtaagata tagggattttt ttatagttt gattttttt ttgatttaatg	2040
ggtaaggggtt gaagaagat tttttttt gtagttttt ggagatattt taaaataaa gaaaaattt	2100
ataggagtgat ttattttt gttttatattttt tttttatattt gtagtttgc aaatatttt	2160
tatattataa attatatgtt agaggttagg atttgataga atttgatataa tttttttt	2220
aaaattttt atttttaataa aaattaatgtt gtaattttt attttataaa taaaataaaa	2280
taagagaaaa ggttagtataa gaaaaaaa tgggtatgtt taagtttattt gagatatgt	2340
agttataattt ttatataattt ataaaaagag tcggatgggtt aagatgatgta gagattgtt	2400
aaagtattttt ttattatagg aataaaaaaaa ttaattttt agatgatataa ttaattttt	2460
aattttttt	2470

&lt;210&gt; 12

&lt;211&gt; 7001

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 12

aatgtatgg aaaaagagag attgtaaagt tagaagggtt aggaattgtt ttttgcattt	60
gtgtggaaagg taagggaaaa ttatgtttcg aagaagatg tgatgtttt atttgggtgg	120
ttggagagat agtgcattt ggtatagata cggggaaagg gagaggata ttatgtttga	180
gaatgggtat ttatattttt ataaatgtt aatgttttgc agatcggtt aaaaatgggg	240
ttggagatattt atttaacggg ggagtttgc taattttttt ttttttttgc ttgagagat	300
tagtaagttt cgggttgcac gtgtgtttt agtgcattt ggttagggagg gaagtttgc	360
gagttgggag ttgcgttgc gtttttttgc aaggttgcag aggaaatgtcg gctgttgc	420
gtatattttt ttattttatgtt ttatatttttgc taggttgcag gtttttttgc atgatgttttgc	480
aagagaatgtt tggagagaaaa gtttttttgc aatatttttttgc tatttttttgc ttgggtttaa	540
tttttgcattt aatatttttgc ataaatatttttgc ttgttgcattt gatgttgcattt ttgggtttaa	600
ttttttttttt aatatttttttgc tttttttttttgc tttttttttttgc tttttttttttgc	660
tttttttttttgc aatatttttttgc tttttttttttgc tttttttttttgc tttttttttttgc	720
ttgttatttttgc tgatgttttttgc gaggttatttttgc ttgttatttttgc aatatttttttgc	780
tttaatatttttgc attttatatttttgc tttaatatttttgc attatggatgc gagtttttttgc	840
gtgttttttttgc attttatatttttgc ttggggtttttgc ttaaatttttgc aaaatataat ttgttgcattt	900
gttatttttttgc atatttttttgc gtttttttttgc tttttttttttgc tatttttttttgc aagatgttttgc	960
tataaaattttgc ttatgttttttgc ttttttttttgc ttgttgcattt ttgttgcattt ttgttgcattt	1020
gtgatttttttgc ttatgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1080
gggtgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1140
tttagtatttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1200
tttatttttttgc aatgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1260
tttagtatttttgc aatgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1320
ttatgttttttgc ataaatgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1380
ttatgttttttgc ataaatgttttttgc ttgttgcattt ttgttgcattt ttgttgcattt ttgttgcattt	1440
tttttttttttgc aacgttttttgc aggatgttttttgc ttttttttttgc ttgttgcattt ttgttgcattt	1500
tttttttttttgc aacgttttttgc aggatgttttttgc ttttttttttgc ttgttgcattt ttgttgcattt	1560
tttttttttttgc aacgttttttgc aggatgttttttgc ttttttttttgc ttgttgcattt ttgttgcattt	1620

atttatatat ttttGattgg tattttattt tagtcgtaag attatgattt atagtaagtt	1680
tgttttttt tttgtttggg gtggtagtag aaagtatagg gtattttttt gttttaagg	1740
gtaggggtaa aggggttggg gtttttttt ttagtatacg ttttttttgg ttgtgttata	1800
tgttttttg tgtagtagata gtaagtttt ttttattttt tattgttatt tatttagcgt	1860
tgtgttagtag ttagttgcg ttttgcgg gagggttgg taagtgtttt gtttattgg	1920
tgtttttcgat attttgtta tttacgtat aaatataattt atatattttt tttgttttagt	1980
ttatataattt agttattcgt atatgcgagt atatttttt tttttttt atttttcgg	2040
tttttgattt ttataagttt atgaaatattt tttgaaaga cgtttttgat ttagtaggg	2100
aggtttgttt tgattttttt tttgttagtt ttagtattt gaaaaagtaa ttatattttt	2160
tgttagtgat ttgttattttt gtagggagat gaggattgtt gttttttatg gggtagtg	2220
tgtttttttt ttgttattttt gatattgttag gattttttgtt gttatgttata tataattttgg	2280
taggtttata tttttaaga gttttatgaa gtgttttttg tatgtgtttt aaaaaggat	2340
ttgaaaattt aagtgtgat ttatggaaat taaattattt gtaaaaattt gtttggaaa	2400
gtaatgattt ttggatataa agggaaatattt ttgcgtatgtt ttaatgtgt tttaattttt	2460
ttatgttata ataattata gttattaaatg ttaaatttcgtt ttttggtttt agttatattt	2520
gtatattgtt taataatggt ttatgttattt aagaattttaga taaaatgtat atttgatata	2580
aaatagttaa aaatgttaattt ttagtataa gtaagttttgg tatttagata gattatgaat	2640
atttcgttag atatttgtt ggggtttttt gatagtaattt aaaaataagt attgatagtt	2700
gtatttaggtt ttatttaggtt gtagtaaagg aagtttattt aaaaagtataa attatttaaag	2760
attatagacg tatgatataat ttatgtgtt tttgtatgtt ttaatgttata tataatata	2820
tatatataat tataatgtgtt tttgtatgtt cgtgtgtat ttaatattttt	2880
aatttagttt aaaaattttt ttatgttattt tttttttttt gatattgtt ttgtatattt	2940
tagtttaagt gaatcgagaa gatcgagttt taggattaaa ggtatagat gtagaaatgt	3000
attttaaaaa ttgttagttt ggttagatc gataatgtaa tataattgtt aaagttttgg	3060
ttcgtgattt gaggatgtt ttgtatgtaa aaggttatattt ttatattttt gttttttgaa	3120
gttttgggtt tataattata ttgttggaaagg tatgaatattt tatgtcggtt ttaattaaag	3180
gtttttttttt attatgttata atatggaaat tttaatggg attaagtata gttatgtgtt	3240
ttaatataaa tatataagttt aggtttagag aatttttagaa gtttggaa ggttttattt	3300
attttgggag tattttgttag aggaagaaat ttaggtttttt gtaggttgc tttttttttagt	3360
gtaaaatgtt agttttttt atatgttata tttaatgtt tttttttttt ttttttagatg	3420
ttttttgtt gttttttttt tagtttaataa tagttgtttt cgtagtgc tttttttttt	3480
cgtatattttt attttttttt ttttatttttgc gttatgtgtt agttttttt aagggttattt	3540
tatgtatata ttacgttattt ttagttaacg aggagggggaa attaaataga aagagagata	3600
aatagagata tattttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3660
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3720
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3780
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3840
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3900
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	3960
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4020
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4080
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4140
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4200
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4260
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4320
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4380
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4440
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4500
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4560
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4620
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4680
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4740
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4800
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4860
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4920
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	4980
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5040
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5100
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5160
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5220
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5280
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5340
ttttttttttt ttttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc gtttatttttgc	5400

ttgttagttt	agtgataagt	ttgttttattt	cggggagaat	gtttcggagt	ggcgtgcggg	5460
tttagtaggg	tttgcgttcc	gtagttattt	tggaaaggagc	gcggctcggtt	taggatata	5520
gagattattt	tgtgattttt	atggcgaagg	ttgtgtgtt	ttatttttaat	ttttttttt	5580
ataagaattt	ttttttttt	ttttttttt	tttttttattt	ttttttgttt	agttttttt	5640
tttgcgtttt	ttttttgtt	ttttgtatgg	gtttgttagag	ggat taggtg	ggcgttttg	5700
gtgaatattt	ttttaggtgg	ttataggata	ggtgtattt	ggat tgggtt	tggaaagttt	5760
agggcgtt	atggttgggt	tttgaattt	gtattttttta	attgtatattt	ggtattcgg	5820
ttgggtgttt	tatattttt	tgtttgtaa	gtcgtggatt	agttttgtt	tagtatttt	5880
tttttaggga	tatttatagt	agaaggaaagg	ggatttttttt	gtagtttgg	tttagaggat	5940
attgaagggt	agattttggg	ggtattttt	gtgttattttt	agtctttt	gagaaatttta	6000
gagttttta	tagttacgtt	gattttttt	gtttttttttt	aaaagataaa	taatgaataaa	6060
aatttttaaa	ggttggtata	ttttaaattt	attttatttt	ttttaaattt	gggttaaaat	6120
agagaaaaag	gattttttt	gttttatttt	tttttttttt	atggaaagat	aaagtata	6180
gattaagt	ttttttat	aatattttaa	attgtttt	gtgaaggaaag	gtatttggat	6240
gatgtgaatt	tttataatttt	atgatggatt	tttagaaattt	ttttttttt	tatthaattt	6300
ttagttttt	tattgtaaat	taatgtt	gaattttttaat	gggtttaat	gagattttt	6360
tttggtagat	tattttattt	tttggtaata	attataaaat	gaatttggtt	aaatata	6420
gggatcgtat	tttattttaa	attgtttt	atttttagt	taatgtt	tagtgtata	6480
tgttttattt	tatattttt	gtatttat	atattttaaat	atttttagaa	taataaaaaaa	6540
agagataagg	aatttaaaaaa	tttttttttt	aatttgtata	aatgggattt	tgtgtggaaa	6600
tttagttta	gaatgtttt	ttttgtgttt	tatttttcgg	attatttttt	ttttttttgtt	6660
agaattttgt	ttgttattat	tttagtaagga	aaagaagat	ttatgttaat	tttttatat	6720
gatagatatt	atttagtatt	ttttttttt	tagtttttt	gtttaat	ttttgggtat	6780
aaagggaaagg	attgattggg	tttttttagg	aaatttttaag	tttttaagt	agtttttaaa	6840
agttttgggg	ttgaaagttag	tttttttaaa	ttgtttgtt	tgattttag	ggttat	6900
ttagtttagt	gagtttagaa	tattttttaa	aaggattttaa	atgaaagga	atataataga	6960
aatattttaga	gtgtatggta	tttgcgtt	ataagttttt	g		7001

<210> 13  
<211> 7001

<212> DNA

<212> DNR

<213> Artificial sequence

<220> chemically treated genomic DNA (Homo sapiens)  
<223>

<400> 13

cgtttttttt atagtggttg cgaggcgtag atttgggtt attcgtaacgt tatttcgggg	1560
tatttttttc gggggata ggtttgttat tgggttggta ggagattatt ttaagtatt	1620
tgtgtttta tatggtttgc ttaaattcg cggatattt ataaatttc ggtgtttaga	1680
agttatatgt tagtaattcg ttttagcgcg gatttagtta gttatttcg aaatttagatt	1740
tatthaattt ttaatcgttt ttaaaggtt taggacgtgg ggtgggagg agggaaagc	1800
gggtgatagg aatcggttt tagaaaggta ttattatagt tgatataattt ttaattaaat	1860
agtttagatg aaaggaaatt tggggagttt attaaataaa aatattaaaa ggataaataa	1920
aattttgtt agttttgtt attttaataa ttttaattt taaatgtttaa gagcagatt	1980
tttttaagtg atttaaagcg tttcggtttt atttgggtt aggtgtttt ttttataaatt	2040
aatttgggtt ttgtttgggt ttttaacgtg tggtttgtt ggaagttcgg gtttcgggt	2100
ttgttttcg tacggacggt aagtgggtt agagtagt ttttttagt gttcggcag	2160
agaatttgat tttgaacgta ggcgggtt tacgtagaat tticgggtt ggtcgccgt	2220
ttcgggtttt ttgcgcgtat ttcgggtcgc cgcgttgcg gttttcgta gtttttagg	2280
ttttttttt tttttttt ttttgcggg cgccgggtt atttcgacgg	2340
gccccgggg cccgggtatt tgtagaaatg cggccgggtcgtt gttcgcgtt tcgttagt	2400
gttgggttcg ttttttagt agtagggat ttgttggtcg tgggttgc gggaaaggcga	2460
tagttgcggc ggcgggttga gtatgttgcg cgggttgcga gatacgttgc tgagtgggg	2520
gaaattttt aggtcggtt agtcaacgt cgtattttta gattcgggtt cgtaggggag	2580
gtcgggttgc tcgttagattt ggcgttgcg ggcgttgcg gcttgcgtt cgtaggcggc	2640
gttttcgggg tagttgtata cggccgggtt gttttgtt aggtatattt cgtttaggg	2700
tcgttttagg gggatttga gttgcggacg gtttaggggtt ttagttcgt tttttggat	2760
ttgatgttagt agggttattt tagatgtttt ggtgtggagg gttatgttta tggtcgttgc	2820
tcgcgggtag ggttagatc gtgtttcgtt agggtagaaag gtttagaaat cggccgggtt	2880
tttggaaaaa gagtataattt cgggtttaga ggcgacgtt cgtatgttgc gtcgatacgc	2940
gagttttgtt ttcgggtttt ttcgggtt ggtgaagtgc ggcgatttgc	3000
cgggagtaag ttttttttta gacgaaacgt ttttcgtt gttttgggtt ttcgggtttt	3060
taatttttaaattt tattttttt ttcgttattt atgtattataa aaggtgttgg agacgggtt	3120
gggattttgtt ttttttttgc atattttttt aaatattttt ttaggtataa ttgcattttgg	3180
agcgattttttaaattt aagatgtt tttttgttattt ttattttttt ttcgtcgtt gttggataga	3240
ggtttagttt tacgggtttagg gggccggggc gtacgaggat ttgtttaaagg tggttttaggg	3300
aagattgggtt taaaataaaa cgcgaaagac ggatttaggg gtcgggtttt ttatgtgtt	3360
tggtttatgtt gtttgcgtt agatttgcattt atattttttt gttttttttt ttttttttgc	3420
ttttttttt ttcgttgcgtt gaaatacgtt gttgttgc ttgttgcgtt ggttgcgtt ggttgcgtt	3480
tatattgttaa ttcgttgcgtt gtagatagaa tgggttgc gtttgcgtt gtttgcgtt	3540
atagatgtt atattttttt gttggggaa ttgtatgggg gtttgcgtt gtttgcgtt	3600
ggagattttt ggttatataa taggaagagt tgtagttttt gtttgcgtt gtttgcgtt	3660
ttaggattttt agttttttt tttgtttttt gtttgcgtt gtttgcgtt	3720
tttttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt	3780
tttttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt	3840
tttttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt	3900
gggtgtttt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt	3960
aatgtgtt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4020
gttatttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4080
tttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4140
tttagatgaa aaataaaatag aaaaaggtt ttaatttttttgc ttttttttgc ttttttttgc	4200
gtatatataat atatataat atgtgttattt atatataat atatataat atatataat	4260
aggagataaa aaatagggtt gtttttttgc ttttttttgc ttttttttgc ttttttttgc	4320
tgaataaaattt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4380
taatttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4440
gttaagttt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4500
attttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4560
atcgagttt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4620
gtgtatcgta gtttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4680
tagatgtt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4740
gtaaaaaggta ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4800
tataaagaat ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4860
tagtaattttt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4920
taaaatgttaa ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	4980
gttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	5040
ggaaaggatgtt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	5100
tggatgtttt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	5160
gttagttttt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	5220
ggggagttgtt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc	5280

-18- 11.00

ttttatgttt	tttggttta	tttaagtaa	gaggaaaaat	aggttgg	tgaattata	5340
tttacggtt	aaaatagaat	gttagtaaa	agtgtatgga	tattaagttt	ataaaatagg	5400
atatgggtgg	tttttcgaa	agaatataat	ttaataataa	aagtttttg	ggatataatgt	5460
ggattaaatg	tttatttgg	titagtttt	agttttgaa	tagaggtatt	gttatgttt	5520
cgattgtatt	agggaaattag	attttggaaat	aaatgtttt	gtatittag	gatgtgttt	5580
tagttgaaat	gtaatatttt	tttatttcgt	taattaaattt	tataaatttt	tttatgaata	5640
gtttagtga	ttgtttttt	taaatatgt	aaaaatacgt	attattaaaa	gtttagata	5700
tgaatataag	ataaaaggta	atattttgt	tttaaattga	ttttaggtt	tcgagtgt	5760
ttgatcgtga	ttgggaacga	ggtttttat	tttttagtgg	cgtttatgt	gattttttt	5820
ttgattattt	tttaattat	tttttcggtt	atagtattaa	tacgtataat	tgagggttt	5880
tttagagtgtt	tacggtttag	gttttaggt	atatgatatt	taatggaggt	tttgcgttta	5940
gatatttagtt	attattttgg	atattaaatg	atttttaatta	taatgtttag	agtggtcggt	6000
ttttgggttt	gggatattat	gtagttattt	agagatttt	gagtggttt	tgagattagt	6060
ataaaaaaaga	aatagaaagt	tataaaaatg	ttaatgtat	tattatgtaa	atatatgttt	6120
ttgtgtttt	aaagattttt	agtattgt	tgtttgagta	taggagagtt	ttttttatag	6180
tttagtattga	aaataaaat	tggatataaa	taaatattga	aaagaaaagat	tgtttatttt	6240
tggtgggtat	agtgggtttt	ttttaggtt	aataatggtt	attttatgtt	tagattagtt	6300
tttagaaaaaa	gtaagagttat	ttagggaggg	aggagagagg	aatagggaa	aggagaagga	6360
aaggaaaggg	gatttgtat	tgtttattat	tgatataagga	agaataagaa	gtttagttgt	6420
ttttttatag	gttttgattt	tttagagatt	tataattaaa	gttagtttaa	gaagtttagt	6480
aaaggtagtt	tttttaatta	ttttttttt	agtattttt	tttaaattta	tttgggtgag	6540
ttttgtttt	gggtttgggt	agtatgggt	ggaaagtata	ttgtgttacg	tcgattttt	6600
ttttttgtt	ttggtaaaaa	tttatttcgg	gttttagtt	tttttgggtt	tttttttat	6660
tttttttgt	tgatataata	cgttttagtc	gtgattttt	gttttttta	ggtgaagaag	6720
ggttaaagatt	gatttggttt	tttcgttga	tgtgttttt	gttttatttt	tttagcggtt	6780
tgttgggtat	ttaggtttt	tttaaatatg	agtattattt	tttaaatatg	gtgtttttt	6840
taatttttc	gtttttgtgt	tttagtattat	gtttttttta	gttattttaga	ttaaaaatttt	6900
attgtttttt	tcgagggtt	atttttttt	gtttttata	tttaattaag	aggtaatttt	6960
taagtttttt	agtttataaa	ttttttttt	tttatttgc	t		7001

<210> 14  
<211> 11001

<211> 11001  
<212> DNA  
<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 14

ttaagttaga	tgtttttaa	ttatttgtgg	ataggttagg	tatatttga	gtttaatttt
attttataagg	ttaaatattt	tggagttaga	aagtttttag	gtaaaaaagt	tgaagggggt
ttttttatgt	tattagatgg	attttgtat	ttttagaaga	tttttataat	tagaaagat
taaagtatta	aggtatattt	ttttgggttt	ttgggataat	tttaggtttt	ggtatgagtg
gtttggaagt	ttttgtttta	gttataatgt	ttatataattt	ttgaaattgt	ttttaggtttt
ttgtttttta	gtataatttt	tttttaagt	tttattgttag	ttatagttta	ttagttttgt
ttagtgataa	ttaagaaatt	aagaattatg	tatttacgtt	tatttttta	gagttatttt
tttttaggat	aaagtttagg	gttttgttat	tgggttttg	taggagtcgt	agtcgtaggg
gttgttattt	atthaatagt	tttcgttaagt	atattgtgaa	gggaaagtaa	tgattagaga
tagggtagt	tgttttagttt	ttgtatgttt	agggtatgc	gtatataattt	ttatataaggg
taggggtggg	tgggaagttt	attttggtcg	tgacgtttag	cgcgtttaaa	gagtgttaat
ttgcgggggt	tattttattat	taagaatttt	cgtagtaggg	tttaatgtat	tttacgttt
tttgtgcgtg	atagtatatg	taggtgtttg	atagtatttt	tgggttaggt	aaaggaagtg
ccgcgtttga	tatttgtgtt	tcgttttggg	tttcgtcggg	tatttgtaa	ggaggggtgg
tttttgttgg	agggtataga	gatagggcgt	attagttta	gttgaatttt	gatgaagttt
gtgtaaagat	cgttttgg	ttaaagaaat	agagaaattt	aattttgata	ataggtttt
ggtgagatgt	tagtttattt	ggggtttaggt	tgggtatgt	taaatttattt	tttgcgttta
tttaagataa	ttttagttgt	gatttttga	gtatttaggt	tatagttggg	tatgtttttt
tttttacgtt	tttttttga	gtagtttaatt	tattaagttt	atgaagaggt	tgttgttgat
ttgggtattt	tattttttga	ttttttgttt	aatttttagtt	tgagaaaggt	taggtttttt
ttattttata	ggtcgtttt	gtaaagatggg	ttagtatgga	tatagggttt	ttgaggaatt
tagggttttt	ttgaaaaatg	gtttttgggg	tagttttgg	aaattgattt	tttttggttt
tttggttttt	atgtatataat	atatagttgg	tgtttaatttt	gaatttattt	ttgtttttgg

05.11.04.

ttttgtatgt	tttgggtgga	taaggaaag	atagaattat	ttggttttt	tttgggttt	1440
gtttagggt	ttagtattga	atgtatgtt	aaggatatta	tagaagtagg	ggttaattgaa	1500
ggtatatgt	taggggttag	gaatagtta	gggattttga	agagggattt	ttattnaaag	1560
taaaattagg	ttgggtgtgg	ttgtatgtt	ttgtatgtt	agatattttg	gaggttaagg	1620
taggaggatt	atttgatttt	taggagttt	agattatgtt	ggtaatata	gtaagatttt	1680
attttattta	aaaaaaagaa	aaaaaaattt	agtaggtgt	ggtgggtgt	ttgtatgtt	1740
aattgtttag	gaggttgagg	ttggaggatc	gtttagttc	gggagattt	agttatagta	1800
agttatttac	gtgttattgt	attttagttt	gggaaattga	gtgagattt	gtttaaaat	1860
ataaaaaata	aaaataggtt	gggtacgtt	gttacgtt	gtaattttag	tattnnggaa	1920
ggtcgaggcg	ggtggattat	ttgaggttag	gagtttgaga	ttagttttag	taatatggag	1980
aaatttcgtt	tttataaaa	atataaaaatt	agtaggcgt	ggtggatata	gtttgttaatt	2040
ttagtttattt	aggaggttga	ggttaggagaa	ttgtttaat	tcgggaggtg	gaggttgtag	2100
tgaattgaga	tcgtgttac	gtattttagt	ttggtaata	agagcgaat	tcgggtttaa	2160
aaaaaaaaaa	aatttagtaaa	attatatttt	aattgtatata	tttgattata	gtattttagt	2220
tgagttggag	tgaggggtt	tttgagagaa	ggtatttat	ttttttttt	tgttccgtta	2280
cggggttatg	atttattgt	gggtgagagg	agtggagagt	ggtgtatata	agtagtttag	2340
ttattatgtt	atagagtagt	atttggagtt	agttttttat	gtttatata	tagtggagaaa	2400
aattattgtt	atatgtatgtt	taatttttag	ttagttttag	taaaaggtag	ttttaggtta	2460
ggtttttaatt	tgtagaggt	atataaggt	ttttttgtg	ggtttttgt	tttgggttg	2520
ttgtttggag	atttggttt	aagattttt	tttttttga	gacgaattt	tattngtcg	2580
tttaggttgt	agtgtatgtt	ttggattttt	gtttatttga	agttttgtt	tttgggttta	2640
agcgattttt	ttgttttaga	tttgcgtt	gttgggattt	taggcgcgt	ttataataat	2700
attcggttaa	ttttttagt	tttagtagag	atgggattt	attatattgg	ttaggttggt	2760
tttgaattttt	tgattttaag	tgattcgtt	gttttattt	tttaaagtgt	tggattata	2820
ggcgtgaatt	atcgatttgc	atttagagat	tttaatttgc	attattttt	tttattttta	2880
tttagggatt	ggatttttgc	cgaaagggtt	gagtgtggg	taggttagt	agggttttga	2940
atcgattttt	ttttttaga	ttttttgtt	tttatttgc	tagtttatt	tttgggttgc	3000
tttagatagg	tttttagtt	aatgcgtt	ttatagatat	agttatgtt	agcgttgcatt	3060
aatattttgt	tttagaagaa	ttttataag	gttttttgc	gaatgatttt	gtgttttagt	3120
taggagat	agggtttttt	ttgatttgc	tttggagttt	ttttaagtat	ttaaattttt	3180
tgatggggat	aaatggagag	gatagatag	ggagtaggtt	ggagcgtttt	agtagaaatgt	3240
tttttattta	gaattcgtt	ttatttttgc	tttagtaagg	atgtgggtt	aagaattaaag	3300
tttagggttt	tatggaaaa	agttaaagg	ggaggggtgg	gaatttaagt	tttatttttt	3360
ttttaagtat	ttaaaggtt	tttggatgg	gaagagtatt	ggagtaaaa	ttttagtata	3420
aattttattt	gggatagtgg	gtattttgc	cggtttagta	aaaataatg	gtgtgggtt	3480
tggaaaatga	gggttggagg	ttgtgaataa	agtagtggat	gtgtttgtt	agatattttaa	3540
cgggaagaag	tatttagat	ggaggagtt	tagggtagg	agaaatgtt	gatagatttt	3600
agtgttaggg	taagaaggaa	gattattttt	ttttagtata	aggagggta	taggtatgtt	3660
gttaattttt	ttttgtatgt	gttttgcgtt	tttattttaat	aatgagaaag	tttgggtttt	3720
ttttttttt	tggtgattt	aggagttt	ggttgggatg	tagtattttt	attttttagt	3780
ttttttttt	tggtgatgaa	ttttttttt	tttattttaga	aaatagattt	ggatttagagg	3840
tattgtatag	tttttttagg	attttaaagg	aggaagagtt	ttttttttt	tttttaaagt	3900
ttttttttt	aaggaggattt	taatagtat	tttagtcgga	tgtatagttag	gattatggaa	3960
ttttttttt	gtattatagg	gatttatttt	ttattttatt	attgtttata	aaaattgtat	4020
ttttttttt	tgagatagag	tttcgttttgc	tttttttaggt	tggagtgttag	ttgtgcgtt	4080
ttggtttatt	gtattttttgc	ttttttgggt	tttaagtat	tttggtttta	tttttttaag	4140
tagttggat	tataagggtt	gtttattata	attgtttaat	ttttgtattt	tttagtcgag	4200
acggggttttt	attattttgg	tttaggttgc	tttgcgtttt	tgatattttt	tttattttat	4260
ttcggttttt	taaagtgtt	ggattaaagg	tgtgagttat	tgtattttgt	ttaaaatttga	4320
tgtttttttt	tttttttttta	atataataat	ttggattttt	tagttttta	tttttttttt	4380
ttttttttt	tttttttttga	gatagagttt	ttttttttta	tttaggttgg	aatgtatgtt	4440
tttagtttcg	atttatttgc	atttttgtt	tttgggtttt	agtatattt	ttgttttagt	4500
tttttttagt	gttgggattt	taggtatata	tttattatgtt	tagataattt	ttttgtattt	4560
tttagtata	cggggttttgc	ttatgttgc	tttggtaggtt	tcgaattttt	gttttttaagt	4620
gatttggttt	ttttgggtttt	ttaaaatgtt	gagattatag	gtatgatgtt	ttaaatgtt	4680
ttttttttt	tttttttttgc	atagagttt	attttgttgc	tttaggttgg	gtgttagtgc	4740
acgattttgg	tttatttgc	tttttttttgc	tcggttgc	tgatttagtt	tttttaagtag	4800
ttgggattat	agttatataat	tattatgttgc	ggttaattttt	tgtatgttta	gttagagatag	4860
ggtttttattt	tggtgatgtt	gtttagtttgc	aatttttgc	tgttaatgtt	ttattngttt	4920
tggttttttta	aaggatttgc	attagaggtt	tgatgttgc	tatttgggtt	ttttttttat	4980
ttttgagata	gagttttattt	ttgttatttgc	ggttggagtt	tagtgcgtt	attttgggtt	5040
attgtatattt	ttgttttttgc	ggttaatgtt	tttttttttgc	tttattttttt	taagtagttt	5100
ggattatagg	tggtatgtt	cggtgttagt	tttttttttgc	aattgtttag	tgttttgttg	5160

tttttttatt tttttatagt ggaaaatggg ttaggattga ttgatataa gataagttt 5220  
ggggtttata ttaatttaa tttttgtatt taagttttgg gtttagatt tggcgtgtt 5280  
agtattattt attttgtaa gaattttgtt aaattttatt tgaatgttta ttataattt 5340  
tattttttt atttaataa ggattttcg tttatttttt ttaggtat ttaggttat 5400  
agttttgtt tttttttt ggtgtttagg tttggtttt tgagtttgg gtttatatt 5460  
atggtattt gtagatgtt ttgcataat gggatattt aggaggttt gagatattt 5520  
atagtttgg gtagtaatt tggattttt tttttattt ttaggtatt ttataattt 5580  
gtttttttt tttttgtgg taaagtggtt ttagatgtt atggttaaa ataagattt 5640  
ttttttattt attttaaat ttttttttag atttattt gaggaaaggga atagaattt 5700  
ttatatttta gtagttggg ataggttaga ataggaaaga ggtgagggtt tagttgtt 5760  
tatataaggag ttagatggg ggagtaggat tttttttgt ttttaagtt ttttaataa 5820  
tatttttaa ttttggcga ggatttttt tttttat ttttttag ttttttaag 5880  
gagggagtag gtagattcga acgcccgaat cgaggttta gtttaattt ttcggcgg 5940  
tttagtata gttggataat gtcgggtt gtttattt aagttatata gttgttttt 6000  
tcgtgtttaa ttgtttgtt atagaaatta aggggttcc ggtatttagt atttagcgg 6060  
tggaaatcggg gtttacgta cggtttgcg ggttaggtt cggtaggat tcgcgggag 6120  
ttacgttagt aggagggtgg ggttgggtt cgatttagga cgcgttaacg gatcgggag 6180  
ggcggagtt tagcgtacgt tttttttt gtcgtcggt atttttgg ttttatttgg 6240  
ttcggcgcg gtttgcgagt tagcaggtt cgcgcggta agtattgtt gatttcggag 6300  
ttcggatttt tttgggtgtt gtagttattt ttcgtcgtt ttttttagt tatttcgaaa 6360  
gaaggcgtt tcgttgcgtt tatacgta ttcgttgcgtt ttttagttt ggcgttcgt 6420  
agtcgttaat ttcgtttcgt gtcgcgtcgt tgcgtgtacg cgtttagt gtcgcgtcgt 6480  
ttcgggttag agtcgcgtcgt taatcgtaa gattgaaacg tagatcgta ggtttagtt 6540  
tttgggttag tgggttaga acgtcggggc ggggataacg acgttgcgtt ttttaggaatg 6600  
attttatcgt ttcggagttt tatttataa ttttattt tataaggaaac gggggcgggt 6660  
gttagcgttc gggtaagcgt ataagagtgg ttttgggtc gaggcgaggg cggaaagggt 6720  
cgggaaagtgc ggcgtgcgcgg agttgggtt agttgggtt cgggttcgtt tgcgcgggt 6780  
ggagtattt cggagtcgtt aatttaggtt ttttttttag tttcgcgtt gaatttagttt 6840  
tttgggtcg tcgggaaatc ggttaattt ggttgcgtt tttcgtttt tttatacgt ttcgggttc 6900  
ttcggagaatg tttgtattt ggttgcgtt tttcgtttt tttttttttt agtttaggtt cgggggttcg 6960  
gcgttattt cgttgcgtt ttcgtttatc ggggggtttt agtttaggtt ttcgggttcg 7020  
taatagttt gtagacgag cgcgcggtag cggtaggtt aggtgaattt gtaatttgcgt 7080  
gagagttt gcggtgagc ggaggagtt taggtcgggg aaatgttgcg gagattgaag 7140  
ggaagtttta gggagaggtt cgttgcgtt taggtttcg aggttcgatt tatttttagt 7200  
ggttattttta tattgttacg cggattttaa tttttttttt agtttaggtt ttcgggttcg 7260  
cggaaggtt taggttagaga gtttgcgtt atagttggat ttttatttgcgt tagtataaa 7320  
ttttttttt ttttatttgcgt aattaaaaaa ataataataa aaaatttgcgt tttgttttt 7380  
ttatttaggt tggagtgtt tggcgcgtt tcgttgcgtt gtaattttcg tttttgggt 7440  
ttaagcgatt ttttgcgtt agtttttgcgtt tttttttttt agtttaggtt ttcgggttcg 7500  
gttagttaa tttttgtatt ttttagtagag tttttttttt acgggggtttt attatgtt taggttgcgt 7560  
tttaattttt tgatttttagg tgatttttgcgtt tttttttttt gttcgggtt ttaaagtgtt tgggattata 7620  
ggtttaggtt atcgtatttcgt gttttttttt gggaaacgtt atgaaatata tttgtttttt 7680  
tatttgaagg aaaaattttaa tatttttaat tttttttttt acgggggtttt attatgtt taggttgcgt 7740  
ttattttttt tagattaaga tattttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 7800  
ttttttttt atttttagt ggttgcgtt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 7860  
tttagcgatt tttgttattt taaatggaaat tttttttttt tttttttttt ttttatttttgcgt tttttttttt 7920  
tagtattttt tgaagttttt tttttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 7980  
tttattttttt gtagttttt ttttagtttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8040  
acgtgaagt ttgggtttt tagttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8100  
agatttacgg ttgaaatatt gattttaaatt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8160  
tatttagatg tttttttttt gttttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8220  
tagttttattt gtttattttt ttttagtttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8280  
tagtttttttgg agataaaaat ttaaattttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8340  
taaataatgtt taaattttt tttttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8400  
cgttgtatgt ttttagtttt tttttttttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8460  
attttgcgt ttaaggttgg gggtaggtt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8520  
ttgtgttttaa gtaattttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8580  
tattacgttt ggttattttt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8640  
taggttgggtt ttgaaattttt gatttttaggtt tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8700  
gggattatag gtatgagtt tcgcgttccg tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8760  
attttgcgtt tttttttttt gattttgtt tttttttttt ttttatttttgcgt tttttttttt 8820  
atgtatataat agatttgggaa tattttttt tttttttttt ttttatttttgcgt tttttttttt 8880  
atgtttaatt tagattttt ttttataataa tttttttttt tttttttttt ttttatttttgcgt tttttttttt 8940

tagggtttat	ttttagtagt	tgatttaata	ggtttgcgg	gggatttagg	ttagcgggga	9000
ggattgtaaa	agtattttt	gtgatttt	ttgggttta	tttaggggag	agtaatttt	9060
gtttgttgc	gatttttag	ggtgtagaag	gattgttgg	tgtgtgtt	cgtgtatatt	9120
tttagtattt	atttatttgg	ttagaaaagg	gtgtttgtt	aataaaagatt	taataaaaatt	9180
tttggttt	gggggttta	taaagggtt	aaattttttt	aggtttttt	ttataggtgg	9240
taattttt	ttattttaaa	ggttttgg	ggggttatg	gtgtttgaga	agaggtaat	9300
ttgggaagat	ggatttcgag	gatagttagt	ataaattttt	ttttaagaag	gtttaaggta	9360
ttttaaagat	aagaaaattt	aaatttagcgt	attttataat	ataagtagt	atttttgtt	9420
atttgtggtt	tagatacag	tggagtgcga	taaggataa	attattttcg	cgtattttt	9480
acgcgtggg	cgaaagtaac	ggatttagt	ttcggaggt	gttttcgtcg	atttttttt	9540
tcgcgattt	attcgcggc	attgcgtt	ttttgtt	ttttttcgt	ttcgttaggc	9600
gcgcggggtt	attattttac	cgcgtattt	aggttttgc	gtacgacgtt	ttagatgaag	9660
tcgttataga	ggtcgtatta	cgtgtgcgt	gcgggtttcg	cgggttggaa	gcgggtggta	9720
cggtaggaa	ttagttgtcg	tgtgggtt	tacgcgggt	ttcgcgcgt	gcgtacgcg	9780
ttggtagcgtt	ttagtcgggt	gcggttttt	ttagcgcgtt	tagcgggt	tagtttct	9840
agtttaatga	gttttaggtt	tttcgatat	gttcgttgg	tttcgtgtt	cgttggttt	9900
gggcgttagt	aagcgcgggt	cggcggggt	tataggcgg	tttcgattt	tagcgtttt	9960
tttaggattt	agattggcg	gcgggaagga	gtttagggaga	gtcgcgtat	gaaatttgg	10020
gtgttagggat	tgtgggttc	gaaggcgggg	tttggcgcgt	tttcgttagag	ttttttcgt	10080
tttggttttt	ttttttttt	tcgtttttt	tttatattt	atttcggacg	tttataacga	10140
cggcgtatgt	aaagtattac	cgggagat	tcgtttttt	ggaggttagt	tttattgtgt	10200
tagaggaaga	gggtttttat	attcggttt	ggttttttt	tttcgtttt	ttgaagtaat	10260
atatttggtt	tatttattgg	gtgggtt	aagtttcgag	tttttattt	gggttagggag	10320
gagggagatc	ggtttagtagt	tttacgttc	gttttgc	ttattgcga	gattgggtt	10380
tcggtagagg	ttggatcgt	atttgcgt	tttaggggt	atttgggt	gattttttt	10440
gtatgggtgg	tcggttttt	gtatgtt	ttttatgt	ttttgtt	tttgggtt	10500
tagatataa	gtttttttat	gttttttta	gtgtttgatt	ttgttatttt	ttgttaggtt	10560
ttggtattga	ggatgttaat	gtatgtgggg	gtatgtggag	taggtttt	aggttttaagg	10620
ttttaggata	tttttattt	tagtaatatt	atttatttt	gtatgttgc	tagcgtttt	10680
aagtttttgt	attgttagaa	gtatagcgg	gtcggtttt	agttattgtt	tttagtataat	10740
ttagtttgc	gttttttagt	tatttgggg	aaagtttaga	agttttgatt	gtttttggaa	10800
ggtgggggtt	tttttattt	atttatgtt	tttgcatttt	tttttattt	tttgcattt	10860
ttataggttt	tatttgcgt	tttgcattt	taggtttt	tttgcattt	tgaatataat	10920
ttggaggttt	tggttggtaa	ttgttgc	tttgcattt	tttgcattt	tttgcattt	10980
tttagatttt	gggattttaga	a				11001

<210> 15  
 <211> 11001  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chemically treated genomic DNA (Homo sapiens)

<400> 15

tttttagattt	tagaaattt	ggagcgggt	gagcgagaaa	atagaggtaa	gtggtaggt	60
attgttaagt	attagttt	gtatgtttt	agttttt	agtaggattt	gcgggtt	120
gcgcgaaggt	aagggtt	gaaatgg	ggagggtgg	ggggatgt	gagggtatgg	180
tgtgggtgg	gtgtttt	tttttaggt	tagtt	tttttattt	tttttttaggt	240
gggtttaggt	ttataggtt	gatgtgt	agtaggtt	tttagagcgg	ttcgtt	300
tttattgtt	tgttagagg	ttaagcgtt	gtttacgt	ttagaatgag	tgttattgtt	360
gtaggtttag	gtatttt	attttggatt	ttaagttt	attttat	tttttatat	420
tattgttatt	ttaatattt	atttgcgtt	aggagtgtt	aagttagta	ttggaaaag	480
tatggaaaga	tttgcgtt	ggtgttt	ggtgtatag	ttaaatgagg	gttgcattt	540
ttgagggtcg	attatttt	ttaaggaaat	tttttagaa	tgtattttt	atttttaaga	600
ttacggttt	gttttgc	gagttt	tttcgtat	gaggtatag	cgccgcgtaa	660
agttgttgc	cgattttt	ttttttt	ttaagtgaa	gttcgagatt	tttgcattt	720
tttagtgggt	aggtaatgt	tttgcattt	gttaatcg	ttaggagggt	taggttgcgg	780
tgtggggatt	ttttttttt	agtagtagaa	agttggttt	tagaaatacg	gttatttttgc	840
cgtgtgttt	tgcggtcgtc	gtcgttgc	tcgttgcgg	tgggtgt	ggaggggac	900
aaggagggaa	ggaagggtaa	ggcgggggg	gtttgcgc	agcgcgtt	gttgcgtt	960
cgggtttat	agtttttgc	tttaggtttt	tattgcgc	tttttttgc	tttttttgc	1020

tcgttttagtt	tggattttgg	gggaggcggtt	gaagtccgggg	ttcggtttgt	gttttcgttc	1080
gttgcgcgtt	tgttagcggtt	taaagtttagc	gaagtacggg	ttaatcggg	ttatgtcggg	1140
ggagtttgag	tttattgagt	tgcggaggtt	ggtattcggtt	ggcgcgttg	gaaagggtcg	1200
tattcgggtt	gagcgtgtta	acgcgttgcg	tatcgcgcgg	ggtatcgcgt	gtaattttat	1260
acggtagttg	gttttggtc	gtggttatcg	tttttagttc	gcggggttcg	ttacgtatac	1320
gtgggtcgat	ttttgtggcg	attttatttgc	ggcgctcg	cgtaaagggtt	tgttagtgcgc	1380
gcgtgagtag	tggttgcgcg	cgtttacgag	acgccaagggg	gtagttaaagg	gttagcgtag	1440
tcgtcgcggg	ttaagtgcgcg	gtagaggggg	tcggcgggg	tagtttcga	gatttaggtt	1500
cgttattttc	gttttatcggt	tgaagagtgc	gcgaaaatgg	tttatttttt	gtcgtatttt	1560
attcgtattt	gggttataga	tgagtagagg	tggttgtta	tatgtaaaaaa	tacgttgatt	1620
ttaagttttt	tattttaaa	atgtttttgtt	tttttttag	aaagggtttt	tgtttattgt	1680
tttcggagtt	tattttttta	ggtttgggtt	tttttaata	tttatgattt	tttttagaaat	1740
ttttaggggt	aaggaaaatt	attattttatg	ggaggaggtt	tggaaaaattt	tagaaattttt	1800
ggtgggtttt	ttgtaagtag	gagttttgtt	gagttttat	ttagtaata	tttttttttg	1860
atttagtggaa	ttagatgtta	aaatatgtac	gtagttat	atttagttagt	ttttttgtat	1920
ttttgggaat	cgttagtaag	taaaggttgc	tttttttgg	gtagatatta	gttggaaatta	1980
ttaggggtgt	ttttatagtt	tttttcgtta	gtttggattt	tatcgtagat	ttgttgaatt	2040
aattgttggg	agtggatttt	aggtatttagt	aaattttaaa	aatttttaa	attattgtaa	2100
tatggagttt	gggtttagta	ttattttttgtt	ggtttattta	ggaatttgg	gatggatagt	2160
tttttaggtt	tgtgtgtgt	tggagatttt	tttattcggt	ataagaggat	attataaatt	2220
tagttgggg	gagtataaaag	ttgtgataga	atgtaaagaa	tgaataaagg	gtcgagcgcg	2280
gtgggttatg	ttttaattt	tagtatttcg	gaaggcggag	gcgggtggat	tattttaggt	2340
taggagttt	agattagttt	gttaatattatg	gtgaaattttt	atgttttattt	aaaaataaaa	2400
aaaaatgagt	taggcgtagt	ggcgggtgtt	tgtatttta	gttattcggg	aggtttaggt	2460
gggagaattt	ttttaatata	ggaggcggag	gtttagtgc	gtcgagatcg	tttttatttt	2520
tttttagttt	ggcgatagag	tgagatttttgc	ttttaaaaaa	aaaaaaa	aaaaaaaagaa	2580
taagggttggg	atattgtac	gttttaaaag	agaaataaaag	tagttatgg	gataagaagt	2640
aggatgattt	gggtatgttt	attagaggtt	gagataagg	agaaattttaa	gataagtttg	2700
gtttttttgtt	tttagtaatt	gggagtttag	tggttatttt	tgtttaaag	aggaagtttg	2760
gtaaagtgtag	tagttaggtt	gaagaaaagg	gaattaaattt	ttggttatgt	ttatttgaaa	2820
cgttttttag	atattttatgt	gtttttttttgtt	gtttttttttttt	ttttttttttttt	ttttttttttttt	2880
tagtggtttta	gtcgtggattt	ttgggttagat	ttttttttttttt	ttttttttttttt	ttttttttttttt	2940
atttagtttta	gattttatcg	tgagatatgg	ttttttttttttt	ttttttttttttt	ttttttttttttt	3000
gttaggagttt	taggggttag	gaggaaaattt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3060
agtaagttttt	aaatgtatgtt	gaggggttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	3120
ggttagtatat	agatcggttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3180
ttgggttggag	tgggttagagg	ggagagttgaa	ttttttttttttt	ttttttttttttt	ttttttttttttt	3240
tttttgggtt	gagggggagta	gagataggttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	3300
gttttagttt	tttttaaagt	aaatgggttag	ttttttttttttt	ttttttttttttt	ttttttttttttt	3360
tcgggtcgccg	tggtttaagt	ttgttagttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3420
attttagattt	aggagtttgc	gatttagtttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	3480
aaatataaaaa	attatgtggg	ttatgtggcgt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3540
tgaggttagaa	gaatcgtttgc	aatttaggag	ttttttttttttt	ttttttttttttt	ttttttttttttt	3600
attgtattttt	agtttgggttgc	ataaaagtaa	ttttttttttttt	ttttttttttttt	ttttttttttttt	3660
tgttaatgag	gaaagggggaa	gttttgggttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	3720
ttttttgttt	gtgggttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3780
gcgttagtagt	gtgaggttaat	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3840
gtttttttttt	ttgggttttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3900
cgttttatcg	tttaggttttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	3960
tttcgttttttgc	ttggatttttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4020
ggatacgaac	gtggtgagcg	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4080
tatagtgttag	gtatttttcg	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4140
cgatttttcg	gcggtataga	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4200
tgtcggttgc	gtaaagtattt	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4260
ttcgcgtac	cgtattttttc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4320
tcgcgtttgtt	cgacgtttttgc	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4380
ggagtttcgg	agcgtatgagg	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4440
ttttttgtttt	aatgagataa	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4500
gcggcgccgt	tttgggttcgg	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4560
tcggggcggt	ggttggcggt	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4620
gggcgaggcg	gaggcgtttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4680
ttgttagttaa	gaggatttcgg	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4740
agttcgttag	tcgcgtcggtt	ttttttttttttt	ttttttttttttt	ttttttttttttt	ttttttttttttt	4800

agcgggtcggtt ggaggtttcggtt ttttttcgggtt tcgttgcgc gttttgggtc ggtgggttagt 4860  
tttatTTTTT tggttacgtg gttttcgcg ggttttggc ggggattttt tcgcggaaatc 4920  
gtcgtaaga tttcgattt atcgttaga tgggggtgtt cgggggtttt ttgggtttt 4980  
ttatagatag gttgaatacg gaaaaagtag ttgtatgggtt tgggttagat ttgagtcggg 5040  
tattatTTTT tagtattaa agtcgatcg tttggggag tttgggtttt ttgggtttt 5100  
ttcgaatgtt tttgtttt tttggggag tttgggtttt ttgggtttt 5160  
ttcgttagga attgagaagt atgtttagga aatTTTgaga ggttagagaga gattttgtt 5220  
tttattttgtt attttgtat ggagtttagtt gatTTTttt tttttttt tttgggtttt 5280  
ttattatTTTg tggaaatgtg gaagattttg tttggattta taagtattta ggagtatttt 5340  
gatttggaa tagataggaa agaattttt tttggattta aatgtttaa agagggtggaa aaagagattt 5400  
atttataggaa agggggaaag ttagattata cggaaatttt taggtatttt tattatcgga 5460  
agtttattaa tttaggatgt taagggtgtt tttgggtttt tttgggtttt 5520  
gaattgtgtg ttagatgtt ttgggtgtat tttgggtttt tttgggtttt 5580  
taggaaaaag aaataggat tttgggtttt tttgggtttt 5640  
tttatttaag taaagaaagt ggagttgtga tttgggtttt agataaaatt ttataaaatt 5700  
tttataaaa tgggtgggtt ttagtacgtt tttgggtttt tttgggtttt 5760  
gttgagttga gtgttagatt ttgggtttt tttgggtttt 5820  
tattgtggaa aggtggggaa attataagat tttgggtttt tttgggtttt 5880  
ggaggtgtat atttgttaatt ttagtatttt tttgggtttt tttgggtttt 5940  
tttgggaggtt gagggtttagt tttgggtttt tttgggtttt 6000  
gagttagatt ttgttttaaa aatagaaaag tttgggtttt tttgggtttt 6060  
tgttaatgtt ttgggaggtt aaggttaggt tttgggtttt tttgggtttt 6120  
tttgggttaat atgggttaat tttattttt tttgggtttt tttgggtttt 6180  
gggtgtgtat tttgggtttt tttgggtttt tttgggtttt 6240  
gttgtagtga gttaaatcg tttgggtttt tttgggtttt 6300  
ttttaattttt aagaaagaag gttgggtttt tttgggtttt 6360  
ggaggttaag gtaggtat tttgggtttt tttgggtttt 6420  
gtttttttt gttgttattt tttgggtttt tttgggtttt 6480  
gtttttttt gttgttattt tttgggtttt tttgggtttt 6540  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 6600  
ataggaggtt gttgttattt tttgggtttt tttgggtttt 6660  
gtttttttt gttgttattt tttgggtttt tttgggtttt 6720  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 6780  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 6840  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 6900  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 6960  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7020  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7080  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7140  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7200  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7260  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7320  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7380  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7440  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7500  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7560  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7620  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7680  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7740  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7800  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7860  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7920  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 7980  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8040  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8100  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8160  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8220  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8280  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8340  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8400  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8460  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8520  
ttttagttttt aatgggtttt tttgggtttt tttgggtttt 8580

aatattatg ttatagtgtat tttttttatt atgtgtgaga tatggagaat tgggttttaag	8640
tattattttg ttatattgggt gttggattat tgatgtgtat tattttttat tttttttatt	8700
ttgttagtggg ttatggttc gtgtccccgt agaggagaaa aatgggtgt ttttttttagg	8760
ataaaatttt atttaattt aatttaggggtg ttgtgattag aatgtgtaat tgaggtgtga	8820
ttttattgtat tttttttttt tttgagatcg agtttcgtt ttgtgttta ggttggagtg	8880
cgatggtacg atttagtta attgtatatt ttattttcg agtttgagta atttttttgc	8940
ttagttttt taagtagttg ggattataagg tatgtgttat tacgtttgt taattttgt	9000
tttttagtag agacgggggtt tttttatgtt gtttaggtt gttttaaatt tttgatttta	9060
ggtgattat tcgtttcggt ttttaaagt gttagaatata taggcgtgag ttaacgtgtt	9120
tagttttttt ttgtttttt tttttttt tttttttt taggtttttt tttttttt taggttggag	9180
tgttagtata cgataatagt ttattgtat tttttttt tttttttt cgggtttaaa cgatttttt	9240
atttttagttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	9300
ttttttttt ttagtagaga tgaggtttt ttatgttta taagggttta ttaaattttt	9360
gaggattaag tgatttttt atttttagttt tttttttt tttttttt tttttttt tttttttt	9420
attatatttta gtttgattttt attttttatg agagttttt ttttagatgtt ttttagttt	9480
tttggttttt ggttatgtt ttttagttt tttttttt tttttttt tttttttt tttttttt	9540
tttagtggtt aggtttttt taggttagt agagaagtta aatgattttt tttttttt	9600
atttattttt agtatgtaaa attaggatg tttttttt tttttttt tttttttt tttttttt	9660
tatatgtata ttagggatag ggggttaaag gtagtttagt tttaaagatt ttttttagagg	9720
ttatttttt gagaagttt gggtttttta agggttttt gtttatgtt gtttattttt	9780
taggacgagt ttgtggagtg ggagatattt gttttttttt aagttgagat tgagtagaa	9840
attaaggagt ataatgttta gattaatgt aattttttt tttttttt tttttttt tttttttt	9900
tttaggaagg gggcgtgggg aggatgtt atttagttt tttttttt tttttttt tttttttt	9960
tataattttag gtttttttgg ttttttttta gtagtaattt gtttatattt agtttagttt	10020
taagtagatt gatattttt ttttttttta ttatttaaggt tttttttt tttttttt tttttttt	10080
gaataaggac ggtttttata ttttttttta taaggtttt tttttttt tttttttt tttttttt	10140
ttttgtttt ttttagtaaga agttttttt tttttttt tttttttt tttttttt tttttttt	10200
gggtataagt gtttggcgtc gttttttt tttttttt aaggatgtt gttttttt tttttttt	10260
gtatgtgtt gtttggcgtc gttttttt tttttttt tttttttt tttttttt tttttttt	10320
ggtgggttggat gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10380
ttttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10440
ggggttttagt agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10500
agttttttt gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10560
ttttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10620
tagttttttt gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10680
aggaattttt gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10740
ttaaaggaaa gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10800
aagaattttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10860
tttattttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10920
aaggtattttt gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	10980
attttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	11001

&lt;210&gt; 16

&lt;211&gt; 3501

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 16

gtgggggttgg taggggtgtt gttttttt tttttttt tttttttt tttttttt tttttttt	60
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	120
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	180
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	240
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	300
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	360
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	420
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	480
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	540
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	600
tttgggtttaag agttttttt tttttttt tttttttt tttttttt tttttttt tttttttt	660

tggtagggt ggtgttaggg tgggtattgt gtttttttt tttgtattat ttttttaat	720
tgggtaatt tttttgagg tggaggtgt tggttttg gttttttt ttttatttg	780
ggtaagttt tttgtttga atgattttt ttgaagtggaa tattttattt aaattggta	840
atgtttta aaagggttat tgtgtttgaa tagttttt tttgaagtt ttagtattta	900
gttaggtgtt ttgggtgtg taggtgttt tggtttttt tttattgggt gttgttatt	960
ttttttttt tttttgggtt tgggtgggtt gttttgggtt tttatttttag aggttagttg	1020
ttttttgtt ggtgtttagg ttgttaggggtt gatgttttg tttagtttag ggaaggggaa	1080
gtggagggga gaagtgttg gttgggttta ggtgtttagg gtgtgtatg gtttttattt	1140
ggttgggtg tttttgttta ggagagtgtg ttgggttagat gatgttggat atgtggagg	1200
tgtttggta ttttaggttag ttgttgggtt agtttaataa tttagtgtatt aagggtttt	1260
tgtgtatgtt gattattgtg gtgtagaatg ttttttttg tttgtataag aatgtgttg	1320
tggtagtag tttttttttt aagtttttg tgggttatga taattttgtt aattttggatt	1380
atgatatggt gagtttggtt gtgtttgtt tgggtttgaa ttttattttt attgggtt	1440
tgtgtatgg ttttaggtgtg gttgtgggtt tgggtgtgtt tttgggggtt gagttgagtt	1500
tgggtgtgtt gttgtgtttt tttagttattt tttttttttt tttttttttt tttttttttt	1560
agaaatgttt taagtgttat gttaagtatt gttttttttt tttttttttt tttttttttt	1620
gtgggtatgtt gttttatgtt tgggtgggtt ggggtttgtt gttgttatg tttttttttt	1680
agtttggta tttgtttta gttgggtttt tgggtttgtt tttttttttt tttttttttt	1740
gttttaggggt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1800
ttgtgttattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1860
agaagagttt gttgggtttt gttgtgttag agtttgggtt tttttttttt tttttttttt	1920
tgtgtttggta tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1980
tgggtgtgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2040
tatttttgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2100
gtttaggtgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2160
gtttttttta tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2220
gttggaggtgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2280
tgtttggggg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2340
ggtttgggtgt ggtgtgtatg gttgtatgatt ataagagtag tttttttttt tttttttttt	2400
gtgaggattt tagttttttt gttgttattt tttttttttt tttttttttt tttttttttt	2460
atggtgagtt tgagagttttt gttgtataatt tttttttttt tttttttttt tttttttttt	2520
ttttttagtt tgtagtagttg aatgtgtatg tttttttttt tttttttttt tttttttttt	2580
tgtatggtag ggtttaggtgt gttgttaggtt tttttttttt tttttttttt tttttttttt	2640
ttggaggtgg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2700
ttattttgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2760
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2820
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2880
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2940
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3000
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3060
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3120
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3180
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3240
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3300
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3360
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3420
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3480
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	3501

&lt;210&gt; 17

&lt;211&gt; 3501

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 17

ttgagtttaag gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	60
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	120
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	180
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	240

ttagtatttt	ggttgtttt	ttgggggttga	ggtttagttt	ggttgtgaat	ttggtttagtg	300
ggtagaggtt	ttttagtgtt	atttgggtt	tgttaggaa	gtgtgtggtt	tgtgttagta	360
gtttgggtgt	ggttgtttt	ttttagttagt	tttaggtttt	ttgtttgggt	gtgaggttag	420
ttatagtaaa	gatgtttt	gggaagtgttga	gttgggtttt	gttgggggg	ttggggatgt	480
tggggagttt	ttttaagttt	tttagtgtttt	ttgtgtgtt	gttgggtgtt	tttatgtgt	540
gtatttttat	gtgggtgtat	aggtgtgtt	gttgggtgttga	tttgggtgtt	tatattgtgt	600
attttaggg	tttttggttt	gagtggatgt	gtatgtgttt	tgtgaggtgg	tatgggtgt	660
tgaattgtat	gttgtatgtt	ttgtatgttga	agggttttag	gtttaggtgg	ttgtgtatgt	720
gggtgtttat	ggttttatgt	tgtgtgaatt	ttttttgttga	gatgggtgtat	gggttaggggt	780
gggttagtta	gtgtttttt	ttgtgtgtt	gttagtgtgtt	tgggttttg	tagttttgt	840
tgtatgtat	gttagtggtag	gggtgttagta	gttttttag	gttatttgg	gttttgggtga	900
ttttgtttttt	gttgggttttta	aaaggggggtt	tttaggttgg	gtttaggtt	gttattttgg	960
ttgttttgggt	tttgggtgtat	agtgtttttt	ttttttttat	gtgaggtttt	atgtgtgtgt	1020
tttagttgtt	agagttgggg	aagtttttgt	tgtatggaaat	gtatatgtat	aggtgtttat	1080
tgaagttttt	gggtttgtta	taggttaggt	gtgggtatgg	gtagttttt	aggtgggtgt	1140
taggtgggtt	gggggtttt	ttgttattgg	ttttttgtt	gttggttttt	tagttgtgt	1200
tgtgttgggt	tgtgttgggt	ttgttaggt	tgttagggta	gtgtgtgtt	gggttaggt	1260
tgagtgggggg	ttttttgggt	gagatgggtt	tgtttttatt	atgtttttt	tagttgtgt	1320
tggggggagt	gtgtttttgg	tttagttgt	tgttatagtt	attaggttt	gttttgggtt	1380
ttattttagt	atagaggaga	ttaggttgt	ttgggtgggtt	gggggtttt	gtttttgggt	1440
tgtgttgggt	gttgtgaaat	gggttggaaag	gtgtgtgtt	tttttttagt	tttttggaaagg	1500
gtagtggtgg	tagtgtatgtt	agggtgagag	gtgtttttt	gtaggtgggt	gggttgggt	1560
tgggaggggtt	gtttgggtgt	gggggttagt	tgtgttttagt	tagtgggtgt	tttgggtgtt	1620
tggagtttttgg	tgggtttttt	ttggatagtt	ttaggttata	aagaggggag	tagtgggttt	1680
ttgaggtata	gagtgtgtt	gttgggttgg	gtttttagt	gtatagttt	gtgttagtgt	1740
tgttggattt	gtttttttgg	tttgggggtt	gtttttagt	agtggtgtt	ggaggtttga	1800
ttggggatgg	gttagtaggtt	tggatgttt	gtgtgtgtt	ttgttagttt	tggttttgtt	1860
gattataggg	tgtgttagtt	ttgtgtgtt	tgtgtgttt	ttgttaggtt	tagtattttt	1920
tgtgtgtttt	gagggttttt	ttgtatagtt	tttaggtttt	ggggattttt	aggtgttgg	1980
tgggtgttag	tatgtgtttt	aggttttgtt	tagttttttt	gtttagtatt	gtgggtgttag	2040
ttgtttttgt	gttggtagtt	agggtgggtt	tgttagatgaa	gtttagtatt	aggtggaaata	2100
tgggtgggtt	tattatgtta	ttgttaggt	ttagttaggtt	gtttagtatt	attagggtatt	2160
tgaggttaggt	gttgggtgtt	gttagtatgt	ttttgtgtt	gtggaagagg	gtgttttggta	2220
ttatgtat	tatgtgtat	aagaagtttt	ttgtgtgtt	gttggtagt	tgttagtagta	2280
gttgggttga	gtgggtgggt	gttttattt	tgttagtatt	gttttggta	gtatattttt	2340
ttgtggggat	atatattgtt	tgggtgagag	ttgtgtgtt	tttgggtt	ttgggttttag	2400
tttggatttt	ttttttttta	ttttttttt	tttaggttga	gtgggggtat	tagttttgtt	2460
gttgggtat	tggtaagga	ttggttttt	tttggaggtt	gagtttaggt	tggttttgtt	2520
ggatttaggag	aaggagtagg	aggtaggtt	tttttttttgg	aggggaggtt	aggtgggttt	2580
gtatgttttta	gggttattttt	ttgggtgtt	gggttttttga	gaagaaaatt	gtttaggtgt	2640
agtatttttt	ttggagatag	ttatttgatt	taagtaaaat	gttggtttta	ggaaaagttt	2700
tttaggggttgg	agaattttat	ttaagtaggg	agaaaggggag	ttgaggaaatt	agtgtttttt	2760
tttttggggag	aagtgtttt	agttggggga	agtgtatattt	aggagggggag	tgtgtgttt	2820
tttttgggtt	tgttttgggt	gggggttgg	aattttttgtt	tggggtttgg	gtgggtgttt	2880
tgtggggagt	ggaggttagt	gttgggtgtt	tgggttagagt	gtgaaggttt	gttttgggtt	2940
ggggaggggtt	ttatattttgg	gttagggatgt	gaggttaggaa	gtaggtgggg	gggaggggggg	3000
agttatgtat	tttttaggggg	agggaggggg	tagtggtttt	gttgggtatgt	gtgtatagtt	3060
ggttgtgtt	ttgattttgg	tttgggtttt	atttggttt	tggttttgtt	ttgggttttttta	3120
tatgtgtgtt	tttgggtttt	ttttttgtt	ttttttttgtt	tttttttttt	tttggaaatttt	3180
gttggttttaa	atttggggaa	aagttttttta	attttagata	gggtggggagg	agtgtgttgg	3240
tttttaggttt	ttgggttttta	gttttttttta	aattttgggtt	tagagttttt	3300	
agttagtta	ttagttttt	ttttttgtt	ttttttgtt	gattttgttt	ttttttttgtt	3360
ttgtgggggtt	ttgtgggttt	ttattttgtt	ttttttgtt	ttgggtttttt	ttttttttgtt	3420
tgggtgttagt	tttttagtttga	tttttttattt	tttgggttttta	gttgggtt	agtgttaggg	3480
tagtttttt	gttagttttt	t				3501

&lt;210&gt; 18

&lt;211&gt; 2501

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

27 11.04

<400> 18

tttttatagt	gtaaaatgtgt	tttttattttt	ttttggagta	attttatttt	aaattgtttt	60
tagataaaaa	tttaaatattt	taaatatgt	tttgggtt	ttgtttttgt	ggtttttattt	120
ttttttttt	taaatttagt	tagtgggtt	gttgggtt	atgtttttt	ttttttgttag	180
gggttggtt	tttaggtttt	ggttttttt	tagaaagttt	ttttttttt	tttttagtgg	240
ggatagggtt	tgtttatttt	gatattatta	gttttatttt	atatattgtt	tataagttt	300
ggtgttattg	ttattgaaag	tttattttt	gatttgagt	agtttgagga	tttttattaaa	360
atttaggaga	tgttttagaa	atgttggatt	aattatgtt	gttttaata	tataaatgtt	420
agatttattt	ggaatattt	ttaaaatgtt	tttgggtttt	gagattttt	tttggaggtt	480
aagtagtggg	gtttaggt	tttggatttt	gatagtttt	tgatgtttt	atgtagaagt	540
gtagggatta	ttatattgt	aaattttt	tattttaag	ggggattttt	tttttttaggg	600
gttattttt	gaagttttt	aaggataggg	gttgtatgtt	gttttttag	gttagtaatt	660
aaatttagaa	aatgtttatt	gagtgaatga	tgaatgata	ggtaataga	tgaatgttaag	720
gtgtttagtt	aatttatttt	ttatataatgt	tttagtagtt	tttattgttt	tttagttgttag	780
aaatggtttt	tggaaaggtaa	gttttttagt	gagttggatt	attttaattt	atattttta	840
ggatttttaag	ggagttgtgt	gttttgggtt	tattttttta	ttagaaattt	gttaagttt	900
gattttgtt	ttgtttttgt	tatttttt	ttttttttgt	ttttagttt	gtgtttagt	960
gttttgggtt	tttgggtgtt	tttgggtgtt	gttttttattt	atgggtttat	tggtttaggtt	1020
tgatgggtgg	gtgggtattgg	ttatgggtgt	gggggttaggt	gagttgttga	agggtggagg	1080
ttgttgggtt	ttgttgggtt	tagttggtt	ttttttttgg	gttggtatat	gtgtttagtt	1140
gtagttgagg	ttattttggt	gaggtgggtt	ggaggggaat	gttattttt	gaggtattgt	1200
atttttttag	gaggaaagag	ttggaaataat	ttgggttttt	aagtaggtat	agtttggttt	1260
tttttagtat	tttgggtgtt	gttttttaag	gttttggttt	agaggagagg	ttaggttggg	1320
ttgttggattt	taaaatttggg	tgaagttttt	ttttgatttt	tatgttggg	tattgtattt	1380
tatttttttt	gtaattttaatt	tttttagatt	tttggttt	tttttaaagg	attgaaaagt	1440
tgtgaggggt	gggggttgg	atttggttt	tgaatgttag	agatgttagt	tttgaaaag	1500
ttatgggtt	gttttagtgtt	ttttttttt	ttttgtttaaga	tttaagttt	gtgagaggat	1560
tttttttaaa	gaggggtttt	gataagagg	tttttttgg	ggagtttgg	tgttttagtaa	1620
gttataattt	gttttgaaa	tttatttggag	ttttggtaga	gttggtaat	ttaaatgtgt	1680
atagggggtt	gggtgtatgt	ggagaaagaa	aatgggagta	ggatgggtat	atttggagaa	1740
ttggagagta	gagaattttt	aagtggatgt	gttagtggg	aagttttt	tattttagga	1800
gtggtaaaat	ggaaaattgt	tatgtgaaat	agtttatttt	tttaaagtat	aaaaaattaa	1860
aataaattat	ttatattat	atagatgtt	tgttagttaga	ttttatattt	gttttttattt	1920
agtgggtat	ttttgttatt	tttaagtgt	gggatttttga	tattatgtat	ttttgatttt	1980
ttattggtag	tattttat	ttggaaaggt	tttaatgtat	gaattattt	atttataatt	2040
taaatgttat	aaatttggat	tttggtaatt	aatttttatt	tattttata	tttggatttga	2100
taaagtgggt	ttttatgtt	tttttagaa	aatgttttt	gtgtttagt	atagttaat	2160
attttatatt	tatgttgtt	ttgttatttt	tgtatggta	tgtatttggg	tgttagttata	2220
ttttttaaat	gtttttagga	aaatattttt	tttataatttt	gtttttattt	taaataatgt	2280
attttataat	gtttgggttt	ttaaattttt	tttgatagtt	tttggataat	ttttatgttag	2340
gagggtttagg	gatttatttt	taagatgtt	tttttattgt	taaggagatt	tttttttttta	2400
ggggttataat	ttgaaaatttta	tttaaggata	gggattgtt	tttttgatat	tattgtata	2460
tttatataat	gtatgtatgt	tattttataat	tagtatttt	t		2501

<210> 19

<211> 2501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 19

attgagtatt	ggtgtaaaat	gtattgtata	ttatgtgtaa	gtatgttaat	ggtgttaaaa	60
gaagtagttt	ttattttga	atgattttta	gatatagttt	ttgaaaagga	agttttttt	120
agtgtatggta	aaaatgtttt	agaatgtt	tttggattt	tttgtatgtt	aattttttaa	180
gagttgttaa	aaaagatttta	aaatattttaa	tgtgtaaaa	tatattttt	ataataaaaag	240
taaagtgtaa	ataaaatgtt	tttttaaaaa	tatttagaaag	gtatgtttat	attttttttt	300
atgtttatgt	agagataatt	agatgttat	gggtataaaa	tatgtgttta	tttattttata	360
ttgaaagtat	tttttggaaag	gtatgtataag	aagttttttt	attaatata	atatgaaaagt	420

atataggaaat	taattgatag	aatttttagtt	tgtaatgtt	aatatataat	ttaaataatt	480
tatgtattag	ggtttttta	ggtataaggt	attatttagtg	gagaataaa	ggtgtataat	540
gttaagattt	ttgttatttgg	aggttataga	ggttattttat	tggtagaaaa	ttaatgtaaa	600
attttattgt	atagtattta	tggtggat	aatggttgt	ttaattttt	tgtattttaa	660
aaaatgggg	tatttatata	aataattttt	tattttgg	tttttgaat	ataggttaatt	720
tttttattgg	ttgggttatt	ttgaaatttt	ttgtttttta	ttttttaga	tgtgtttatt	780
ttatttttat	ttttttttt	tattatatgt	ttgatttttg	tgtgtattt	agtttataat	840
ttttgttaag	attttagtgg	atttgagaa	tagattgtga	tttggtaat	atataaattt	900
taatggggaa	gggttttat	tagatgttt	ttttaaagaa	gtttttta	tgaatttaaa	960
attttatgt	agagggaaat	aaatattgaa	tgattgaatg	attttttagg	agttgatatt	1020
tttgcgtttt	agggggtgaa	tttagtttt	tggtttttgt	gttttttag	ttttttaaaaa	1080
gattaggtaa	agattaaga	gagttaaattg	taggaagagt	aataattgtat	gtttataagat	1140
aaagggttagg	gagaattttt	atttagttt	gttaatttagt	gtttatgg	gttttttttt	1200
ttaggttagga	tttggaaag	tttatattgg	gggtttgggg	agaagtgggt	tgtatttgg	1260
ttagagagat	gggtttttt	ttttttttt	tttaagaga	tgtggtttt	taagaataat	1320
tatttttttt	tttatttattt	tagtggggtg	attttagttt	ttgttgcgt	tgtatgttg	1380
tttgaaaaga	gtagttagtt	gtgttttagt	aagggggtgt	gttttaatt	tttgcgtttt	1440
tatttgcgttt	tgtgtttttt	atttagtta	tttgcgtttt	gaattttat	gttgcgttt	1500
tgaataaggt	ttgttaatgtat	atataatata	ataagtagag	ttgttgcgt	ttgattgtgg	1560
gataggagga	ggtggggaaat	ggtgggggtt	ggatgagggt	tagtgcattt	ttgatttttt	1620
gttaggaagat	gagtgttag	tgtgtttttt	tttttggaaatt	ttggaaatgt	tagttaaagag	1680
tgattttttt	tgttggaaag	ttttttttt	aggggttatt	tttgcgttt	gaagtaatgg	1740
gagttgttag	gattttgtta	gaagaatagt	taatttgcata	tttttgcgtt	atttattttat	1800
ttgttgcgtt	atttattttt	taataaattgt	tttttgggtt	tagtgcattt	tttagagaaaa	1860
tagtatgtgg	ttttttttt	tgagggggtt	tttagagatag	tttttggaa	ggaaagtttt	1920
tttttagggat	ggtaaaagatt	ttgttagtga	ataatttttgc	tattttata	tgtaaatattt	1980
aggggattgt	taaaatgtag	agttttgtat	ttttatttttgc	tatttttaa	aatagaattt	2040
taaggggtaa	aaatatttttgc	ataagtgttt	ttaatgtatt	ttgttgcgtt	atgttgcagaa	2100
tagttatagt	ttaattaata	tttatttgcgt	atttttgcgt	ttttgcattt	atttttaatgt	2160
tattttagagt	tagatggtaa	attttaata	atgtgttagt	ttagatttgc	gattatgtt	2220
tgtaaatgtag	ttaatgtgt	taaaataat	agattttatt	tttgcgtttt	agaaaagagga	2280
aaaatttttt	gaaggaggat	tagatttaa	agttgtgtt	tttgtaaaga	aagaagggtt	2340
ttataggttag	tataaataatt	agttagttt	ggggagaaag	aggtaaagt	tataaaagta	2400
aagttgtaa	gattatgttt	agatgttga	atttgtgtt	gaaaatgtt	ttaagttagga	2460
ttattttaga	gagtgggtgg	aatatattta	tattatggaa	a..		2501

&lt;210&gt; 20

&lt;211&gt; 2470

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; chemically treated genomic DNA (Homo sapiens)

&lt;400&gt; 20

aaagatgatt	aaaagtttaa	ttgttttattt	gaagagttga	tttttttattt	tttgcataataa	60
agggtatttt	tagtagttt	tgttttattt	gttttatttg	ttttttttgt	gtttgtgtaa	120
gttataattt	tttgcgtttt	agtaaatttg	tgtatgttt	tttttttttt	tgtttatttt	180
tttttttttta	ttttgcgttt	ttattttgcgt	gtaaaattat	ttgttaattt	tatttgcataat	240
gagaaatttt	aagggtttata	ttatttaaat	tttgcgttagat	tttttttttt	tttgcataatgtt	300
ttataatgtt	ttgggttattt	tttagatttttgc	tttgcataat	tttgcataat	aaaataatgtt	360
ttatttttgt	ggattttttt	tttatttttgc	agatgttttt	tttgcgttttgc	ttatttttttt	420
atttttttgtt	tattgatttt	aggagggtttt	ttaatttgcgt	gtgcattttt	tatttttatttgc	480
aagagggttat	gttatgttgc	tatttttata	atataatttttgc	tattttatata	gtattttttat	540
tttttagtata	tttttttttta	ttatattttaa	taatatttttgc	gtatgttgc	tttgcgttttgc	600
ttgtaaatgt	ttatttataa	attgtgaaat	gaattttttat	gaaagggtttt	aaagggttttgc	660
atgatttaggt	ttgaaattttaa	tatataatgtt	ttaatttttttgc	ttaatttttttgc	attttttgcgt	720
gtgatttttttgc	tttgcgttttgc	tttgcgttttgc	tatttttttttgc	tatttttttttgc	tatttttttttgc	780
attgttagattt	tttagtttttttgc	tagatttttttgc	tagatttttttgc	atgatttttttgc	tgttttttttgc	840
ttgttagagttt	tttttttttgc	tgaatttttttgc	tatttttttttgc	attgttagatttgc	tttgcgttttgc	900
ttttgttttttgc	tttttttttgc	tttttttttgc	attatagagg	tatttttttgc	atgttttttgc	960
gttttaagtat	tttttttttgc	tttttttttgc	aatatatttttgc	agtttatttttgc	taatttttttgc	1020

aggttaggatt ttatTTgttt taaaatgatt tgatTTaaat taaaaagaga atgtggattt	1080
tttgaatttt attTggTtaa ttttaatata atTTTtagta ttTTataatt ttTTTaaag	1140
tttttttatt tgTTtatttt ttgtatTTTT ttTgTTTTTT ttTTTTTT tttagTTataa	1200
taattgttag atTTTgtttt atTTTTTTT gatagTTTTT atTTTtaagg ttatTTattt	1260
tttttaggta ttTTTggTT tttagTTTgag tatagtagat tttaagatttata tataTgttat	1320
agtataggTT attatagTTtta atTTTTgaa taaatgtgat tgaattttat gtttagtaatt	1380
tttattttattt atTTTTTTat taaaaaggTT taaagTTTTT atTTaatgTT ttTTTTTatg	1440
tttattttgt taaatgattt gTTTTTaaatg atatTTtaga atTTTtagaatt tatttttatta	1500
tgggaggatgt gtaagattag ttTTTTattta aataaaaaagt gtgaaatgga atatgtaatt	1560
ttattttattt atTTTggTT taaaatTTTg tgattattag ataaaattta gaaataaaaat	1620
agtattttattt atataaataaa atTTTTattta taatttatatt ttttaagTTT tggTTgtaa	1680
aatgggtaaa atatTTTaa aattttgaag aaatttattat ttgatagaaa gtttaattta	1740
tttgtgagaa ggttaatgtt tttagatata atTTaaagTTT ttTTTTTTT ttttaatttt	1800
tttattttgtt attaagattt tattttttt ttttttttaga tggTTTTatt tgaataatata	1860
tgttttgaga taaaaattta gtatattaa ataaatTTTT ttaaatgTTT taagagtTTT	1920
gtttttttta ttTTTTTTT taaaaataag tagTTattaa atTTTTtagt agtgaatttt	1980
aaaattttttt ttaattttat aggttaagg gtagTTtaagg atggTTgttag ttTTTatgaa	2040
ttagTTgtta aagttaagtgg aggtattgaa gatggagaat ttaaatTTTT gataagagTT	2100
agaagataat ttaattttattt ttataaaattt ggaatttggag gtatTTataa tgaaggTTatt	2160
aagattgtga ttTTTaaatgg tagTTTTTTT atTTTTattt agtatttttt tttgTaaatt	2220
tgaggttaaga tatttttattt aaaagtgtat tttaaaatttaa gtaataatata gtaaaatTTTT	2280
ttttgtaaaa gtttagtattt atTTTTTTaa ataaagatata ttgaattttat ttagtgaatt	2340
atataaagaaa aataagtgtt aaatTTTaaat ggttagTTT tagTTTTTTT ttTTTaaagat	2400
taaagagaag agattaaata tagtattattt gtattgaggt aaggTTTTT ggttagTTTaa	2460
tagaaatttag	2470

<210> 21

<211> 2470

<212> DNA

<213> Artificial Sequence

.<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 21

ttagttttta tgaattata agaaaaatttt gtttttagtat agtgatgtta tatttggttt	60
ttttttttta attttaaaaaa gaattaagaa ttaatttagttt atggagttt tatattttt	120
ttttttatata gatttattga atgaatttaa tatattttat taaaaaatat aaatgttaat	180
ttttgtttaaga aagagtttat atattattgtt ttaattttaa atatattttt aagtaaagtg	240
ttttttttta agtttataag agggaatattt gaataaaaat ggataaatta taattttaaag	300
ttatagttttt gatattttta tatttagatgtt ttagttttt agtttggtaa gatgatttgg	360
attattttttt agtttttggtaa gaagatttga gttttttattt ttagttttt taattttttt	420
taataattttga ttatatgaag ttgttagttt ttttggttt tttggattt ataaggtaa	480
aaaggattttt gaaatttttattt attaaaaaat ttagtgggtt tttgtttta aagaaagggg	540
taaaggaaat aaaattttta agatgtttaa gaagaattgtt gtaatatgt tagttttgg	600
ttttaaaaata atattgtttta agtagtagta tttaagagga tgaatatgtg gagttttagt	660
ttaagataaa tgaattttaa atagaagaga gaatttttagt tgggtttgaa tatatttttt	720
tttttataaga tggatttaaat tttttattttaa gtaataattt ttttaaggtt ttaaagatata	780
tttattttattt ttataggtt aaatttttagga aatataattt tgataaaaat ttattttat	840
tagtaatattt attttttttt tgaattttat ttgatagttt tagaattttta gagtttagat	900
ggatttaatgtt gatttataat tttttttttt attttttttt tgataaaaagg ttaattttat	960
atattttttta tgggttttttta gtttttttttta ttaagatgtt tatttttttttta taattttttt	1020
ataaaatggta tatgaaggag agtatttttttta gaagattttta agttttttttt ataggaagat	1080
ggtaaataag atttttttttta atttttttttta attatattttta tttaaaaaggt tgattataat	1140
agttttatgtt atggatatttttttta ttttttttttta atttttttttta tttaattttta gtttttttttta	1200
tattttttttaaga gaatggatgtt ttttttttttta agagatttttttta aaagagaaaat gaagtagagt	1260
ttggtagttt ttatgatttttttta gagagataaa gaagatataaa aagatagttt	1320
ggtaaagagga ttttaggaag aatttttttttta tgtttaggtt tatattttttta ttaatttttttta	1380
aagattttttttaagg agatttttttttta gtttttttttta aaaaagttt aagttagttt tatttttttttta	1440
aattttttttttaatgtt attttttttttaatgtt tttttttttttaatgtt tttttttttttaatgtt	1500
atatttttttaatgtt attttttttttaatgtt tttttttttttaatgtt tttttttttttaatgtt	1560
taaggtagat aggttggtaat attttttttttaatgtt tttttttttttaatgtt tttttttttttaatgtt	1620

- 30 -

gattttatta aaggaaatta ggggatttat ttagattta gttagttta taatggtag	1680
aatttatagt aaatttggta taatttaatg atatttgagg aggaagggga gttttgttagg	1740
tagggattat ttataaaagt ttttgggtga aaaaattga gttttgtgtg ttaattttag	1800
gtttgggtat gatttaattt ttgtttttt attttaattt attttataat ttgttaatga	1860
atatttataa ttgtttttaa tataatttat agtcatattt ttaggattaa taaaaaaagg	1920
tatgttaaaa ataaaagttat tatgttaatg taagttataat tatgaaaata tataatgtat	1980
ataatttttt tagtaagata tagggtttat ttatagttaa gattttttt ttgattaatg	2040
ggttaagggtt gaagaagttaa tgttagttaa ggagatattt taaaaataaa ggaaaaattt	2100
ataggagtga ttatttattt gttttatattt ttttaataaa gttaggttga aatatttag	2160
tatatttataa attataatgtt agaggttaggg atttgataga atttgaataa tgtgaatttt	2220
aaaattttttt attttaataa aaattaatag gtaattttat attaaaataaa taaaataaaaa	2280
taagagaaaa ggttagtaata gaaaaaaa tgggtatgtt taagtttattt gagatataga	2340
agttataattt ttatataattt ataaaaagag tggatgggtt aagatgatgta gagattgtta	2400
aaagtattttt ttattatagg aaaaaaaaaa ttaattttt agatgatgta taaaattttt	2460
aatttattttt	2470

<210> 22 .

<211> 7001

**<212> DNA**

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 22.

aatgtaatgg	aaaaagagag	attgttaaagt	tagaagggtt	aggaattgtt	ttttgattag	60
gtgtggaaagg	taaggaaaaa	ttagttttg	aagaagatag	ttagattta	atttgggtgg	120
ttggagagat	agtatgttg	ggtatagata	tgggaaagtt	gagaggaata	ttatgttga	180
gaatgggtat	ttatatttg	ataagttgt	aatgttagt	agattgttgg	aaaagtgggg	240
ttggagatat	atthaatgg	ggagttagat	taattttat	tttttttat	ttgagagagt	300
tagtaagtt	tggttgaat	gtgtgtgtt	agtaggagag	ggttagggagg	gaagtttaaga	360
gagttgggag	tttgagtgaa	gtttttgtta	aaggtagaaag	agaaaagttg	gtgttagtata	420
gtatattttt	ttatattatgt	ttatataagtt	tagggataag	gttattaaag	atgagtttgg	480
aagagaatgt	tggagagaaa	gtggtaaga	aaattgtttt	tattgaattt	tttgggttaa	540
ttttgattgt	aagtttttg	ataattaaag	tttgcgagga	gatagttaat	tttttttattt	600
tttttatgtt	aatagtgaat	aattgtagat	ttttttttt	ttttttttt	ttttttttgt	660
ttttttttt	ttttttttt	aatattttt	ttttttttt	ggattggttt	agagtatggg	720
tggttattgt	tgatttata	gaggtattat	tgttattaaat	aaagggttaat	agttttttt	780
ttaatattt	attatattt	agtatttatt	ttaatattt	attatggaga	gagtttttt	840
gtgtttaaat	attgttaat	tgggggtttt	ttaaagtata	aaaatataata	tttgcgtat	900
ggtatttatta	atattttat	ggtttttat	ttttttttt	tattggttt	aagaggattt	960
tataaatttt	ttagtaattt	tatagtgtt	tagggttaga	gattggttat	ttttgggtatt	1020
gtgatttagag	ttatthaata	tttaaggtgg	tgattaaatgt	ttggttaataa	agttttttt	1080
gggtgtttag	tggggggga	tttgagttgt	gggttattta	ggagtatttt	agttattgtgt	1140
gttagtatta	tggttgagag	aatagttgag	aaagtggta	agaggtggat	ttatgtgaat	1200
gttattggga	aatgagagat	tttgcgtttt	attatggta	gttaattttt	aaagtttaaaa	1260
attagttaa	aataaaaggta	tttattttt	ttttatgttt	atatttttag	tttttaataaa	1320
tatgtatattt	ttatatgttt	atagaaagta	gttaatttgag	ttatttatgg	aaaggtttgt	1380
ggggttgggt	aatgaagtgg	aggagttata	tattttagtt	gaaaatataat	ttttagaaatg	1440
ttaaaatatt	tattttaaaag	tttgcgtttt	tggtgttaatt	ggaggtatgg	taatgttttt	1500
gttttagagat	tgggggttag	ggttagtaag	gtatttgatt	tatatgtatt	ttagaaggtt	1560
tttatgtta	attatattt	ttttggaaaa	attattatgt	ttttattttg	taaatttgat	1620
attatataat	tttgatttt	tatttttttt	tagtgttaag	attatgattt	atagtaagtt	1680
tgtttttttt	tttgcgtttt	gtggtagtag	aaagtataagg	gtatttttta	gtttttaagg	1740
gttaggggtaa	aggggttggg	gttttttttt	tttagtata	tttttttttg	ttgtgttata	1800
ttgttttttg	tgagttagata	gtaaagtttt	ttttattttt	tattgttatt	tattttagtgt	1860
tgtgttagtag	tttagttgt	tggtttgtgg	gaggggtgt	taagtgtttt	gtttatttgg	1920
tgttttttga	atttttgtt	ttttatgtat	aaatataattt	atataattttt	tttgcgttagt	1980
ttatataattt	agttattttt	atatgtgagt	atattttttt	ttttttttt	atttttttgg	2040
tttttgattt	ttataagttt	atgaaatatt	tttggaaaga	tggttttgat	tttagtagggt	2100
agggttgggtt	tgattttttt	tttgtagttt	tttagtatttt	gagaaagtaa	tttatttttt	2160
tggttagtgt	ttgtattttt	gtagggagat	gaggatgtt	gtttttatg	gggtatgtg	2220

tgtttttttt ttttttttta ggattttag tagttttgtt gttattttaa tataatttgg	2280
tagttttata ttttttaaga gttttatgaa gtgtttttg tatgtttttt aaaaaggtat	2340
ttggaaaattt aagtgtat ttatggaaat taaatttattt gtaaaaaattt gttttggaaa	2400
gtaatgattt ttggattataa aggaaatattt ttgtatgtt ttaatgtt tttttaatttt	2460
ttatgtt gtaatattataa gttattatgtt taaattttaa ttttggttt agttatattt	2520
gtatattgtt taataatgtt ttatgtt aagaattttaa taaaatgtt atttgatata	2580
aaatagttaa aaatgttattt ttttagtaataa gtaagtttgg tatttagata gattatgaa	2640
attttggtagt atatgtt ggttgggg gatagtaattt aaaaatgtt atttgatagtt	2700
gtattagat ttatttagttt gtagtaaaagg aagtttattt aaaaatgtt attttaag	2760
attatagatg tatgatataat ttatgttattt ttttgggg ttaatatgtt tataatata	2820
tataatata tataatataa tatgtt gttgtatgtt ttttgggg ttaatatgtt tataatata	2880
aattttagttt aaaaattttt ttatgttattt ttttgggg atatgtt gttgtatgtt ttttgggg	2940
tagtttaagt gaattgagaa gattgagttt taggattaaa ggtatgtt gtagaaatgt	3000
attttaaaaa ttgttagttt ggatttagttt gataatgtt taaaatgtt aaagtttgg	3060
tttggattt gaggttatgtt ttggatgaa aagtttattt ttatatttaa gtttttggaa	3120
gtttgggtt tataattttt ttgtggaaagg tatgaatattt tatgtt gtttttggaa	3180
gttttttttga attttttttt atatgagaat ttttattttt attaagtataa gtattgtgtt	3240
ttaatataaa tatataagttt aggttgagag aattttagaa ggttggaa ggggttattt	3300
atttggggag ttttggtagt aggaagaat tttttttttt tgagttttt gtaggtt gttttttttag	3360
ggtaaaatgtt agttttttt atatgttattt ttttattttt tggtttttt tttttagatg	3420
ttttttgtt gtttttttag ttgtttaataa tagtgggtt gttttttttt agttttttt aggttattt	3480
tgtatattttt attttattttt ttttattttt gttatgtt gttttttttt agttttttt aggttattt	3540
tatgtatata ttatgttattt ttagttaatg aggagggggg attaaataga aagagagata	3600
aatagagata tattggagtt tggatgggg tatataaggtt agtattttt agtattttt agaaagttgg	3660
tttttggattt tggtttttt gtttattttt agtttagttt ttttgggtt attttttagt	3720
gatttttggttt tggtttttt gtttgggtt gaaattttttt ttttattttt tagtgtatgt	3780
aagttaaatgtt aagtttaggg aagttttttt ttgggattttt tttaatgtt gttttttttt	3840
gagtgtatgtt taagtttaatg ttagggtaag gtaatattttt ttgggtt gttttttttt	3900
ttgtatgtt tatgttattt gtagattttt attttttttt ttgggtt ggtttttttt	3960
gttgggttggag ggttgggtt ttgggattttt attttttttt tggtgtt gttttttttt	4020
tggattttgtt gttttttttt gtaggggtt ggttagagttt ttggatgtt gttttttttt	4080
gttgggtt gttttttttt ggggttggtt tttttttttt tggtgtt gttttttttt	4140
ttttttttt tttttttttt tggtggata tgggtt gttttttttt tggtgtt gttttttttt	4200
ttttttttat taaagttttt gggatggttt tatttttattt gatttaaggg aatgagttgg	4260
agttttttttt gttttttttt tggtttttt gttttttttt gttttttttt gaggtgtt	4320
tggatgttagt taagttttttt gtttattttt attttttttt ttggatgtt gttttttttt	4380
ttgtgtt gttttttttt tggtttttt attttttttt ttggatgtt gttttttttt	4440
ttgtgtt gttttttttt tggtttttt attttttttt ttggatgtt gttttttttt	4500
ttgtgtt ggttgggtt tttttttttt ttggatgtt gttttttttt ttggatgtt	4560
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4620
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4680
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4740
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4800
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4860
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	4920
aaatgttattt ttattttttt tattttttt gttttttttt ttggatgtt gttttttttt	4980
ttaataaaat atatgtt gttttttttt ttggatgtt gttttttttt ttggatgtt	5040
tttagttttt taaatatgtt gttttttttt ttggatgtt gttttttttt ttggatgtt	5100
aaagttgggg gttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5160
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5220
agttatgtt atgattttttt gggatgtt gttttttttt ttggatgtt gttttttttt	5280
ttttttttt gggatgtt ggttgggtt aggttgggtt ggttgggtt ggttgggtt	5340
ttgggtt ggttgggtt ggttgggtt ggttgggtt ggttgggtt ggttgggtt	5400
taggtt ggttgggtt ggttgggtt ggttgggtt ggttgggtt ggttgggtt	5460
ttgttagttt agtgtatgtt ttgttattt tggggagaaat gttttttttt ttggatgtt	5520
ttgttagttt agtgtatgtt ttgttattt tggggagaaat gttttttttt ttggatgtt	5580
gagattttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5640
ataagaattt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5700
ttttttttt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5760
gtgaatattt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5820
agggtgtt atggttgggtt tttttttttt ttggatgtt gttttttttt ttggatgtt	5880
ttgggtt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	5940
tttttaggtt tttttttttt ttggatgtt gttttttttt ttggatgtt gttttttttt	6000

gagttttta tagttatgtat	gatttaagtt gtttttattt	aaaagataaa taatgaataa	6060
aatttttaaa ggttggata	ttttaaattt attttatttg	ttttaattttaa atggaagaat	6120
agagaaaaag gatttttttt	gtttattttt ttttttttaa	aaagtatagt	6180
gattaagttt aattttatat	aatattaaa attgtttgat	gtgaaggaag gtatggat	6240
gatgtgaatt ttataatttt	atgatggatt ttagaaattt	ttttttttt tatttaattt	6300
ttagttttt tattgtaaat	taatgttgtt gaattttaaat	gggtatttaat gagattgttt	6360
tttggtagat tattttattgt	tttgttaata attataaaagt	gaatttggtt aaatataagag	6420
gggattgtat ttatattaaa	attgtttattt atttttagtga	taagtggat tagtgtata	6480
tgttttattt tatatttttt	gtattatatg atattttaaat	tttttttagaa taataaaaaaa	6540
agagataagg aattttaaaaa	ttaaaaaaaa aatttgtata	aatgggattt tgggtggaaa	6600
tttagttta gaatgatttt	ttttgtgttt tattttttgg	attatttttt tttttttgtt	6660
agaattttgt ttgttattat	tttagtaagga aaagaägtat	ttatgttaagt tttttatatg	6720
gatagatattt atttagtattt	ttttttttt tagtttttt	gtttaaatga ttttgggtat	6780
aaaggaaagg attgattggg	tttttttagg aaatttttaag	tttttttaagt agtttttaaa	6840
agttttgggg ttgaaagtag	ttgaaaattttaa	ttgtttgtta tgatttagag	6900
ttagtttagt gagtttagaa	tattttttaa aaggattaaa	atggaaagga atataataga	6960
aaatattaga gtgtatggta	ttttgtäagg ataagttttg t		7001

<210> 23

<211> 7001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 23



34 05-11-04

ttagagtgtt tatgttttagg gttttaggat atatgatatt taatggaggt tttgttgtta	5940
gatatttagtt attattttgg atattaaatg attttaatta taatgttagg agtgggttgg	6000
tttgggttt gggatattat gtatgtttag agagatttt gagtgggtt tgagatttagt	6060
ataaaaaaga aatagaaaatg tataaaaatg ttaatgtgt tattatgtaa atatatgtt	6120
ttgtgtttt aaagattttt agtattgttag tggtttagta taggagagg tttttatag	6180
ttagtattga aaataaaat tggatataaa taaatattga aaagaaaagat tgttatgtt	6240
tgttggtgat agtgggttt ttgttaggt aataatggt atttatgtt tagatttagt	6300
ttagaaaaaaa gtaagagtat tttagggaggg aggagagagg aatagggaa aggagaagga	6360
aagaaaaggg gatttgaat tggttattat tgatatagg aagaataagaa ggttagttgt	6420
ttttttatag gttttgattt ttttagagatt tataattaaa gttagttaa gaagtttagt	6480
aaaggttagt ttttaattt tttttttttt agtattttt tttaaattta ttttggtgag	6540
ttttgtttt gggtttggtg agtatgggtt ggaaagtata ttgtgtttagt ttgattttt	6600
ttttttgtt ttggtaaaaaa ttttatttgg gtttttagt ttttgggtt tttttttat	6660
tttttttgtt tggatataata ttttttagt gtgattttt ggtttttta ggtgaagaag	6720
ggtaaagatt gatttgggtt ttgtgttga tttgtttta gtttttattt ttttagtgggt	6780
tgttgggtat ttttaggtttt tttaaatatg agttattttt tttaaatatg gtgtttttt	6840
taattttttt gttttttgtt ttgttattat tttttttta gttttttaga tttaaatattt	6900
attgtttttt ttgagggttg attttttttt gtttttata tttaaatata aggtatattt	6960
taagttttt agtttataaa tttttttttt tttattgtat t	7001

<210> 24

<211> 11001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 24

ttaagttaga tgttttttaa ttattttgtgg ataggttagg tataatttga gtttaatttt	60
attttataagg ttaatataattt tggagttaga aagtttttagt gtaaaaaagtt tgaagggggt	120
ttttttatgt tattagatgg atttttgtat tttagaaga ttttttatat taggaaagat	180
taaagtatta aggtatattt ttttgggtttt ttgggataat tttaggtttt ggtatgagt	240
gttttggaaatg ttttgggtttt gttataatgt ttatataattt ttggaaattgt tttttaggggt	300
ttgtttttta gtataatattt tttttaatgt tttattgttag ttatagtttta ttagttttgt	360
tttagtataaa ttaagaaattt aagaattatg tattatgtt tttttttta gagttatattt	420
tttttaggat aaagtttagg gttttgttat tggggtttgt taggagttgt agttgttaggg	480
gttgggttattt atttaaatgt ttttgaatgt atattgtgaa ggggaagtaa tgattagaga	540
taggggttagt tgtttagttt ttgtatgtt aggtgtatgt gtatataattt ttatataagg	600
taggggtgggg tgggaagttt attttgggtg tgatgtttt tagtggttaa gagtgtaaat	660
ttgttgggggt tatttattat taagaatattt tgtagtaggg ttttaatgtat ttatgtgtt	720
ttgtgtgtgt atagtatattg taggtgtttg atagttttt tgggttagta aaaggaagtg	780
ttgtgtttga tattttgtgtt ttgttttggg tttgttggg tattttgtaa ggagggtgg	840
tttttgggttgg agggatataga gatagggtgt attagtttta gttgaattttt gatgaatttt	900
gtgtaaagat tgttttgtt taaagaaat agagaaatta aattttgata atagttttt	960
gttgagatgt tagtttattt ggggttagt tgggtatgtta taaattattt ttgtgttttta	1020
ttaaagataa tttaggtgtt gatttttga gtatttaggtt tataatgtgg tattttgtttt	1080
tttttatgtt ttttttttga gtatgttattt tattaaatgtt atgaagaggt tggtgtttag	1140
ttgggttattt ttttttttta aatttttagt tgagaaaggt taggtgtttt	1200
ttatttataa gttttgtttt gtaagatggg ttagatgtta tataagggtt ttgaggaatt	1260
tagggttttt ttgaaaaatg gtttttgggg tagttttggg aaatttattt tttttgggtt	1320
tttggttttt atgtatataat atatagtgtt tgtttattttt gaattttata ttgtttttgg	1380
ttttgtatgt tttgggttggta taagggaaag atagaattat ttgtttttt tttgtgttt	1440
gtttagggtt ttagtattga atgtatgtt aaggatatta tagaagttagg ggtattttaa	1500
ggtatatgtt taggggttagt gaaatgttga gggatatttga agagggtttt ttatataag	1560
taaaatttagg ttgggtgtgg tggttattat ttgtatattt agtattttgg gaggttaagg	1620
taggaggattt atttgatttt taggatgtt agatttagttt gggtaatata gtaagattt	1680
attttattta aaaaaagaaa aaaaaaaattt agttaggtgt ggtgggtgt ttgttagttt	1740
aattttagt taggggttagt gggaggattt gttttagttt gggagattgt agttatgt	1800
agttattttt gtgttattgtt attttagttt gggaaatttga gtgagattttt gttttaaaat	1860
ataaaaaataaaaatagttt gggatgttgg gttttagttt gtaatattttag tattttggaa	1920
ggttggaggat tttgagggttagt gatgtttaga ttgtttagt taatatagg	1980



ttatattta gtagttggtg ataggttaga atagggaaaga ggtgagggtt tagttggttt	5760
tatataggag ttagatgga ggagtaggat tttttttgtt ttttaaagt ttttaaata	5820
tatttttaa tttttgta gatttttt tttttatat ttttttttag ttttttaag	5880
gagggagtag gagtattga atgtggaaat tgaggtgtt gttaaatg ttttgttgg	5940
tttagttata gttgataat gtttgttta gtttattat aagttatata gttgttttt	6000
ttgtgtttaa ttgttgtg atagaaatta aggggttt ggtttagt atttaggtgg	6060
tgaattggg gtttatgtt tggttttgtt ggttagttt tggttaggt ttgtgggag	6120
ttatgttagt aggaggggtt ggttgtttag tgatttagga ttttgttgg	6180
ggtggagttt tagttaggt tttttttt gtttgttgg attttttgtt ttttatttgg	6240
tttgtgtg gtttgtgat tagtgaggt ttttgtgtga agtattgtt gagttttgag	6300
tttgagttt ttgttgta gtagttattt ttttgtgtt gtttttagt tattttgaaa	6360
gaaggtgtt ttgttgtt tatagtgtt ttttgttgg ttttgttgg	6420
agttgttaat tatttttg gttgtgtgt ttttgtgtat ttttgttgg	6480
tttgggttag agttgtgtt taattgttaa gattgaaatg tagattgtt ggatttagt	6540
tttgggttagt tgggttagga atgttgggtt gggatatgt atgttttgtt ttttaggaatg	6600
attttattgtt tttggagttt tatttataga ttttattttat tataggaaat ggggtgggt	6660
gttagtgtt gggtaagtgt ataagagtgg ttttgttgg gaggtaggg tggaaagggt	6720
tggaaagtgt gtgtgtgtt agttgggtt agttgggtt tgggtttgtt ttttgtgtt	6780
ggagttttt tggagttgtt atttttaggtt ttttttttagt ttttgtgtt gaatttagtt	6840
tttttgttgg tttggaaattt gtaatttga atgtttttt gttgtgtt ttttgtgtt ttttgtgtt	6900
tttgagaatgt tttgtattgtt gtttgttta ttttgttgg ttttgttgg	6960
gtgtttattt ttttgtgtt ttttgttgg ttttgttgg	7020
taatagttaa gtagatgag ttttgtgtt ttttgtgtt ttttgtgtt	7080
gagaggtttt gttgtgtgtt ggaggaggtt taggttgggg aatgtttt gaggattgaag	7140
ggaaagttttt gggaggggtt ttttgttgg ttttgttgg agtttgatt ttttgttgg	7200
ggttattttt tattttatgt tggattttaa ttttgttgg ttttgttgg	7260
tgaagggtta tagtagagaa gtttgttta atagtggat ttttgttgg ttttgttgg	7320
ttttttttt ttttgttgg aattaaaaaa ataataataa aatgttgg ttttgttgg	7380
ttattttaggt tggagtgtaa tgggtgtattt ttgtttttt gtaattttt ttttgttgg	7440
ttaagtgtattt ttttgttgg agtttttgtt gtttgttgg ttttgttgg	7500
gtttagttaa ttttgttgg ttttgttgg atgggtttt attatgtt taggttgg	7560
tttaaattttt tgatttttagg tgattttt gtttgttgg ttttgttgg ttttgttgg	7620
ggttttaggtt attgtatttg ttttgttgg gggatgtat atggaaatata ttttgttgg	7680
tatttgaagg aaaaattaaa tatttttaat ttttgttgg ttttgttgg ttttgttgg	7740
ttatttttt tagattaaga ttttgttgg ttttgttgg aatttttgg ttttgttgg	7800
ttttttttt attttagttt gtttgttgg ttttgttgg aatttttgg ttttgttgg	7860
tttagtgatt ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	7920
tagtattttt tgaagttgtt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	7980
tttattttt gtagttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8040
atgatgaagt ttgggttttag ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8100
agattttatgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8160
tatttaggtt ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8220
tagttttttt gtttatattt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8280
tagttttttt gtttatattt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8340
taaatatgtt taaattttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8400
tgttgtaattt ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8460
atttttgtt taaagggtt gggtaggtt atgtttgg ttttgttgg ttttgttgg ttttgttgg	8520
tttgtgtttaa gtaattttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8580
tattatgtt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8640
taggttgggt ttttgttgg gttttttt ttttgttgg ttttgttgg ttttgttgg	8700
gggattatag gtaggttta ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8760
atttttgtt gttttttt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8820
atgtatataat agattttggg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	8880
atgtttaaattt tagattttt gttttttt ttttgttgg ttttgttgg ttttgttgg	8940
taggtttagt ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9000
ggattgtaaa agtattttt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9060
tttgtgttgg gttttttt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9120
tttgtgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9180
tttgtgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9240
taattttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9300
ttggaaatgt ggtttttt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9360
ttttaaatgt aaaaattttt aaattttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9420
atttttgtt tagatgtt gttttttt ttttgttgg ttttgttgg ttttgttgg ttttgttgg	9480

<210> 25  
<211> 11001

<212> DNA  
<213> Artificial Sequence

<220>  
<223> chemically treated genomic DNA (*Homo sapiens*)

<400> 25

tttttgttattt gggttataaga tgagtagagg	tggttgggat tttttttttt	tatgtaaaaa tatgttgatt	1620
ttaaggttttt tatttttaaa atgttttggt	tttttttgag aaagggttt	tgtttattgt	1680
ttttggagtt tatttttttta ggtttgggtt	tttttaataa ttatgattt	tttttagaaat	1740
tttttaggggtg aagggaaattt attatttatg	ggagggagtt tgaaaaattt	tagaaattttt	1800
ggttggggtttt ttgttaagtag gagttttgtt	gagttttat ttagaaata	tttttttttg	1860
atttagtcaa tttagatgtt aaatatgtat	gtagttatat atttagtagt	ttttttgtat	1920
ttttggaaat tgtagtaag taaagggtgt	tttttttgg gtagatatta	gttggaaatta	1980
tttaggggtgt tttatagtt tttttgtta	gtttggattt tattgttagat	ttgttgaaatt	2040
aattgttggg agtggatttt aggtatttagt	aaattttaaa aatttttaa	attattgtaa	2100
tatggagttt gggtttagta ttattgttt	ggittattha ggaatttgg	gatggatagt	2160
gttttaggtt tgggtgtgt tggagatttt	tttattttgtt ataagaggat	attataaattt	2220
tagttgggg gagtataaag ttgtgataga	atgtaaagaa tgaataagg	gttgagtg	2280
gtggttttag tttgttaattt tagtattttg	gaaggtggag gtgggtggat	tatttgaggt	2340
taggagtttta agatttagtt ggtaatata	gtgaaattttt atgtttatta	aaaaataaaaa	2400
aaaaatgagt taggtgttagt ggtgggtgtt	tgtaattttt gttatgggg	aggttgagg	2460
gggagaattt gttgaatata ggaggtggag	gtttagtga gttgagattt	tgttattgtt	2520
tttaggtttt ggtgatagag tgagattttt	ttttaaaaaaa aaaaaaaaaa	aaaaaaagaa	2580
taaggttggg atattgttagt gtttttaaaag	agaaataaaag tagttatgga	gataagaagt	2640
aggatgattt gggatgtttt attagaggta	gagataaggg agaaaatttt	gataagttt	2700
ggttttgtt ttttagtaattt gggagtttag	tggttatttt tgggtaaag	aggaagttgg	2760
gtaagtgtag tagtgagggtt gaagaaaagg	gaatttaattt ttgggtatgt	ttatttgaaa	2820
tgtttttagt atatttttagt gaaggtattt	gtatggagga tttagttga	gggtttaggt	2880
tagtgttttta gttgtggatt tgggttagat	gaatgttagat agatttaggtt	agtgatttag	2940
attgagtttta gattttatgt tgagatatgg	aagttgagtt agaatttgg	aaggagttga	3000
gtaggagttt taggggttag gggaaaattt	gggagaggtt agttttggg	agttaaagg	3060
agtaagttttaaaatgatgtt ggggggtgt	gaatggagaa tggatattt	gattttattt	3120
ggtagtatat agattgttg ggtttttgtt	ttgggttagt tttggagga	agaggttaagt	3180
ttgggtggag tgggttaggg ggagagtgaa	ggtaaggat tagagtgtat	agagatttagt	3240
gttttgggtt gggggagta gagataggtg	ataattatag ggtagatgt	ggttaaagg	3300
gttttagttt ttttttaagt aaatgggtag	atgtatttttataatgtttt	tagtgaaggg	3360
ttgggtgtgg tgggttaagt ttgttagttt	agtatttttgg aaggttgagg	tgggtggatt	3420
attttaggattt aggagtttga gattgtttt	gttaataatgg tggaaattttt	tttttattaa	3480
aaatataaaaa attatgttggg tatgtgtgt	gggttttggta atttttaggt	tttaggaggt	3540
tgaggttagaa gaattgtttt aatttaaggag	gtggaggtt gttgagttt	aaattgtttt	3600
attgtattttt agtttgggtg ataaaaatgaa	gatgttagttt tttgttgg	tttttttaat	3660
tgttaatgag gaaagggggaa gttttgtgtt	aggtgataga gatttaattt	ttgagtaggt	3720
ttttttgtttt gttgtttttt ggttgggtttt	tagatgtta ggtggtaat	attagagttt	3780
gtgttagtagt gtgaggttaat ttattgttagt	aggttgggtt tggaggtttt	gggtgagtagt	3840
ggttttttttt tttgggtttt ttttaattt	ttgggatatt ttttgattt	ggagtttttt	3900
tgttttattt ttaggttttt ttgttagattt	taagtttattt tggattttt	ttgttgggt	3960
gttttgggtt ttggattttt gttgggtttt	ggatttgggt tggaaatttt	tgggtggagtg	4020
ggatatgaat gtggtgagtg tgggttgag	gggtatgggg aagggtgagg	atggtaggt	4080
tatagtgtag gtattttga gggtttttgg	gggtttgtgt gtaaggagt	ttttattgt	4140
tgtttttttt gttgtataga gaggtaattt	ttgtgtgggg gttggaggg	gagtttggat	4200
tgttgggtttt gtaagtattt tattttgtt	aagtggattt gggtttaggt	tgatttaggt	4260
tttgtgtatg tttttttttt gtattttttt	ttttttgtt ttgggttagag	tttatttttgg	4320
tgtgtttttt tggatgttgg tattttttttt	ttttttttgt ggtaggtgg	ttttgtgagt	4380
ggagttttgg agtgatgagg ttattttttgg	gggtgaagt gttgtgtttt	ttttttgggt	4440
ttttttttttt aatgagataa gagtttagatt	ttgggtgattt atgttttagt	tttaatggtt	4500
gtgggtgtgtt ttgggtttgg gttatgtgt	atattgtat gttatgtat	atgtatgtga	4560
ttgggggtgtt gttgggtgtt tatggatgt	taggattttgg ggtatgggt	gtatggttat	4620
gggtgaggtg gaggtgtttt tttttgaaat	gatttggagt agttagatgt	gtatgggtt	4680
ttgttagttaa gaggattttgg attttggagtt	tgagtagtat ttattgtgt	gaattttgtt	4740
agttttaggg ttgtgttggg attaggtggg	agtttaggggg tgggtgtgg	tgggagggaa	4800
agttttaggtt ggagttttgtt tttttttttt	ttgttgggtt gttttgggtt	ggtgggtagt	4860
tttattttttt tgggtatgtg gttttttttt	gggtttgtt ggggattttt	ttgtggaaatt	4920
gtgtgtaaagttttt tttttttttt	ttgtggat tttttttttt	ttgtggttttt	4980
ttatagatag gtgtaaatgt gaaaaatgt	ttgtatgtt tgggttagat	ttgagttggg	5040
tattttagt ttagtattaa agttgattgt	gtgttttgg ttagtattttt	tttattttgt	5100
tttgaatgtt ttgtttttttt tttttggag	ttttttgtt gatggggag	gatgtggaga	5160
tttggtaggtt attgagaagt atgtttaggt	aaatttgaga ggtagagaga	gatttttttt	5220
tttattttgtt atttttgtat ggagtttagtt	gagttttat tttttttttt	tttgggtttt	5280
tttattttgtt ttggaaatgtg gaagattttt	tttttttttt ttaggggtgg	tttggagaaaa	5340

gattttggaa tagataggaa agaagtttg tttggatta taagtattta ggagtatttt 5400  
attttagga agggggaaag ttagattata aaatgtttaa agaggtggaa aaagagattt 5460  
agtttattaa tttaggattt taagggttt tggatttt tagtatttt tattattggaa 5520  
gaattgtgt ttagatgtt ttgggtgtat tattagttt agagaattag gtttaggtat 5580  
tagaaaaag aaatagggt tggaaagttt agtatgttg gtagaaatgg ggtggaaatt 5640  
tttatttaag taaagaaagt ggaggtgtga gtgatgttt agataaaatt ttataaaatt 5700  
tttataaaa tgggtgggt ttagatgtt aaaattttt tagtattttt ggggtgttaagg 5760  
gttgaggta gtttagattt ttgggtttt tttatgtt gtttagttt agtttatttt 5820  
tattgtggaa agtgggaaa attataagat attaattaat tgaaaaggag gtttagttat 5880  
ggaggtgtat attttaattt ttagtttattt gggagggta ggtagaagga ttattttgaat 5940  
ttggaggtt gagggtgtat tgagttaga ttgtgttattt gtatttttagt ttgagtgata 6000  
gagttagatt ttgtttaaa aatagaaaag gaagtttaatg atgtgggtt atattttaa 6060  
tggtaatgtt ttggaggtt aaggttaggt gattattttt aatttaggaat ttgaggtag 6120  
tttggtaat atggtaaat ttatttttta ttaaatatata aaaaattttt tgggtatgg 6180  
ggtgtgtat ttagtattttt gttatttggg agattgaattt atttaatttggaggtaaag 6240  
gttgtagtga gttaaagattt tgtagtttta ttttaatttgg ggtgataggg tgagggtttt 6300  
ttttaaaaaaa aagaaagaag gttgggtttt gtagttatg tttgttaattt tagtattttt 6360  
ggaggttaag gtaggttagat tatttgaggt taaggtttt agatttgta ggttaatata 6420  
gtaaaattttt gttgtattt aaaaatataaa aaaaattttt ggttatggg gttgtgtttt 6480  
gttaattttttag ttattgggaa ggtttaggtt ggagttattt ttgaattttt aagatagagg 6540  
ttgttagttag ttgagtttgg gttattttttag ttttagtttgg atgagagat aagattttgt 6600  
ttttaaaaaaa aaaaaaaaaaa aaaagaaaga ataggaggtt gagaagttt aagttatag 6660  
ttttaaaaaaa aaaaaaaaaat attagttta gtttaggtt agtggtttattt atttttaattt 6720  
tttagtattttt gggaaagtttga ggtgggtgg ttagttagttt aatataaaa aatttagttttag tttgtgggtt 6780  
gttaaaatgg tggaaattttt gttttagttttaa aatataaaa aatttagttttag tttgtgggtt 6840  
agtttattttttagt aatttttagttt attttggagg ttagttagttttaa gaaatgtttagt aatttaggag 6900  
gttagagattt tagttagttttaa agattttttagt ttagttagttttaa gttttttttttagt aatagagttag 6960  
attttttttt aaaaaaaaaaa tttagttagttt ttagttagttttaa ttatggatag tggtagagt gagggtgggtt 7020  
ttttatgtt tagaagggaa attttatgtt gttttttttttagt aatagttttagt aatttaggag 7080  
gaaattttttt ttagttaggtt agttttggaa atagaaaaag aatattttttt ttttttagaa 7140  
ttttggaaagg gttgtgtat gtttttaattt tagttagttttaa tttttttttttagt tttttagt aatagaggag 7200  
gttttattttttagt aagaaagggaa ggggtggaaa tgaggttattt gtagttttagt ttaggtttttttagt 7260  
tgggttattt tagaagggaa gaaggagttaa gttttttttttagt ttttagttagt gagtttagag 7320  
tttattataag aataagtttag tattttttttagt gttttttttttagt ttttttagt aataaaatgt 7380  
ttttttttttagt gttttttttttagt tagttagttttaa tttttttttttagt ttttttagt aatattttttttagt 7440  
tttattttttttagt gttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 7500  
gttttttagt tttttttttttagt aaggttttata tttttttttttagt tttttttttttagt tttttttttttagt 7560  
tttattttttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 7620  
gagattttttttagt gatattttggg gaagaaaatgtt tttttttttttagt tttttttttttagt tttttttttttagt 7680  
ttttttttttttagt aaggttttggg ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 7740  
gtgtgggtt ttgggttaagg agtattttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 7800  
ttttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 7860  
ggggagaattttttagt tgggtttttttagt ggggttaggtt tttttttttttagt tttttttttttagt tttttttttttagt 7920  
attttttttttagt gataaagtat tgggttagttt tttttttttttagt tttttttttttagt tttttttttttagt 7980  
tttaattttttagt gtttatttttga tggtaatattttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8040  
gtttgggaga agaaagtttgg ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8100  
ggtaagaattt tagtttttttagt atgaggtggg tttttttttttagt tttttttttttagt tttttttttttagt 8160  
ttgggtatgtt tgggtttttttagt ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8220  
attttgaggtt aggagtttaa gattaattttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8280  
aaatataaaa attagttggg tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8340  
gtttgaggtt ggagaattttttagt ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8400  
gttattttttagt ttttagttttttagt ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8460  
ttgggttaaa tttttttttttagt ttttagttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8520  
tattttttttttagt agattttgggtt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8580  
aaatattttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8640  
tattttttttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8700  
ttgttagttttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8760  
ataaaattttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8820  
ttttattttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8880  
tgatgtttagt atttttagttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 8940  
tttagttttttagt taagtagttttagt ggtttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 9000  
gttgattttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 9060  
ttttttttttagt ttatgtttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt 9120

tagttgttt ttgtttttg tgtttgaag tagggttttta	tttagtttt taggttggag	9180
tgtagtata tgataatagt ttattgttagt tgtaattttt	tgggtttaaa tgattttttt	9240
attttagttt tttgaatagt tgggattata ggtatattat	tatatttggt taattttttt	9300
ttttttttt ttagtagaga tgaggtttt tgatgttttt	taagttgtt ttaaattttt	9360
gaggattaag tgattttttt atttagttt ttaaaaatgt	tgggattgtt gatgtgagtt	9420
attatattta gtttattttt attttaaatg agagttttt	tttagagttt tttagttgtt	9480
tttggttttt ggtatgtgt tttagttgt tttgttttt	gtggtatttt taaggttata	9540
tttagtggtg aggttttagg taggttagtag agagaagttt	aatgattttt tttttttttt	9600
atttattttag agtatgtaaa attaggagta gtgggggtt	tagggtgggtt attagttatg	9660
tatatgtata tttagggatag ggggttaaag gtagttagtt	tttaaagatt gtttagagg	9720
ttattttta gagaagttt gggttttta agggttttgt	gtttatgtt gtttattttt	9780
taggatgagt ttgtggagtg ggagatattt gattttttt	aagttgagat ttagttagaag	9840
attaaggagt ataatgtta gattaatagt aatttttttta	tgagttttgtt gagttgattt	9900
tttaggaagg ggggtgtggg aggagtagt atttagttat	gtgtttgata tttagagggt	9960
tataattttag gttattttgg gtgggtgttta gtagtaattt	gtgtatattt agtttagttt	10020
taagtagattt gatattttat ttggaaattttttaaattttttt	ttgggtttttt tatttttttta	10080
gaataaggat ggtttttata taggtttttat taagtttag	ttgaagttgg tgtgttttgt	10140
tttggttttt tttagtaaga agttattttt ttttaggtt	gtttgggtgg gtttaggatg	10200
gggtataagt gtttaggtttt gtattttttt ttattttttt	aaggatgtt gtttagtattt	10260
gtatgttttg ttatgtataa gggtatgttga agttatttttt	gtttgttggt gaaagttttt	10320
ggtgggtggat gatttttgttga agttttgtattt ttttaggtt	gtttagtggt atggtaagg	10380
tgggtttttt attttattttt gttttatgttga agggatata	tgtatgttatt ttagttagtta	10440
gggggtttagt agttggttttt gttttttagttt attttttttt	ttttatagtg tattttgttga	10500
agttgttggaa tgatgagtag tttttgtgt tttgtttttttt	ggtagggttt agtgataagg	10560
tttttagttttt ttttttgaag gaaaatgattt ttggggaggt	gaatgtgagt atatagtttt	10620
tagttttttt gttgttattt gataggattt gatgggtttaa	gttatagttaa gttttggagg	10680
aggaattgtt tggaagata agttttgttta aatagttttta	ggagtgtata ggtattgttaa	10740
ttaaagttaaa ggtttttaga ttatttatgt taaagtttttag	ggttgtttta agaagtttagg	10800
aagaattgtt ttgggtttttt gatttttttt ggtgtggaaa	attttttttga gatgttagggag	10860
tttattttat gatatgagga gttttttttt agattttttta	tttggaaagtt ttttggtttt	10920
aaggtattttag gtttggagtg tgaaattttaga tttagaaatat	gtttgattt gttataggtta	10980
atggggaaat attttagttt g		11001

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP2004/011577

International filing date: 14 October 2004 (14.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: DE

Number: 103 48 407.8

Filing date: 17 October 2003 (17.10.2003)

Date of receipt at the International Bureau: 19 January 2005 (19.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**